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The research concerns sub-cloning the gene for HGXPRT from Plasmodium 
falciparum from a vector with a His-tag facility to one without, expression of 
the protein in E. coli, and purification. On an analytical scale (40 ml culture), a 
purification procedure was developed that involves extraction of 
contaminating proteins by anion exchange chromatography (HGXPRT does 
not bind under the conditions used), followed by Reactive Red 120 agarose 
affinity chromatography. A single-manoeuvre preparative scale purification (1 
L culture) was then achieved using a DE52 column in series with a Reactive 
Red 120 column to yield the required protein of >95% purity. The protein was 
inactive as isolated, but could be activated by incubation over 5 h at 4°C with 
Mg2+ + phosphoribosyl pyrophosphate (PRPP) or PRPP + hypoxanthine to 
yield a specific activity of 1-5 J.Lmol/minlmg of protein. Free Reactive Red 120 
is shown to be a fairly potent inhibitor of catalytic activity (Ki < 2 IJM). 
In previous work, the chalcone, (2E)-3-(4"-iodophenyl)-1-(2',4'6'-
trihydroxyphenyl)prop-2-en-1-one or 4"-I-chalcone, had been found to 
specifically accelerate the catalytic turnover of HGXPRT from Plasmodium 
falciparum - it had no effect on the homologous enzymes from humans or 
Toxoplasma gondii. In the present study, nine analogues of this chalcone 
were synthesised, altering the positions and substituents on the two rings. 
The chalcones were synthesised by condensing appropriate acetophenones 
and halogenated benzaldehydes in a Claisen-Schmidt reaction. NMR, mass 
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spectrometry, IR spectrometry, and elemental analysis confirmed the desired 
products. 
Out of the nine new chalcones synthesized only two accelerated catalytic 
turnover, and these only differed from the lead chalcone in the identity of the 
halogen. In ring A, changing the 2'- and 6'·OH groups to chloro, or removing 
the 4'- and 6'-OH groups, eliminated the accelerating effect, as did changing 
the position of the iodo substituent in ring B. It shows that the requirements for 
activation are extremely strict. 
The chalcones that accelerate catalytic turnover were transformed into potent 
inhibitors when Ca2+ replaced Mg2+ as the divalent cation cofactor (KG < 0.1 
\JM for 4"-I-chalcone). In addition, at least one of these chalcones (4"-1-
chalcone) was able to replace PRPP in converting the isolated inactive 
enzyme into the active form, except that neither purine nor divalent cation was 
necessary. These effects of the halogenated chalcones suggest that they bind 
at the active site. A model for activation of inactive protein, and inhibition in 
the presence of Ca2+ is presented where the chalcones bind at the PRPP site 
with or without divalent cation. The model provides a rationale for the greater 
strength of the ternary complexation of HGXPRT/divalent cation/chalcone 
when the cation is Ca2+ compared with Mg2+. If rate limitation is ascribed to 
nucleotide release (as in the human enzyme), then the chalcones may bind 
differently to accelerate turnover. It is also possible that another step is rate-
limiting, and the PRPP site is vacant to allow the chalcone to bind and 
accelerate a slow conformational change. 
iv 
The results and model suggests that these particular chalcones are good 
analogues of PRPP, the tri-hydroxyl aromatic portion with adjacent carbonyl 
and its symmetry and rotational mobility mimic PPi, the halogen and its unique 
bonding ability substituting for Pi, and the second aromatic ring overlapping 
with the ribose moiety. Alternative binding positions with the latter ring 
outside of the active site are also considered. 
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Malaria is a major world health problem that affects the tropical, sub-tropical 
and some temperate regions (Figure 1.1). In many instances, the countries in 
these regions are also the poorest in the world. This makes the fight against 
malaria very difficult in these countries. According to Roll Back Malaria, a 
United Nations publication, 40 % of the world population is at risk of malaria 
(httD:/Iwww.who.intlinf-fs/en/lnformationSheet01.Ddf). Every year, 300 - 500 
million people, mostly children and pregnant women, are infected by malaria 
(Greenwood and Mutabingwa, 2002; Miller et al., 2002). As one review puts it, 
across the globe, a child dies of malaria in every 40 seconds (Sachs and 
Malaney, 2002). In all, up to 3 million people worldwide die of malaria every 
year (Butler, et al. 1997). Malaria affects Africa more than any other continent 
in the world. It is estimated that 90 % of the malaria deaths occur in sub-
Saharan Africa (WHO/UNICEF, 2003; Greenwood and Mutabingwa, 2002). 
This is in spite of the fact that many of these malaria deaths can be prevented 
by early diagnosis and administration of appropriate treatment. 
Malaria is transmitted by intracellular protozoan parasites of the genus 
Plasmodium. These parasites are carried by the female Anopheles mosquito 
especially A. gambiae and are passed from one person to another through 
mosqUito bites. A. gambiae is particularly effective at transmitting malaria 
among humans because it preferentially feeds on humans and is long-lived. 
There are fOUf Plasmodium species that transmit malaria and these are P. 
ovate, P ma/anae. P VIVaJl, and P fa/clparum Of Ihese , P falciparum IS Ihe 
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1.2 Life cycle of P. falclparum 
Figure I 2 summanzes the life cycle of the malana paraSIte as It occurs In the 
mosquito and human hosts For a comprehenSIve reView, see Miller el al 
2002 The life cycle of the malana paraSite can be said to start with an 






Fl{lure 1 2 The PllISmodium sp. life c~el. <_t •• t IOf des.enPlIOtl) n lll Fig"" IS taken 
from http .. www ... a!a .. al!~s; com/cycle hlml webill~e 
parasites known as sporozolles 11'110 subcutaneous tissue, 01 less often. 
directly mto the blood-stream where they are transponed to Ihe liver 
Sporozo,tes are an infective form of the parasite found in Ihe salivary glands 
of the mosqUito Once in Ihe hepatocytes (parenchymal cells of Ihe liver), the 
sporozoltes undergo asexual multipl ication generating thousands of liver 
merOl oltes, another form of Ihe parasite. The infected hepatocytes eventually 
rupture resulting in the release of merOl Oltes back into Ihe blood stream The 
merOl oltes in Ihe blood then Invade erythrocytes where they complete 
another round of asexual multiplication that takes about 48 h In the 
erythrocytes, the paraSITes first dlfferentJate from ring stage Into trophozoltes 
that become schizonts. The schizonts eventually tum into red blood cell 
merozoiles Each Infecled erythrocyle can produce up to 20 addilional 
merozoites The fever associated with malaria Is thought to be the result of 
the synchronous release of merozoltes from red blood cells In fact. malaria 
pathogenesis IS assoCiated only with the blood stage of the Plasmodium 
parasite (Egan, 2003) The production of merozolles in erythrocytes IS 
accompanied by the degradation of haemoglobin by the parasite Itself 
l1elee,ed merozoite, can either infect fresh red blood cell, end rep eel the 
asexual reprodUCtion cycle or develop inlo male and female gamelocytes that 
are taken up by the Anopheles sp. mosquito host In the mosqulIo, the 
parasite continues ItS multiplication following a se)(lJai route that starts With the 
gametocytes fUS ing to form a zygote (Greenbaum 8t al., 2002). Zygotes form 
oocysls in the wall of the mosquito stomach The oocysts develop over a 
period of time and conlaln numerous sporozoltes, ready 10 start the cycle all 
over again 
1.3 Malaria drug ta rgets 
1.3. 1 The genome 
The sequencing of the P falcipMum genome in 2002 hils provided "n 
unprecedented opportunity for exploring new drug targets (Gardner et a/., 
2002) The genome contains about 5 300 proteln·encodlng genes and 60% 
, 
of these could not be assigned any functIOn This constJlutes an enonnous 
group of possibly unique malanal proteins thaI are potential drug targets The 
parasite also has several other unique features such an aplCoplasl with Its 
own genome of 30 genes an unusual electron transpor1 chain WIth cflllcal 
ublqulOol cyclmg a seemingly non·functlOnal FIFe AlP synthase. and 
poSSible reliance on a proton-Ifanslocatlng pyrophosphatase for developing 
an electrical potential across the plasma membrane 
The aplcoplasl probably arose by endosymblosls, like mitochondria and 
chloroplasts, and Imports most 01 the 551 enzymes for diverse functions The 
organelle syntheSizes fatty aCids, Isoprenoids, and haem. and IS Involved in 
DNA replication and repair transcnpllon and translation. protein import and 
turnover, and malana paraslle-speclflc metabol ic pathways Many of the 
enzymes compris ing fatty acid syntheSIS. Isoprenoid syntheSIS, and the laner 
metabolic group m"y be ooon drug !;:!rOAt,,- Til,. pm!eln Import m;:!r.hlnf!ry 1"-
Itself a potential drug target 
The parasite obtainS liS ATP from glycolySIS - all the glycolytiC enzymes are 
present, mcludmg two unusual phosphofructoklnases \,·"tllch are related to. or 
are pyrophosphatases A complete tricarboxylic aCId cycle was identified , but 
With several deViant features. perhaps because It IS mainly directed to the 
synthesIs of SUCClnyl CoA for haem bIOsynthesIs 
All pathogeniC protozoan parasites do not synthesize punnes de novo and 
rely on Ihe host for pUrine needs (Shennan , 1919) The genome contams 
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punne and nucleoside transporters and the pUrine salvage enzymes 
hypoxanthine phosphonbosyltranferase (HPRT). which converts 
hypoxanthine guanine Of xanthine Into IMP GMP or XMP and punne 
nucleoside phosphorylase (PNP). wtllch cleaves the glycosidIC bond or 
InOSine 10 produce hypoxanthine and ribose-I -phosphate all of which are 
possible drug targets (see below) 
During the intra-erythrocytic phase the parasite e)(ports several proteinS to 
the cytosol of the erythrocyte and plasma membrane This reqUIres crOSSing 
of the parasitophorous vacuole surrourlding the parasite It IS not clear how 
th is IS achieved, but the genome beSides corltalnlng a classical secretory 
protem pathway and vesicle transport proteins also harbours proteins thai 
may provide a secondary route Tl1ese proteins are potel1l1at drug targets 
After InvaSion of tl1e red btood celts by parasites the host celts become much 
more permeable to a vanety of small molecular weight compounds, a process 
termed New Permeability Patl1ways (NPP). see Staines el al .. 2005 for a 
review It IS not clear whether these transport systems or iginate from the 
paraSite or host but they can be good drug targets Compounds that target 
the NPP have been syntheSIZed For IfIstance. phlondlln (Kutner et a/. 1987, 
Slifen ef al 1988). and glibenclamlde (Knit ef a/ .. 1993) target NPP and inhibit 
parasite growth in culture 
The malana parasite exports some of its proteins to the erythrocyte 
membrar'le. These proteins are Importar'lt Viru lence faClors aSSOCiated With the 
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manifestations of the disease. They could also help in the binding of the 
parasite to organs within the host. Some are also antigenic determinants of 
our immune system. There is a huge potential for identifying new 
determinants among the surface proteins and for developing vaccines. 
1.3.2 Biological targets of: 
1.3.2.1 Quinolines 
Quinoline derivatives are the main drugs used against malaria. They are 
believed to inhibit haem detoxification. 
During the intra-erythrocytic stage of the malaria parasite's life cycle, the host 
haemoglobin is a primary source of amino acids. Haemoglobin proteolysis 
occurs within the vacuole of the parasite, a lysosome-like organelle, and free 
haem [Fe(lI)protoporphyrin IX] is produced, which is oxidised to haematin 
[HO-Fe(lII)protoporphyrinIX], and is toxic. It can cause cell lysis and the 
generation of damaging reactive oxygen species (Wiser 2003). The paraSite 
detoxifies haematin by forming haemazoin (malarial pigment), which has been 
characterized as a polymer of ~-haematin (Slater at al., 1991; Adams at al., 
1996). The latter is a dimer of haematin linked via two of the propionic acid 
groups and the Fe(lll)s (Pagola at al., 2000). The mechanism of haemazoin 
formation in vivo is controversial. Synthetic ~-haematin formation occurs 
spontaneously in concentrated acetate (pH 4.5) and elevated temperatures 
(Egan at al., 1994), but may be too slow to account for haemazoin formation 
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under physiological conditions. Its formation is possibly catalyzed or initiated 
either by histidine rich proteins, e.g. HRP-2 (Sullivan at al., 1996; Schneider 
and Marietta. 2005). or through aggregation with lipids, e.g. linoleic acid (Fitch 
at al., 1999 and 2000). The natural process may occur through a combination 
of methods, perhaps depending on in vivo conditions. 
The quinoline antimalarials interfere with the process of haem detoxification. 
4-aminoquinolines e.g. chloroquine, quinidine, halofantrine, 
desbutylhalofantrine, and mefloquine. inhibit the formation of synthetic 
crystalline p-haematin by associating with haematin (Egan at al .• 1999). 
Solvent and electrostatic factors play an important role in this interaction 
(Egan and Ncokazi. 2004). Substituents at position 7 (see Figure 1.3) 
influence the pI<. of the quinoline and tertiary nitrogens, thereby possibly 
affecting their accumulation within the acidic compartment of the food vacuole 
(Kaschula at al .• 2002). Quinoline and quinacrine derivatives also inhibit the 
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Figure 1.3 Chloroquine and numbering of atoms In the ring system. 
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inhibits the dimerisation of haematin mediated by lipids through increasing the 
proportion of lipids unable to promote the dimerisation process (Fitch et al., 
2003). Therefore it appears that these quinoline antimalarials inhibit all three 
of the recognized methods of haemazoin formation, pointing to them 
interacting with the haem or haematin rather than the end catalysts like 
protein or lipid. The inhibition of haemazoin formation results in the 
accumulation of toxic haematin thereby killing the parasite. 
1.3.2.2 Artemisinin 
Artemisinin and its derivatives are becoming an increasingly important 
treatment for malaria. They, alone or in combination with the more usual 
antimalarials like mefloquine, are now the first line drugs for the treatment of 
malaria in several African and Asian countlies. Artemisinin is derived from 
the Chinese plant, Artemisia annua, and is present in a herbal tea, quighao, 
that has been used as an antidote for fever for several centuries, and for the 
treatment of malaria and haemorrhoids for 150 years. It is a sesquiterpenoid 
lactone with an endoperoxide bridge across the seven-membered ring (see 
Figure 1.4) and is rather insoluble in water and oil, but exists in more soluble 
forms such as artesunate and artelinate. Artemisinin is effective at low 
nanomolar concentrations, much lower than its cytotoxic effect, which is in the 
micromolar range (Woerdenbag et al.1993). 
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Figure 1.4 Structure of Irtemlalnln (or qinghlosu). 
These compounds are converted to dihydroartemisinin by haem, 
Fe(ll)protoporphyrin IX, which produces toxic, carbon centred free radicals, 
which are proposed to alkylate critical parasite enzymes (Meshnick et 81., 
1991; Posner and Oh, 1992). It is also plausible the artemisinin acts as a 
source of hydroperoxide that leads to the generation of hydroxyl radicals that 
hydroxylate parasite proteins and produce reactive oxygen species that have 
other deleterious effects (Posner et 81., 1995; Haynes et 81., 1999). The 
production of a wide range of destructive reactive species may make it difficult 
for the parasite to develop resistance, and none has been reported yet. 
Recently, artemisinins have been found to inhibit a malarial Ca2+-ATPase, 
PfATP6 (Eckstein-Ludwig et 81., 2003). Inactivation of the pump and parasite 
death was antagonised by thapsigargin, a potent sesquiterpenoid lactone 
inhibitor of sarcoplasmic/endoplasmic Ca2+ pumps. The inactivation was 
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irreversible and catalyzed by Fe2+ suggesting covalent interaction via a 
reactive form of artemisinin. The protein could be the primary target of the 
activated artemisinins. 
However, it has more recently been shown that Fe2+ is not essential for the 
antiplasmodial effects of artemisinin in parasite cultures (Parapini et al., 
2004). Growth of the cultures in CO rendered the Fe2+ unavailable for 
oxidative electron transfer and reduction of the trioxane ring and yet the 
effects of artemisinin actually occurred in a lower concentration range. These 
experiments also suggest that the oxidative mechanisms alluded to above 
play only a minor role. 
Artemisinin seems also to exert an anti-inflammatory effect through inhibiting 
the inducible form of nitric oxide synthase (Aldieri et al., 2003). This may help 
to alleviate the neurological complications of malaria. 
One potential drawback to artemisinin may be its availability through the need 
to extract it from plants. A cheap, synthetic route to artemisinin or a derivative 
has taxed chemists for many years. One simple endoperoxide structure 
analogue (OZ 277). stabilized by an adamantane ring, has recently been 
synthesized and shown to be more potent than artemisinin and seemingly to 
possess few side effects, at least in animals (Vennerstrom et al., 2004). 
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1.3.2.3 Antifolate agents 
For a number of years a combination of pyrimethamine and sulfadoxine has 
been first line therapy in some African countries, such as Malawi and Kenya. 
These agents target enzymes in the folate pathway. Folate and its 
metabolites provide a number of cofactors necessary for the supply of one-
carbon units. For example, 5,1 O-methylenetetrahydrofolate transfers a one-
carbon unit to dUMP to yield dTMP, which goes into DNA, and to certain 
amino acids such as methionine. The pathway consists of five enzymes 
required for the synthesis of folate, and other enzymes interconvert the 
various folate forms (for review see Hyde 2005). 
Pyrimethamine is a competitive inhibitor of dihydrofolate reductase. This 
enzyme reduces the 5, 6 - double bond in dihydrofolate to tetrahydofolate. 
The activity is actually located in one domain of a bi-functional enzyme (the 
other activity being thymidylate synthase) (8zik et al., 1987). The crystal 
structure of the dimer containing both activities has been elucidated with 
inhibitors bound at the active site (Yuvaniyama st al., 2003). 
The sulfonamide drugs (e.g. sulfadoxine and dapsone) are competitive 
inhibitors of dihydropteroate synthase, an enzyme which converts 6-
hydroxylmethyl-7,8-dihydropterin pyrophosphate and p-aminobenzoic acid 
into 7,8-dihydropteroate. It is also a bi-functional protein, which also catalyses 
the preceding step in the pathway (Triglia and Cowman, 1994). 
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1.3.2.4 Some other drug targets 
1.3.2.4.1 Proteases 
Several parasite proteases are involved in the digestion of haemoglobin and 
they also participate in the invasion and release from the erythrocyte. 
Inhibitors, like peptidyl fluoromethyl ketone (Rockett et al., 1990) and vinyl 
sulfone (Rosenthal et al., 1996), are potent antimalarial agents in model 
systems. 
Aspartyl proteases have two active site aspartic acid residues that activate a 
water molecule to catalyze the hydrolysis of peptide bonds. Two aspartyl 
proteases, plasmepsin I and II are implicated in the early degradation of 
haemoglobin (Gluzman et al., 1994). They are synthesized as pro-enzymes 
and each contains a membrane-spanning section that probably anchors the 
protein to the membrane of the food vacuole before activation by another 
protease (Francis et al., 1997). This is a very active field for drug targeting. 
Many of the drugs developed against the human immunodeficiency virus 
aspartic protease may be effective antimalarials (Skinner-Adams et al., 2004; 
Abdel-Rahman et al., 2004). However, disruption of expression of these 
genes yields viable parasites, although with slower growth characteristics, 
even though they remain sensitive to protease inhibitors, suggesting other 
aspartyl proteases may be more critical than plasmepsin I and II (Liu et al., 
2005). 
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The best-characterized proteases are the cysteine proteases, which have a 
critical catalytic cysteine residue at the active site. Falcipain 1, 2, and 3 are 
expressed during the intra-erythrocytic phase of the life cycle and the latter 
two degrade haemoglobin at acidic pH (Shenai et al., 2000; Sijwali et al., 
2001). Both are targeted to the acidic food vacuole, and falcipain 2 also 
exists outside perhaps to partiCipate in the degradation of proteins of the 
erythrocyte cytoskeleton during rupture (Dahl and Rosenthal, 2005; Dua et al., 
2001). Many inhibitors of cysteine proteases exist and are being explored as 
antimalarials (Chibale and Musonda, 2003). 
A novel approach is the development of "double drugs" in which single 
molecules contain protease inhibitor and quinoline moieties. Thus, both 
processes, namely haemoglobin degradation and haemozoin formation may 
be inhibited. Thiosemicarbazones conjugated to a 4-aminoquinoline moiety 
via an isatin scaffold showed good activity against parasite growth in vitro. 
The thiosemicarbazone contained electrophilic imine and thiol carbonyl 
groups that could covalently derivatise the reactive cysteine (Chiyanzu et al., 
2005). 
1.3.2.4.2 Purine salvage targeting agents 
As indicated earlier, pathogenic protozoan parasites, including P. falciparum, 
lack the ability to synthesize purines de novo and rely on the host to supply 
the bases for purine nucleotides that are essential for energy needs and DNA 
and RNA synthesis. Sequencing the malarial genome has confirmed that the 
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parasite lacks the synthetic enzymes (Gardner et al., 2002). The major purine 
base salvaged is hypoxanthine. It comes principally from inosine via 
adenosine using the enzymes adenosine deaminase and purine nucleoside 
phosphorylase, respectively. Smaller amounts of the bases themselves, 
namely, hypoxanthine, xanthine, and guanine cross the parasite membrane 
as well, perhaps by a different transporter. Hypoxanthine, xanthine, and 
guanine are converted to IMP, XMP, and GMP respectively by the enzyme 
hypoxanthine xanthine guanine phospho ribosyl transferase (HXGPRT). The 
malaria parasite seems to be unique among protozoan parasites in lacking 
adenosine kinase (deduced from the genome sequence), which could 
otherwise provide an alternative source of AMP from adenosine. All of the 
former enzymes, as well as two nucleoside/purine base transporters (evident 
in the genome), are likely to be good drug targets. Removal of medium 
hypoxanthine by xanthine oxidase inhibits the growth of malaria parasites in 
culture, indicating the parasite's reliance on their salvaged pool of 
hypoxanthine (Berman and Human, 1990; Berman et al., 1991). A summary 
of the central role of HXGPRT in purine salvage is shown in Fig. 1.5. 
Two nucleoside/purine base transporters occur in the malaria genome 
(Gardner et al., 2002). One has been characterized and found to transport 
adenosine and adenine, as well as the other bases guanine and hypoxanthine 
(Carter et al., 2000; Parker et al., 2000). The first soluble enzyme in the 
pathway is adenosine deaminase and it seems to differ from the human form 
because selective inhibitors have been found (Daddona et al., 1984; Brown et 
al., 1999). 
1<, 
Red Blood CeU 
Fogure 1 5 Pathway,. for " unne s a lva!le in P. (aldpiJrum The rna", 'Ollle 05 ,lIOlCaIed In 
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As menlloned, pUrine nucleotide phosphorylase (PNP) provides the maIO 
source of hypoxanthll'le in parasites by converting inosine [0 hypoxanthine 
and nbose-I-phosphate The Importance of this pathway is demonstrated by 
the inhibitIOn of thIS enzyme by IrnmuCllbns pUrine nucleoside analogues 
containing a ' -(9-deazapunn.g-yt)-I ,4-dJdeoky..4-lmlnonbitol moiety, wtllch 
mimiC the enzyme 5 transitIOn state through protonatlOn of the imino nitrogen 
and resulting pos!tlve charge (KlCska et al , 2002) The inhibitor kills parasites 
In culture with an IC50 value of 35 nM Growth hfllltallOn IS reversed by 
hypokanlhlne but not InOSine. shoWing the block IS allhe level of PNP The 
human erylhrocyte PNP e)(hlbils a higher affinity for Ihe analogue compared 
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with that of the parasite, and parasite death only occurs at higher 
concentrations where both enzymes are inhibited, suggesting that adenosine 
and not hypoxanthine provides the main pool for purines corning from the 
erythrocyte. A crystal structure of malarial PNP with bound ImmucillinH (an 
immucillin with substituent features of hypoxanthine) and sulphate identified a 
solvent filled cavity close to the 5'-OH, which led to the discovery of 5'-
methylthio-immuciliinH as a potent and selective inhibitor of the malarial 
enzyme (Shi et al., 2004). The parent compound, 5'-methylthio-inosine, is a 
substrate of the enzyme and a parasite metabolite (Ting et al., 2005). 
Several other potent inhibitors of the human enzyme had previously been 
found, including acyclovir diphosphate (Ki - 10 nM) with an acyclic ethylene 
linkage between the phosphate and the guanine (Tuttle and Krenitsky, 1984). 
HXGPRT has long been recognized as a possible drug target against malaria 
and other parasitic protozoans since the early work of Sherman and others 
(Sherman, 1979; Ullman and Carter, 1995). The malarial enzyme, like that of 
other protozoan parasites, is highly homologous to the human enzyme, and 
the active site residues are virtually identical. However, it does differ in 
exhibiting lower Km values for the substrates and showing activity with 
xanthine (Queen et al., 1988; Heroux et al., 1999b; Keough et al., 1999). 
Mutant, inactive, forms of human HGPRT or its absence leads to Lesch-
Nyhan syndrome, a disease identified by hyperuricemia and neural problems. 
Partial deficiencies result in gouty arthritis. The malarial enzyme is the subject 
of this thesis and will be introduced in detail later. 
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1.3.3 Drug resistance 
Chloroquine has been a safe and effective treatment against malaria for 
several decades. However, resistance to this drug appeared 50 years ago, 
first in South East Asia, South America, East Africa, and thence to the rest of 
the continent. Antifolate drugs came into existence as effective agents 
against chloroquine-resistant parasites. However, resistance to these soon 
appeared, and now combination therapies are becoming common. 
Artemisinin has provided new hope, especially in combination with other 
antimalarials. 
The problem of resistance is highlighted by a recent news article in 
NewAfrican (March 2004, no. 427), in which WHO is accused of "medical 
malpractice" by encouraging the use of chloroquine and antifolates. The 
article suggests that artemisinin-class combination therapy would be more 
effective, although the cost is approximately 10-fold higher. 
Chloroquine resistance has been linked to mutations in a digestive vacuole 
transporter termed "chloroquine resistance transporter" pfcrt (Fidock et al., 
2000). This is a 424 amino acid protein with 10 predicted transmembrane 
helices and lys76 to thr in the first transmembrane helix is the principal 
mutation conferring resistance. This mutation is accompanied by an arg220 
to ser mutation in most resistance organisms. The mechanism of resistance 
by this protein is unclear. Possibly the most feasible is that it normally 
functions as an amino acid (or other metabolite) symporter with H+ and that 
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the positive charge on lys76 inhibits its interaction with the protonated and 
charged chloroquine in the digestive vacuole. The mutated protein, without 
the charge, allows interaction and passive downhill efflux of the protonated 
drug, thereby lowering its concentration in the vacuole (Bray et al., 2005). 
A homologue of the mammalian multidrug resistance P-glycoprotein, pfmdr1, 
is also implicated in chloroquine resistance (Foote et al., 1989). It is a typical 
ABC transporter with two ATP binding domains and two membrane domains. 
Mutations in this gene occur in many, but not all, of the resistant parasites 
(Foote et al., 1990). Insertions of the mutations in the wild type gene affected 
sensitivity to several quinolines (Reed et al., 2000). It appears to playa role 
in modulating resistance (Duraisingh and Cowman 2005). It is not clear how 
mutations to the drug pump could affect the accumulation of chloroquine, but 
perhaps the protein normally helps to actively pump the drug into the vacuole 
and the mutations inhibit this. 
Resistance to the antifolate combination of pyrimethamine and sulfadoxine, 
similar to that to chloroquine, is growing in Asia and Africa. Resistance to 
pyrimethamine is due to point mutations in the reductase gene, mainly ser108 
to asn, that lower the affinity of the enzyme for the inhibitor without affecting 
activity (Cowman et al., 1988; Peterson et al., 1988; Sirawaraporn et al., 
1990). Other mutations, like those at pOSitions 16, 51 or 59, in combination 
with the one at 108, exacerbate the resistance. Resistance to sulfadoxine 
requires mutation/s in the synthase gene, mainly ala437 to gly, but also at 
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positions 436, 540, 581, and 683, which again inhibits binding of the drug to 
the enzyme (Triglia et al., 1997; Basco et al., 2000). 
Atomic structures of both mutated and wild-type reductase enzymes with 
bound substrates or inhibitors shows that the resistance mutations sterically 
prevent rigid antifolates like pyrimethamine and cycloguanil from binding 
(Yuvaniyama et al., 2003; Yuthavong et al., 2005). The structures have 
guided synthesis of more potent antifolates that bind to the resistant forms as 
well. 
1.4 The purine salvage enzyme HG(X)PRT 
1.4.1 HG(X)PRT reaction mechanism 
The reaction of HG(X)PRT is shown in Figure 1.6. 5-phospho-a-D-
ribofuranosyl-1-pyrophosphate (PRPP) reacts with hypoxanthine, guanine or 
xanthine (in parasite enzymes) to form IMP, GMP or XMP respectively and 
pyrophosphate (PPi). Mg2+ is required, probably in the form Mg2PRPP 
(Salerno and Giacomello, 1980), and, as we will see below, the requirement 
for two Mg2+ is borne out by the crystals structures. Early kinetic studies, 
mostly carried out on the human erythrocyte enzyme, have indicated that the 
forward reaction is ordered, with PRPP binding first followed by the purine to 
yield a ternary enzyme-substrate complex followed by ordered product 
release (Henderson et al., 1968). Later work cast some doubt on the ordered 
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Figure 1.6 The HG(X)PRT reaction. In this example, guanine (purine) is converted to 
guanosine 5'-monophosphate (GMP) by linking it to PRPP in the presence of magnesium 
ions. 
release of products as random binding of IMP and PPi in the reverse reaction 
(termed pyrophosphorolysis) followed by ordered release of first hypoxanthine 
and then PRPP was found (Giacomello and Salerno, 1978). Isotope 
exchange with IMP-GMP and guanine stimulation IMP pyrophosphorolysis 
suggested slow release of PRPP again indicating ordered binding/release of 
substrates (Salerno and Giacomello, 1979). A more recent detailed study. of 
the human enzyme, combining pre-steady state and steady state kinetic 
measurements, has found the ordered binding of substrates and products in 
the forward direction (Xu at al., 1997). PRPP binds tightly (Kct = 1.3 ~M) first 
and needs Mg2+. The base binds second with a Similar affinity (Kct - 2 ~M). 
The purine did not bind to the apoenzyme. IMP. but not PPi, competed with 
PRPP binding. from which a Kct of 53 ~M was extracted, and showing that the 
affinity for PPi is very low. In the reverse direction IMP binds first and PPi 
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second. Enzymes from other species, such as E. coli, Plasmodium, 
Tritrichomonas foetus have similar Km values for substrates (Liu and Milman, 
1983, Xu et a/., 1997; Keough et a/., 1999; Munagala et a/., 1998). 
There is evidence for both dissociative SN1- and associative SN2-type 
chemical reactions (see reaction pathways below). A two-step SN1-type 
transfer comes out of kinetic isotope effects with orotate-PRT, which points to 
the activation of PRPP through PPi loss and the formation of a distinct 
oxacarbenium-like transition state (see scheme 1.1, Goitein et a/., 1978). A 
later study on the same enzyme confirmed that the transition state had distinct 
oxacarbenium character on the ribose and substantial negative charge on the 
orotate (Tao et a/., 1996). This mechanism is supported by the slow, but 
extremely tight, binding of stable nucleotide analogues of the proposed 
transition state, the phosphorylated immucillins (e.g. ImmucillinHP), in a 
complex with PPi and Mg2+ (Li et a/., 1999). In these analogues the 04' 
oxygen of the ribose moiety is replaced by N and the N9 of the purine is C 
instead of N (see structures in Figure 1.7). N7 in the deazapurine ring is 
protonated. 
PPI 
X .. ) 




Scheme 1.1 SN1 and SN2 reaction pathway. The ~1 pathway is shown in an extreme 
version where the oxacarbenium ion is generated as a distinct species following PPi 




Figure 1.7 Structures of nucleotide analogues that mimiC the tranaltion atate and bind 
at the active aile of HG(X)PRT enzymes (Li at al., 1999). 
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The iminoribitol moiety has a pKa of 6.7, which means that it is largely 
protonated at pH 7, and positively charged, mimicking the oxacarbenium 
state. Later, when the structures are considered, it will be seen that there 
could be the need for significant movement of the C1' ribose from the reacting 
o of the pyrophosphate to the N9 of the purine, implying that a stable 
oxacarbenium intermediate must form transiently, and therefore an SN1 type 
reaction is indicated (Shi et al., 1999a). Evidence of an associative SN2 
mechanism is indirect, and derives from analysis of crystal structures of the 
closed active site with PRPP and an analogue of hypoxanthine, which is 
considered to represent a stage just prior to the transition state, and yet there 
was no evidence of activation of the PRPP to an oxacarbenium form (Focia et 
al., 1998). 
There is also no obvious means of stabilizing the activated oxacarbenium 
cation intermediate with nearby polar amino acid residues, making it difficult to 
understand why the transition state mimics bind so tightly. It has been 
suggested that this may derive rather from an altered ribose configuration and 
H-bonding to N7 (Craig and Eakin, 2000). Also, the presence of a significant 
number of trapped water molecules in the closed active site conformation 
seems to mitigate against stabilization of a reactive intermediate (Heroux et 
al., 2000). 
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1.4.2 Structure of HGPRTs 
The HGPRTs belong to a larger group of PRTs that share a common reaction 
mechanism and a characteristic structural fold. Over 40 ,crystal structures 
have been determined for a variety of PRTs incorporating 16 different proteins 
(for review see Sinha and Smith, 2001). The PRTs can be identified by a 
sequence motif incorporating 4 hydrophobic amino acids, a glutamate and 
aspartate involved in binding the ribose hydroxyls, and 7 variable amino acids 
including glycine and threonine, which form the 5' phosphate binding loop. 
Sequences from 5 HGPRTs are aligned in Figure 1.8. The identifying 
sequence motif is in ~-strand 6 and Loop III. Other conserved amino acids 
are indicated. In particular, Loop I contains a leu-Iys-gly motif that is involved 
in significant structural changes to bind the pyrophosphate of PRPP. There 
is a highly conserved ser-tyr motif in loop II, which overlay PRPP and the 
purine base and occludes the catalytiC site. In Loop III' there are conserved 
Iys and arg amino acid residues, which interact with the purine and fixes the 
loop onto Loop III underneath. Towards the end of the protein is conserved ~­
strand 9, which forms a cap over the base. Further on in the sequence is a 
highly conserved asp (Loop IV) that ligates one of the Mg2+ and the 
pyrophosphate. 
Looking at the tertiary structure, the PRTs have a core domain consisting of a 
5-7 ~-stranded sheet lodged in between 3 main a-helices (light blue and dark 
blue respectively, Figure 1.9). There is also a hood domain arising from the N-
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Figure 1 8 Sequence ailgnmef115 ot PRh trom human, r. gondil, P. falclparum, T. Cruz; 
and r. foetus Green shil<led residues are absolulely conse,....ed across tne PRTs whJIe those 
,n yellow are conservatively subst,tuted Act •• e SIte reS ld~es !\a.e gold Mar!; under (nem The 
2' s{(uct~ral elements 01 the r OOlldll HGXPRT are placed abo,e (he seQuence alignment 
Thos Figure was raken directly trom Heroux e1 al (1999a) 
and C-terminal ends consistrng of Ofle helix and several small strands The 
hood can be a smalllJnrt such as that of E. coli HGXPRT with 29 amino acids 
or it can be extremely large as that of Giardia lamblla that has 97 resid ues 
(Vos el a/ .. 1997, Shi el al ,2000) The active site is fo rmed on one end of the 
central sheet and IS surrounded by several loops and the hood domain thai 
enclose it dunng catalysis. 
Hood dom,,,, 
Flgllre , 9 The PRT fold The protem IS HGPRf from T gondrl with GMP altne active s>te 
(Heroux 81 a/ 1999a) 
Several atomic structures with one or two substrates or products have been 
eluCidated The fol lowing analysis IS based on the T gondii structures, mainly 
based on the work of Heroux and colleagues (Heroux et al. 1999b) Crystal 
structures from other species show the mechanism is applicable 10 the other 
PRTs In the family The apoenzyme has an open active site wllh surrounding 
loops I, II, ill , III' and IV fairly well apart (Figure 1.10. Schumacher et a/ . 
1996) loop I possesses a cnticallys79 which IS oriented outwards In th is 
FI9~re I 10 ActiYe sile residu...; In HGP RT ... from T. gond ;; lSG!1umilCllef eta! 1996 ) 
ReSidues 116-1 I a are mlS$lng In Loop II (oftan ,e!ened to as the I\e.,ble ct eataly\ll: loop) 
onclud,n; set I 11 and lyf118, whICh overla1 the nJcieolde on the i'3nSlhOn stale 
structure and has a trans peptide bond With leu78 (see later for slgnlflcance)_ 
loop II is pOlf'ltJng out of the acllve Site and. In the subunit shown, pall of the 
loop was disordered including the conserved ser-tyr motif and IS omined from 
the structure 
loop III IS somewhat disordered Wl th the thr!S! and thrl54 side chains not in 
an opllmal position for interacl!ng with the S phosphate of PRPP In Loop III' 
arg182 IS pulled well back away from asplS0 and asplg7 loop IV has 
asp206 and arg2 12 turned in and POiSed to bind Mg2' and the pyrophosphate 
mOIety of PRPP 
The Hood doma'n IS angled back and trplgg (Hood domain) and ile148 (Core 
domain) are 14 S A apart. These reSidues Wlil eventualty clamp the pUrine 
ring between them and in thiS structure are too far apart for thiS purpose The 
crystal structures show Mg2' bound to glu146 and asp1 47 The crystals were 
grown In 200 mM MgCll and its presence may be art lfactual We Will see 
belOW that this IS not Ihe true position 01 either of the two Mg1' The Side 
chains of Ihe two aCidic residues are pOinting upwards In a posil ion sui table 
to bind the nbose hydro~yls of PRPP 
Thus. in general. the apoenzyme IS set up 10 bind Ihe pyrophosphate and 
"bose mOIetIeS 01 PRPP Loop III needs to be adjusted and the Hood domain 
IS too far away to bind purine Blfldlflg of Mg2PRPP will bring Loops I. 111. and 
IV together. bul SI,1I leaVIng the Hood domain well back 10 allow the entry of 
the punne The ternary comple~ Wllh PRPP and an analogue 01 guamne. 9-
deazaguanll'le, IS shown In FI9ure 1 11 II represents a comptex just before 
the tranSi tion state and the active site is closed, In particular Loop 11, With 
tyrtt8, is folded over the catalytic site and Loop In has been drawn In by 
arg182 and IS clamped by aspl50 and asp197 (obscured In Figure 1 11) 
Delel/on of a large section of Loop II. includmg the tyrosme, slows enzyme 
turnover 2-3 orders of magOilude (lee et ai , 2001 ) The ternary structure 
shows that PRPP IS bound directly to protem through at least 6 hydrogen 
bonds The peptide bond between ser78 and lys79 IS now in a stramed cis 
conformation. whICh allows the maIO cham amide to Interact with the 
pyrophosphate mOiety. The ribose ring is contorted and adopts a C2 -endo 
pucker. ra ther than the usua l C3'-endo 10 solution Two Mgl • are present on 
either Side of the pyrophosphate moiety and only one is In direct contact With 
the protein (at asp206) This laner Mg2• IS also coordinated to 3 water 
molecules and 2 oxygens of the pyrophosphate of PRPP The other IS 
coordinated to 2 water molecules, the 2 hydroxyts of the ribose, and 2 
oxygens atoms of the pyrophosphate, in particular. one that is directly hnked 
to the SCissile DOnd to C 1 01 the noose. The purine Is lOdged between try 199 
and ilet48 and bonded to the main chain carbonyl of asp206 and side chain 
of lys178 AsplS0 is thought to be Ihe catalytic aCldlbase that accepts a 
proton from N7 of the purme In order to increase the nucleophiliclty of N9 (Xu 
and Grubmeyer, 1998). Closure of Loop II has brought tyrlt8 over the nbose 
moiety and the oxygen Inleracts with the 5 phosphate 9rOUP It IS likely that 
foldmg of thIS loop over the actIVe site is the las\ event before catalysis The 
crystal structure of the ternary bl-product comple~ shows the Situation 
Immediately afler the transItion state (Heroux el al 1999b) Here Loop II and 
Loop III ' were not discerned, pomtmg to thelf fleXibility and open slale. Hence 




F.g""e , , 1 Active site 'Hidues In HGPRT ",,. . .. ,, __ from T. gondii (H eroo~ "01 
2000) Tile PRPP ana oeazaguamne ille 11\ ye110w and the Mg" .... green Bon~. 01 3 A Of 
leSS ",a SI\Qw1I on green Jones 
followed by Loops I and IV allowmg the 61(1\ of PPI These events would 
permit the releCise 01 loop III and the Hood domain In order for the nucleollde 
to diSSOCiate 
ASide from the loop changes there are 3 (the las\ being only a strong 
possibil ity) other significant changes In this bi-produc\ comple)(. The first IS 
tha t the peptide bond between ser78 and lys79, which is still In CIS 
configuration, must loosen the InleractlOn of the amide with the 
pyrophosphate and probably aKl Its release. The second IS that the 
coordinatoon of Mg~· with the 2 nbose hydrOJCYls is broken and replaced by 
water molecules Thirdly, and pOSSibly related to the laUer, the nbose of the 
nucleotide configuration has relaxed back to the normal C2'-exo form Thus 
the Interaction of the protein with the products is less than that seen with the 
bl-substrate complex, the one product is in a lower energy state and the Mg2• 
link to the ribose has been severed , favounng spontaneous and separate 
diSSOCIatIOn of first the PPi and then the nucleotide 
Hood domain 
Fogure , 12 Active sill residues of HGPAT~ ... from T, gondi/ IHero\,tx el al 1999,,) 
GMP IS shown on yellow 
.n 
The departure of Mgz, and PPi promotes relatively large structural changes 
involving loops I, tn ', and IV (Figure 1 12, Herou~ el ai , 1999a) Loop!! 
remains outside of the catalytic site. In Loop t , the side chain of tys79 moves 
Into the space previously occupied by PPI This movement bnngs a positive 
charge alongside aspl47. and may facilitate the bendlllg of Ihls side chain 
downwards releasing the Interacllon With the 02' of the nbose loop 111' has 
moved back and arg182 is no longer associated With asp iSO and aspl97 
Loop IV has also receded and residues asp 206 and arg212 are turned out 01 
Ihe calalytlc Slle 
In order lor GMP 10 be released, these changes must permit the Hood domain 
to II!t backwards opening the trp and lie clamp on the purine ring and loosen 
the gnp Loop III has on the 5' phosphate Departure 01 nucleotide must 
promote further changes thai bring the protein back to the apoenzyme seen In 
Figure 1.' 0 10 complete the cycle 
1.4.3 HGXPRT from p, falciparum 
Malana HGXPRT consists of 231 aminO acids per subunit With a calculated 
MW of 26 232 Oa Analytical ultracentrifugallon suggests thai the enzyme is 
tetramenc and dlmeric at low and high ionic strength respectively (Keough 6/ 
al (999) II IS only active at low ionic strength whICh contrasts with the 
human enzyme, which IS Insensillve to IOniC strength The malaria HGXPRT 
IS 44 % homologous to that of the human HGPRT enzyme (Shl ef al. 1999b) 
The former, like most protozoan parasite HGPRTs has broader substrate 
specifICity compared with the human and IS able to use ~anthlne , as well as 
hypoxanthine and guanine (Queen at al 1988) 
Malana HGXPRT IS unstable and punflC3t1on directly Irom parasites yields 
enzyme with very low activity (Queen et ai , 1988) The enzyme has been 
successfully expressed recomblnantiy In E coli (Shahabuddln and Sca ife, 
1990 Keou9h at ai , 1998: Keough et a/ 1999) The specific activity of the 
pure enzyme was 3 . 8 IJmoles GMPfmlnfmg 01 protein With guanine as 
substrate at pH 8 5, 25 ce, whICh is several times less than that of the human 
equIValent enzyme The enzyme was stabilized by hypoxanthine and PRPP 
and Inactive protein could be reac\lvated by these substrates 
It has been difficult 10 obtain crystals 01 the enzyme due most probably to ItS 
Instability Only one crystal structure eXists and It was obtained with the 
tranSition state mimiC, ImmucilllnHP (Figure 1 7). PPI, and Mg~' (Shl el al 
1999b) The protein crystallises as a letramer wllh 3 ufllque Interfaces Two 
of them are shown Figure 1 13 The figure also indicates how Ihe active sites 
are largely bul not enurely (see extreme left hand subuflll) , away from the 
Interfaces Each subunit of the malana HGXPRT is folded Into a Single 
domain structure consisting of 6 u·hehces and 11 !l,stranded sheet In each 
subunit 01 the malaria enzyme, residues 46 • 149 make up Ihe core region 
while reSidues 1 . 46 and 195·231 form a hood region, The protein fold, 
shown In Figure 1 14, IS very slfTlilar to what we have seen for T gondll 
(compare With Figure 1 9) 
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Figure ' 13 The tour subunits of HGXPRT from p , fale iparum Immucill,nHP. p p, imd 
Mg" afe shown In ~ellow orange and green respect,vely IShl 1.'1 al 1999b) 
l oop PI" 
F.gure 1 14 Protein l o lel o f HGXPRT from p, Falciparum The core sheet 1$ shown ,n IIgl11 
green and lhe 3 ma'o helices Ul dark green The aclllle s>,e contains Imm..collinHP (Sld; 
form) pp, I$t,ck form) and 2 Mg" (yellow balls) Stru cture from Sill e/ 81, 19991:> 
As before the hood IS made up of amino acids that are located on the N- and 
c- termini of Ihe polypeptide The core sheet contains an e. tra p-strand 
because Loop II is folded over the catalytic site 
The crystal structure of malarial HGXPRT In the tranSllion state adds to our 
understanding of the chernlcallnterconverslOn (Figure 1.15). 
Fogu.e 1 1S A~l lve site of HGXPRT from P. '"iclpa .. ,m In Ihe I ",",ilion '"11 with 
bound Immu~llhnH" (Ilghlgr .. n). PPi (o",nge). and 2 Mg" (gteen) TM i)OnOS Involve<! 
Hydrogen bonds 10 me 
subslfatelllanalog...et: a-e s~own In OI"ange and those cOOfdlnallllQ the two MQ'- are WI green 
Structu-e from Shl el ill 199911 
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Firstly, the substrate mimic, with oxacarbenium ion character and distorted 
iminoribitol ring, binds slowly but extremely tightly suggesting that these 
features of the mimic are found in the transition state (U et al., 1999). We 
have seen before in the bi-substrate complex from T. gondii how one Mg2+ is 
coordinated to the ribose hydroxyls, evidently withdrawing electrons from the 
furanose ring. Further, the latter was distorted to favour carbenium ion 
formation (3-exo to 3-endo). The 05' was strained to interact with the 04' 
oxygen. These features are retained in the transition state structure, but in 
addition tyr116 is flattened over the N4', which may provide additional 
stabilization through cation-aromatic interactions. 
Now we see a more extensive hydrogen-bonding network anchoring the 
substrates compared with the bi-substrate ternary complex. In particular, 
arg210 ligates PPi and additional bonding is seen around the 5' phosphate. 
Thus, in the adual readion, the purine, ribose hydroxyls, and 5' phosphate 
moieties and the PPi are tightly held in position. Within these constraints it 
may be possible that the furanose ring is twisted further to allow the C l' atom 
to move in the required direction to aid the readion. 
An NMR study of purine nucleoside phosphorylase from Mycobacterium 
tuberculosis and HGPRT from T. (oetis established that the ImmucillinHP 
bound as the neutral N4' form and was protonated in the development of the 
transition state (Sauve et al., 2003). The C1' atom also developed Sp2 
hybridization charader. The phosphoryl groups decreased their pKas (fully 
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ionized), thereby contributing to an enhanced electrostatic stabilization of the 
cationic transition state. 
1.5 Chalcon •• 
Chalcones are compounds that are made of two aromatic rings (generally 
referred to as rings A and B) joined by a propenone linker. (2E)-Chalcone 
shown in Figure 1.16 below is the simplest chalcone. 
o 
(2E)-chalcone 
Figure 1.16 Structure of the simplest chalcone. 
Chalcones are found in many higher plants (for example, Star and Mabry, 
1971; Stevens et al., 2000). They have been demonstrated to have a wide 
range of biological activity including anti-bacterial and anti-fungal (Lin at al., 
2002; Nielsen et al., 2004; Nielsen at al., 2005; Satyanarana and Rao, 1993; 
Jayasinghe, at al. 2004). They have also been shown to have anticancer 
(Satyanarana and Rao, 1993; Shibata, 1994; Ducki at al., 1998; Rao at al., 
2004) as well as anti-inflammatory (Meng at al., 2004) activities. Hydroxylated 
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chalcones inhibit tyrosinase, an enzyme involved in melanin biosynthesis 
(Nerya et al., 2004). Halogenated chalcones bind with high affinity to 
multidrug resistance P-glycoprotein, which is overexpressed in cancer cells 
(Bois et al., 1998). The most potent of these, 2',4',6'-trihydroxy-4-
iodochalcone [also referred to in this thesis as {2E)-3-{4"-iodophenyl)-1-
(2',4',6'-trihydroxyphenyl)prop-2-en-1-one], is our lead compound for 
accelerating the catalytic turnover of malarial HGXPRT (see below). 
The first chalcone to be reported to have antiprotozoan activity is licochalcone 
A (Chen et ai, 1994). Licochalcone A (see Figure 1.17 below) was isolated 
from Chinese licorice roots and was demonstrated to have antimalarial activity 
against P. falciparum and P. yoelii. Later it was shown to inhibit parasite 
respiratory chain of Leishmania major and L. donovani, and seemed to target 
fumarate reductase (Chen et al., 2001). Li et al., (1995) found that 1-(2,5-
dichlorophenyl)-3-(4-quinolinyl)-2-propen-1-one (Figure 1.17) out of a library 
of chalcones, has high activity against chloroquine resistant and sensitive 
strains of P. falciparum. This chalcone was proposed to interact with a 
cysteine protease. 2,4-dimethoxy-4'butoxychalcone (Figure 1.17) has potent 
activity against human malaria parasite P. falciparum in vitro and murine 
malaria parasites P. berghei and P. yoe/ii in vivo (Chen et al., 1997). The 
target enzyme is unknown. Alkoxylated and hydroxylated chalcones have 
been reported to have antiplasmodial activities, and ring B was the more 
critical one, and size and hydrophobicity of the substituents were correlated 
with potency (Liu et al., 2001). These chalcones have since been 
demonstrated to target New Permeability Pathways, because they in hibit 
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sorbitol-induced lysis of parasitized red blood cells (Go et al., 2004, see 
section 1.3.1). Methoxy or dimethoxy substituents in ring B were important 
determinants for activity. Substituting ring A or ring B with ferrocene, a 
grouping with antimalarial activity for unclear reasons, did not destroy, but 
could not augment the antimalarial effects (WU et al., 2002). 
Some quinolinyl chalcones were synthesized as possible falcipain inhibitors 
and antimalarials, but there was no correlation between the two activities and 
the target enzyme appears not to be the protease (Dominguez et al., 2001). 
Natural product prenylated chalcones also exhibit antimalarial activity 
(Narender et al., 2005). 
OH 




Figure 1.17 Structures of chalcon .. with anti-rnalarial activity (Chen st a/., 1994; Li st a/,., 
1995; Chen st a/., 1997). 
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Besides there being a large number of natural chalcones, chemists find them 
useful because they are readily synthesized and substituents on the phenyl 
rings can result in a large diversity of compounds. This facilitates 
structure/activity relationships with a target protein. 
1.6 Overview of the chemistry involved in the synthesis of 
chalcones 
1.6.1 Claisen-Schmidt reaction 
The key organic chemistry reaction used in this PhD project is the Claisen-
Schmidt reaction also referred to as mixed aldol condensation reaction. This 
reaction is one in which an aldehyde and a ketone are joined together to form 
an a,l3-unsaturated compound. Claisen-Schmidt reactions are generally 
performed in polar solvents like methanol or ethanol in the presence of an 
alkaline catalyst such as NaOH or KOH. Alternative catalysts for this reaction 
have been developed (see Go et al., 2005 for a review). For instance, a solid 
catalyst prepared by adding sodium nitrate to natural phosphate at 900°C can 
be used in the synthesis of chalcones. Other catalysts that can be used 
include calcium hydrotalcites. 
Although chalcones can be synthesized at low (25°C) or slightly elevated (60 
- 70°C) temperature, other methods that employ different forms of energy like 
ultrasound or microwave, have been employed. 
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As mentioned earlier, Claisen-Schmidt reactions are generally base catalysed 















Figure 1.18 Mechanism of base (OHl catalysed Clalsen-Schmidt condensation (adapted 
from http://www.cem.msu.edul-reuschNirtuaITextlaldket2.htm). 
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Scheme 1.19 Mechanism of acid (H+) catalysed Clalsen-8chmidt condensation reaction 
(adapted from http://www.cem.msu.edu/ ..... reuschNirtuaITextlaldket2.htm). 
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also be used to catalyse these reactions. In both cases the ketone reacts with 
either OH- or H30+ to form a reactive ionic species that fuses with an 
aldehyde. The resultant product of the fusion undergoes elimination (E1cB) to 
give the final Claisen-Schmidt product. The catalyst (OH-, or H30+) is also 
regenerated. The types of substrates involved usually determine the specific 
reaction conditions for any given Claisen-Schmidt reaction. While a weak 
base (for base catalysed reactions) such as Ba(OH)2 may be adequate for the 
reaction to proceed, a strong one maybe necessary in another. In general, 
when a base is too strong, a Cannizzaro reaction becomes competitive. A 
Cannizzaro reaction is one in which a benzaldehyde is reduced to a primary 
alcohol. 
1.6.2 Target compounds (chalcones) for this project 
The chalcones (or general class of) targeted for synthesis in order to achieve 
the second aim of the project (see section section 1.7) are shown in Figure 
1.20. Type A and B were synthesized directly from commercially available 
starting materials (appropriately substituted acetophenones and 
benzaldehydes). As such only the Claisen-Schmidt reaction was needed to 
synthesize these target chalcones. Figure 1.21 shows a retrosynthetic 
scheme that was followed to obtain these compounds. Type C required an 
acetophenone that could not be obtained from commercial sources. Figure 
1.22 shows a retrosynthetic scheme followed in order to synthesize this 
particular chalcone. As can be seen, this chalcone required an acetophenone 
that is not commercially available. It had to be synthesized in a number of 
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steps (1 S\ Reimer-Tiemann, 2nd, Grignard, and 3rd, oxidation reactions, see 
section 1.6.2.1 for details) from 3,5-dichlorophenol. 
A B 
x .. I at posItlon 2, 3, or 4 
c o 
HO 
Y :II a halogen at posItJon 2, 3, or 4 
Figure 1.20 Chalcones (or class of chalcones) targeted for synthesis. 
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Figure 1.22 Retrosynthetlc scheme for target compound type C. 
1.6.2.1 Riemer -Tiemann reaction 
This reaction is used to add a carbon atom to a phenol moiety. The C-atom 
(oxidatively added) is obtained from chloroform under basic conditions. The 
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specific protocol that utilises the Reimer-Tiemann reaction employed in this 
project is that developed by Knuutinen and Kolemainen (1983). Figure 1.23 






Add chloroform to a 






Figure 1.23 Reimer·Tlemann oxidative addition of a C-atom to 3,5-dlchlorophenol 
(Knuutinen and Kolehmainen, 1983). 
The major product in this reaction is one in which the C-atom is oxidatively 
added to the para position relative to the hydroxyl group. Figure 1.24 shows a 
proposed mechanism by which the C-atom is oxidatively added to 3,5-
dichlorophenol. An electron deficient carbene is generated from chloroform in 
the alkaline (OH-) solvent. The OH- ion also abstracts a proton from the 
hydroxyl group of 3,5-dichlorophenol to generate a phenoxide species. This 
ionic species then reacts with the electron-deficient carbene to generate an 
intermediate that rearranges (with the participation of water) to form an 
aldehyde. 
CI~CI 




































Figure 1.24 Reaction mechanlam for the Reimer.Tiemann reaction (adapted from 
http://clem.mscd.edul-wiederm/oc2pptlaminesphenols.ppt). 
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A major diadvantage of this reaction is that yields are poor. Typical yields are 
in the range of 5 - 15 % (Knuutinen and Kolehmainen, 1983). This becomes a 
significant drawback when large quantities of product are required such as 
those needed in multi-step reactions where this is a step employed in the 
initial stage. An alternative method for oxidative addition of carbon units is one 
developed by von Hirscheydt and Voss (2004). This is claimed to be a better 
product yielding reaction than the Reimer-Tiemann reaction. Figure 1.25 
highlights the main features of the improved method for addition of C-atoms to 
dichlorinated phenyl (or phenolic) compounds. Unfortunately. this method was 
only published towards the end of 2004 when we were winding up the 













1. n-BuU, ·70 °c 
2. DMF, THF, -65 0C 
3. Deprotect CI 
n= 0,1 
Figure 1.25 Oxidative addition of a C-atom to phenyl group (taken directly from von 
Hlrscheydt and Voss, 2004). 
1.6.2.2 Grignard reaction 
Grignard reactions are employed in instances were a nucleophilic C-unit (alkyl 
or aryl) is to be added to a carbonyl C-atom of an aldehyde (or ketone). Victor 
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Grignard developed this reaction in 1898. In general, an aldehyde is dissolved 
in cold THF at (- 20°C or below) in the complete absence of water and 
oxygen. A Grignard reagent (an organomagnesium halide such as 
methylmagnesium bromide) is then slowly added to the reaction mixture. The 
reaction is quenched with the addition of either acid or saturated ammonium 
chloride. The acid (or ammonium chloride) hydrolyses the O-Mg bond in the 
R-O-Mg-X intermediate (where R is an alkyl or aryl group and X is a halide). 
Figure 1.26 below shows the mechanistic details of the reaction between an 
aldehyde and a Grignard reagent (methylmagnesium bromide). If the 
aldehyde (or ketone) has a -OH or -SH group, excess Grignard reagent must 
be added to the reaction mix because Grignard reagents are known to react 
with such chemical entities. 
.. 
W (acid or saturated 
ammonium chloride) 
R • alkyl or aryl group 
+ MgBrCl 
Figure 1.26 Mechanism of a Grlgnarel reaction (adapted from http://www.organic-
chemistry.orglnamedreactions/grignard-reaction.shtm) 
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Grignard reagents may be synthesized on demand if they are not available 
from commercial sources. Figure 1.27 below shows an outline for the 
synthesis of Grignard reagents. It should be noted here that organolithiums 
(R-Li, where R is an alkyl or aryl group) could be used if a particular Grignard 





R • H, alkyl or aryl group 
Figure 1.27 Preparation of a Grignard reagent such as methylmagnesium bromide. 
1.6.2.3 Oxidation of secondary alcohols 
Oxidation of a primary alcohol yields an aldehyde while a secondary alcohol 
leads to formation of a ketone. Tertiary alcohols do not undergo any form of 
oxidation. Aldehydes are prone to further oxidation (yielding carboxylic acids). 
Oxidation of alcohols can be achieved by use of a wide range of reagents. 
These reagents may be placed into two broad categories, aqueous and 
anhydrous oxidants. Aqueous oxidants include chromic acid, permanganate, 
chromate and dichromate salts while pyridinium dichromate (POe) and 
pyridinium chlorochromate (pee) are examples of anhydrous oxidants. poe 
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Pyridinium dichromate (POC) 







pyridinium chlorochromate (PCC) 
Choice of oxidant depends on the type of alcohol to be oxidized. Cost and 
availability are other factors to be considered when choosing an oxidant for a 
particular alcohol. The alcohol fonned from the Grignard reaction in our case 
(see Results) was not water-soluble hence choice of oxidant was between 
POC and PCC. As the alcohol generated in the Grignard reaction was a 
secondary alcohol, the expected and desired oxidation product was a ketone. 
POC was already available in our laboratory and has been used with a lot of 
success, hence it was the choice as the oxidant for our alcohol. 
Sodium hypochlorite (NaOCI) in acetic acid is another oxidizing agent that 
may be used in the conversion of alcohols to ketones (Stevens et a/., 1980). 
This reagent has several key advantages including speed, high yields and 
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environmentally more friendly waste products than those associated with 
manganese and chromium reagents (Stevens et al" 1980). 
1.6.2.5 Protection of hydroxyl groups 
Target compounds D (Figure 1.10) followed a retrosynthetic scheme shown in 
Figure 1.29. For the synthesis of these chalcones containing three hydroxyl (-
HO 
x > 
x • IlIIIogIIt It MY of 2, S, or 4 position. In ring B 
Deproteclion 




Figure 1.29 Retrosynthetlc scheme for the synthesis of chalcones (type D) containing 
trlhydroxyl groups in ring A. 
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OH) groups in ring A at positions 2',4',6'- of the phenyl ring, it is necessary to 
mask at least two of the three -OH groups. This is done in order to increase 
the yield of the final chalcones obtained (Bois et a/., 1999). Protection renders 
the hydroxyl (or any reactive) group in a molecule temporarily inactive 
(Greene and Wuts, 1999). There are several protecting groups that can be 
used in masking hydroxyl groups (see Greene and Wuts, 1999 for a review). 
Perhaps one of the most common chemical entities is a methyl group. 
Hydroxyl groups are converted to methyl ethers. lVIethyl ethers are quite easily 
formed by reacting the hydroxyl-containing compound with methyl iodide in 
the presence of sodium hydride in OCIVI or THF. They may be removed by 
use of iodomethylsilane in quinoline. lVIethoxymethyl (IVIOIVl), methylthiomethyl 
(IVITIVI) , benzyloxymethyl (BOIVI), tetrahydropyranyl (THP), ethoxyethyl (EE), 
benzyl (R-Obn), t-butyldimethylsilyl (TBOIVIS), and ethoxymethyl (IVIEIVIE) 
ethers are a few examples of an almost endless list of -OH protecting groups 
that can be employed. This project employed the IVIEIVI 
(methoxyethoxylmethoxyl) group to successfully diprotect 2',4',6'-
trihydroxyacetophenone. IVIEIVI ethers are generally stable in base and mild 
acid conditions. Stability in base is particularly important as the formation of 
chalcones was done under basic conditions. IVIEIVI protection may be carried 
out in a solution of the hydroxylated substrate in the presence of 
methoxyethoxymethyl chloride, sodium hydride and THF. Figure 1.30 shows a 
proposed mechanism for the formation of a IVIEIVI ether via the reaction of 
IVIEIVI-CI with a hydroxylated compound. Perhaps a key feature of this reaction 
mechanism is the formation of a reactive oxacarbenium (also known as 
oxocarbenium) ion. The by-product of this step is HCI that is mopped up by a 
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base (usually KaC03). The oxacarbenium ion is a good electrophile that is 
readily attacked by the alcohol to form the desired protected alcohol. 
Removal of the MEM group can be achieved by the use of Lewis acids such 
as ZnBr2, and TiCI4. It can also be achieved by refluxing in diethyl ether 
























Figure 1.30 Probable mechanism for the protection and de-protection of hydroxylatad 
compound with MEM-chloride. 
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1.7 Rationale and aims of the pre.ent .tudy 
This laboratory (PhD thesis, Phehane, 2002) had found that 4"-I-chalcone is a 
specific accelerator of catalytic turnover of malaria HGXPRT (see chemical 
structures in Figure 1.31). This compound had no effect on human or T. gondii 
enzymes. In contrast to the latter two recombinant proteins, it was also found 
that the isolated malarial enzyme was partially active, if stabilized by PRPP 
during cell lysis, and could be further activated by substrates following 
isolation. During enzyme assay at low protein concentrations, the protein 
inactivated within a few minutes. 
The proteins were expressed in E. coli using a pET system that employed a 
histidine tail (his-tag) on the N-terminal end. Phehane (2002) suggested that 
the instability of the malaria enzyme might be attributed, in part, to the 
presence of the his-tag. 
HO 
...... -Chalcon. 
Figure 1.31 Chemicalatructure of 4"·I-chalcone (Phehane, 2002). 
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AIM 1. The first objective of this project was to clone, express and develop a 
purification procedure for the malaria HGXPRT without a his-tag. 
In the previous work, the accelerating chalcone was found by screening a 
library of 38 flavonoids and chalcones (see de Wet at al., 2001 for list). None 
of the others showed any inhibitory or accelerating effects, including 4"_F_ 
chalcone and 4"-OH-chalcone, suggesting rather specific requirements for 
binding and activation. 
As far as we are aware, this is the first time that an accelerator of catalytic 
turnover has been found for any of the PRT family. It could provide inSights 
into the limiting reaction during catalysis of the malarial enzyme and may 
reveal an effector site that may be exploited for drug targeting. 
Aim 2. The second objective was to synthesise a number of related 
chalcones for structure/activity relationship studies. 
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Chapter 2 MATERIALS AND METHODS 
2.1 Materials 
E. coli XL 1 blue cells (purchased from Stratagene) were a gift from Prof. Eric 
H. Harley in the Department of Chemical Pathology, University of Cape Town, 
Faculty of Medicine, while competent E. coli BL21 (DE3)pLysS cells also 'from 
Stratagene, were kindly provided by Associate Prof. Daan Steenkamp also of 
the same Department. Bacto-agar and agarose were purchased from B & M 
Scientific, while Tryptone powder and Yeast extract were from Merck. 
Ampicillin, and OTT were purchased from Boerhinger Mannheim GmbH. 
Lysozyme, PIPES, PPi, water soluble reactive dyes (Reactive Red 120 and 
Reactive Blue 2), agarose bound Reactive Red 120, IPTG, RNase, PRPP, 
PMSF, dialysis tubing, and silica were obtained from Sigma. Recombinant 
pET-15b containing P. fa/ciparum HGXPRT cDNA was obtained as a gift 'from 
Drs. D. Borhani and G. Vasanthakumar of Southern Research Institute (SRI) 
in Birmingham, Alabama (USA), while pET-17b was also a gift from Prof. 
David Pugh of the University of Western Cape, South Africa. 50S was 
purchased from Bio-Rad. Restriction enzyme kits [Nde I and Bam HI along 
with their buffers and acetylated BSA] , lambda DNA and a 1 kb DNA ladder 
were purchased from Promega. The QIAEX II Agarose Gel extraction kit (from 
Qiagen), and T4 DNA ligation kit (from USB Corporation) were kindly provided 
by Dr. Jeanne Rousseau of our Department while Fast-LinkTM DNA ligation Kit 
was purchased from Epicentre Technologies. Protein 50S-PAGE standards 
were bought from Pharmacia. DNasel was bought from Roche Molecular 
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Biochemicals and ~-mercaptoethanol from Riedel-De Haenag (Seelze-
Hannover). DE52 was purchased from Whatman, while Centricon and Sep-
Pak cartridges were obtained from Millipore Corporation. All the other 
reagents were either analytical or biochemical grade. 
2.2 Methods in cloning, expression, purification and activation 
The gene for malaria HGXPRT was obtained as an insert in pET-15b (with 
his-tag) and needed to be placed in pET-17b (without his-tag). The sequence 
of the gene in pET-15b was thoroughly checked and shown to be correct 
(Phehane, 2002). To achieve the insert transfer, both plasmids had to be 
cloned in competent E. coli cells, the gene excised with restriction enzymes 
Nde I and Bam HI, and ligated into similar sites in the other plasmid. 
2.2.1 Preparation of competent E. coli XL 1 blue cells using CaCI2 
E. coli XL 1 blue cells are a mutant strain that is recombination (recA) and 
endonuclease (endA1) deficient. Thus cloned DNA is not cleaved. 
Furthermore, the quality of the plasmid is improved because being 
endonuclease deficient ensures insert stability (Stratagene Instruction 
Manual, 2002). 
Competent E. coli XL 1 blue cells were prepared according to the CaCI2 
method described by Seidman, et al. (1997). XL 1 blue cells (10 J..IL) were 
spread on Luria agar plates (10 gIL tryptone powder, 5 giL Yeast extract, 5 
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gIL NaCI, 1 mM NaOH, 15 gIL agar) without antibiotic and grown overnight at 
37°C. A single colony was then picked and inoculated in sterile 50 mL LB (10 
gIL Tryptone powder, 5 gIL Yeast extract, 5 giL NaCI; pH 7.2 - 7.4) and grown 
overnight at 37°C with shaking set at 250 rpm. This culture (4 mL) was then 
inoculated into LB (400 mL) in a sterile 2-litre flask with shaking set at 250 
rpm. When the OD59Onm of the cell culture had reached 0.4 units, the cells 
were aliquoted into 50 mL pre-chilled sterile polypropylene tubes and 
incubated on ice for 10 min after which the cells were centrifuged at 3 000 
rpm (allowing the centrifuge to decelerate without applying brakes). The pellet 
obtained after discarding the supernatant was then suspended in 10 mL ice-
cold 60 mM CaCI2 solution (containing 15 % (v/v) glycerol and 10 mM PIPES, 
pH 7 and sterilized by autoclaving). The cells were then centrifuged for 5 min 
at 1 000 x g at 4°C. The supernatant was discarded and the cells were re-
suspended in 2 mL ice-cold 60 mM CaCI2 solution, stored in 250 JJL aliquots, 
frozen immediately in liquid nitrogen, and stored at - 80°C. 
2.2.2 Transformation of E. coli XL 1 blue cells with pET -17b and 
pET-16b (containing malaria HGXPRT cDNA) 
Recombinant pET-15b (3 JJL). pET-17b plasmid (3 JJL) [or pUC 18 used for 
checking transformation efficiency] was added to competent XL 1 blue cells 
(50 JJL) in separate eppendorf tubes. The resulting mixtures were then placed 
on ice for 10 min followed by heat-shock at 42°C for 2 min after which the 
tubes were immediately placed back on ice for 2 min to minimize damage to 
IE. coli cells. Sterile 2X TY medium [16 giL Tryptone powder, 10 gIL Yeast 
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Extract, 5 gIL NaCI1 (950 J.lL) without antibiotic was added to each of the 
mixtures and incubated at 37°C for 1 h. The cells were then centrifuged at 
low speed for 1 min and the resulting pellet suspended in residue medium. 
The suspended cells (10 J.lL) were then plated on sterile LB plates 
supplemented with ampicillin (100 J.lg/mL) and incubated at 37°C for 16 h. 
2.2.3 Generation of plasmid preparations (recombinant pET-15b 
and pET-17b with no insert) 
Two methods were tried: 
The Rapid alkaline extraction of plasmid DNA method (with modifications) 
was used to generate plasmid preparations (Birnboim and Doly, 1979). In this 
method, 100 mL sterile LB supplemented with ampicillin (100 J,1g/mL) was 
inoculated with a single colony of E. coli XL 1 blue cells containing plasmid 
DNA (either pET-17b or recombinant pET-15b) and grown overnight at 37°C 
until ODeoonm of between 0.6 and 1.0 units was attained. The cells (4 to 6 mL) 
were then spun at maximum speed for 1 min on a bench centrifuge at room 
temperature. The cell pellet was re-suspended in a sterile solution of 10 % 
glucose, 25 mM Tris/HCI, pH 8, 10 mM EDTA, 10 J,1g/mL DNAse-free RNAse 
A (obtained by boiling for 15 min) and a small amount of lysozyme. The re-
suspended cells were then allowed to stand at room temperature for 5 min. A 
freshly prepared lysis solution (0.2 N NaOH and 1% (w/v) SDS) was then 
added to the re-suspended cells and the resulting solution was mixed 
thoroughly by inverting the tubes several times until the re-suspension was 
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clear after which the tubes were incubated at room temperature for 5 min. 5 M 
potassium acetate, pH 4.8 was then added to the cell lysis mixture to 
precipitate the dodecyl detergent. This mixture was vortexed for 2 s to ensure 
complete mixing. The tubes were placed on ice for 30 min after which they 
were spun for 5 min at maximum speed on a bench centrifuge. The 
supernatant was carefully transferred into fresh tubes and spun again for 5 
min to ensure complete removal of all solids. Plasmid DNA was then 
precipitated with 100 % isopropanol and washed with ice-cold 80 % (v/v) 
ethanol. After spinning, the plasmid DNA pellet was dissolved in 20 J.lL sterile 
deionised water or 10 mM TrislHCI, pH 8 and 1 mM EDT A (TE buffer). The 
DNA was analysed on agarose gel electrophoresis in the presence of 
ethidium bromide and visualised under a UV light. 
Plasmid preparations were also made using an alternative alkaline method 
developed by Brown (1997). In this method, plasmid DNA extraction is done 
using silica powder. In the first step, the cell pellet obtained after 
centrifugation of a cell culture is re-suspended in 50 mM Tris/HCI, pH 8 and 
10 mM EDTA containing SO J.lQ/mL RNase A. The rest of the steps are the 
same as those in the Rapid alkaline plasmid extraction method described 
above, except after the potassium acetate neutralisation step, the supernatant 
is mixed with a silica suspension, incubated on ice for 5 min and then 
centrifuged at maximum speed in a bench centrifuge for 1 min. The 
supernatant is discarded and the pellet washed with a 50 mM NaCl, 10 mM 
TrislHCl, pH 7.S, and 2.5 mM EDTA solution in 50 % (v/v) ethanol. The wash 
solution is then removed by centrifugation at maximum speed for 1 min 
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followed by aspiration of supernatant. The pellet is then re-suspended in TE 
buffer and incubated at 55°C for 2 min. 
2.2.4 Restriction digestion of pET-15b and pET-17b and ligation 
2-4 J.l.L of pET-15b (with insert) or pET-17b (without insert) plasmid 
preparations were digested with 10 U (enzyme units) of each of Bam HI and 
Nde I in presence of the manufacturer's (Promega) 1X Multicore buffer with 2 
J.l.g BSA at 37°C for 16 h. Control digestions were performed with lambda 
DNA. 
The pET-15b and pET-17b digests were electrophoresed on 0.8 % agarose 
gel. The band for the insert and opened pET-17b plasmid were excised and 
the DNA purified by a Qiagen QIAEX II agarose gel extraction kit according to 
the manufacturer's instructions. 
The ligation of the malaria HGXPRT cDNA into pET-17b was carried out using 
the USB Corporation or Fast-LinkTM DNA ligation kits according to the 
manufacturer's instructions. 
The ligation product (recombinant pET-17b) was amplified by transforming 
into E. coli XL 1 blue cells using the same protocol described in section 2.2.2. 
65 
A plasmid prep was carried out as described is section 2.2.3, and the 
presence of the insert verified by restriction digestion and agarose gel 
electrophoresis. 
2.2.5 Transformation of competent E. coli BL21(DE3)pLysS cells 
with pET -17b 
The empty pET-17b plasmid and that containing malaria HGXPRT cDNA 
were transformed into the expression strain E. coli BL21 (DE3)pLysS following 
a procedure described earlier in section 2.2.2. Glycerol stocks of the 
transformed BL21 (DE3)pLysS cells were prepared according to instructions 
given in the pET system manual (Novagen, 2002). 
2.2.6 Induction of protein expression by IPTG 
Two LB plates supplemented with ampicillin (100 Ilg/mL) and chloramphenicol 
(34 Ilg/mL) were streaked with a glycerol stock of BL21 (DE3)LysS that had 
been transformed with recombinant pET-17b and pET-17b without insert. 
These plates were then incubated at 37 °c for 16 h. A colony from each plate 
was inoculated into separate LB media supplemented with ampicillin (100 
Ilg/mL), chloramphenicol (34 Ilg/ml), and 10 mM sodium phosphate. These 
were then incubated at 37 °c until OD600nm 0.4 - 0.6 was attained. At this 
point, IPTG (0.4 mM) was added to the cell cultures to induce recombinant 
protein expression. 
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The expression was monitored by taking 500 J..lL aliquots at 0 min, 30 min, 1 h, 
3 h, and 5 h. The samples were spun at 9 000 rpm for 5 min at room 
temperature to pellet the cells. 50 J..lL water and 50 J..lL 2x solubilization buffer 
(125 mM TrislHCI, pH 6.8, 10 % glycerol, 0.1 mg bromophenol blue, 4 % 
50S, 300 mM ~-mercaptoethanol) was then added to each pellet followed by 
vortexing after which, they were heated at 70°C for 15 min. Each sample (10 
J..lL) was then loaded onto 15 % 50S-PAGE and analysed according to the 
method of Laemmli (1970). 
2.2.7 Cell lysis 
The standard method adopted for lysis of E. coli cells was the following: 
The cell pellet obtained as described in 2.2.6 was placed at - 80°C overnight, 
then thawed, and suspended in 50 mM Tris-CI, pH 8.0, 25 mM NaCI, 2 mM 
EOTA, 1 mM PMSF, and 1 mM OTT, in a volume that was 1110 of the cell 
culture. The viscous cell paste was then treated with ONAse I (20 J..lg/mL) in 
presence of 10 mM MgCI2 for 20 min at room temperature, followed by 
centrifugation at 21 000 x g for 20 min at 4 °c to yield a crude pellet and 
supernatant. 
In preliminary experiments, the effects of added lysozyme, salt, MgCI2, and 
extra freezing and thawing were assessed. 
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2.2.8 HGXPRT purification 
For purification on a small scale, typically 40 mL sodium phosphate buffered 
LB media supplemented with ampicillin (100 /-lg/mL) and chloramphenicol (34 
/-lg/mL) would be inoculated with BL21 (DE3)pLysS containing recombinant 
pET-17b and incubated at 37°C for about 16 h. When ODsoonm 0.4 - 0.6 was 
attained, IPTG (0.4 mM) was added, and the expression of the malaria 
enzyme was conducted at 37°C for 3 h in a shaking incubator (200 rpm). The 
cells were then aliquoted into 50 mL fractions and centrifuged at 8 000 rpm for 
10 min at 4 °c. The pellets obtained were either used immediately or frozen at 
- 80°C and used later. 
2.2.9 Ion exchange chromatography 
The behaviour of the crude supernatant containing malaria HGXPRT on 
cation and anion exchange resins was investigated on a small analytical scale 
through the use of Sep-Pak cartridges. The cartridge was prepared by 
passing through 1 - 2 mL of lysis buffer followed by the supernatant (typically 
4 mL). It was washed with 1 - 2 mL buffer, which was added to the flow-
through, and the retained proteins eluted with 1 mL 1 M NaCI. In some 
experiments, the pH of the applied supernatant was adjusted. 
Using the Sep-Paks, it was established that HGXPRT did not bind to an anion 
exchange resin under the conditions used, but provided significant purification 
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by removing many proteins that did bind, similar to the results obtained by 
Keough at al., 1999. 
Larger-scale anion exchange chromatography was performed on a 2 x 6 em 
column with OE52 resin. The resin was washed with water, placed in the 
column. and 10 mL lysis buffer passed through. The supernatant (100 mL) 
was applied to the column and the flow-through (containing HGXPRT) 
collected by gravity. The column was washed with more lysis buffer, and 
bound proteins (not HGXPRT) eluted with 1 M NaCI. 
2.2.10 Reactive Red 120 chromatography 
Small-scale Reactive Red 120 chromatography was performed with a column 
of 0.5 x 1 em resin. The resin was prepared by washing with water. The 
sample was passed through, followed by 0.5 - 1 mL 50 mM Tris-CI, pH 8 
buffer containing 1 mM of each of on and PMSF, and then 0.5 - 1 mL 50 
mM Tris-CI, pH 8.9, 200 mM NaCI, 1 mM OTT and 1 mM PMSF. HGXPRT 
was eluted with 1 mL aliquots of 50 mM Tris-CI, pH 8.9, 50 mM PPi. 1 mM 
PMSF, and 1 mM OTT. 
Larger-scale experiments (100 mL supernatant) were performed with a 
column of 2 x 15 em resin, and the volumes of the washes and elutions were 
adjusted accordingly. 
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The fractions collected at various stages in the purification were analysed on 
15 % 50S-PAGE according to the method of Laemmli (1970). 
Once the properties of the anion exchange (not binding HGXPRT) and 
Reactive Red 120 (binding HGXPRT) columns had been elucidated, the two 
steps were combined, and the columns placed in tandem, with the anion 
exchange on top of the Reactive Red 120. All procedures were performed 
either on ice or carried out at 4 cc. The supernatant (100 mL) was run through 
both columns overnight by gravity, the columns washed with a small volume 
of lysiS buffer, and separated. The Reactive Red 120 column was washed 
with 50 mL 10 mM sodium phosphate buffer, pH 7.0, 200 mM NaCl, and the 
column developed with 8 mL 50 mM sodium phosphate buffer, pH 7.0, 50 mM 
PPi, 1 mM OTT, and 1 mM PM SF (eluate usually discarded). HGXPRT was 
eluted with a further 15 mL the phosphate/PPi buffer. The eluate was 
dialyzed against 10 mM sodium phosphate buffer, pH 7.0, overnight. The 
sample was then Iyophilised to dryness, dissolved in 1 - 3 mL ice-cold water, 
re-dialyzed, filtered through a 0.45 J.1M filter and frozen at - 80°C. The OE52 
resin was discarded, but the Reactive Red 120 resin was washed with 1 M 
NaCl, and stored. It was washed with water before reusing. 
2.2.11 Activity of malaria HGXPRT enzyme 
Enzyme assays were carried out following the spectrophotometric method 
described by Keough at a/., (1987) on an Agilent 8453 Chemstation 
Spectrophotometer. The assay depends on the difference spectra of base and 
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nucleotide and was performed automatically by the instrument. A typical 
assay was conducted at room temperature (-20°C) in 100 mM Tris-CI, pH 8.5 
(or pH 7.45 for xanthine), 110 mM MgCI2 (or 12 mM MgCI2 for xanthine). 60 
flM purine base (314 flM for xanthine), and 1 mM PRPP. The reaction was 
initiated by the addition of an aliquot of enzyme, generally in the range 5-20 
I-Ig protein/ml, i.e. 1/100 dilution of purified preparation. The increase in 
absorbance was monitored at 245 nm, 257 nm, and 255 nm for the 
conversion of guanine, hypoxanthine and xanthine to their respectively 
nucleotides (at pH 8.5, the difference extinction coefficients [AE] are 5817, 
2283, and 4685 M-1cm-1 respectively while at pH 7.4 the AE used in the 
conversion of xanthine to XMP was 3794 M-1cm-1). The initial rate was 
generally monitored over 15 s, and was calculated automatically by the 
instrument. 
In some experiments the pH, MgCI2, and purine concentrations were varied, 
and the effect of different chalcones was measured. 
2.2.12 Protein assay 
The dye-binding assay of Bio-Rad was performed as described in the 
manufacturer's booklet. 
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2.2.13 Activation of malaria HGXPRT 
It will be seen in the Results section that malaria HGXPRT needed to be 
activated before any activity could be detectable (Keough at al., 1999). The 
general procedure used to activate the enzyme was to add 1 mM PRPP and 
60 J.1M hypoxanthine and incubate on ice or 4 °c for 16 h. Various other 
agents and conditions were tested as described in Results. 
2.3 Chemical Synthesis 
2.3.1 General information 
NMR spectroscopy, Elemental Analysis, and FT-IR spectrophotometry are 
core service facilities in our Chemistry Department, and the Mass 
Spectrometry was a service provided by the Pharmacology Department. 
All compounds synthesized were subjected to 1H NMR (new chalcones were 
subjected to both 1H and 13C) analysis. The NMR analysis was carried out at 
ambient temperature using either Varian Mercury (300 MHz) or Varian Unity 
spectrometer (400 MHz). TMS was used as internal standard. Therefore, 
chemical shifts (8 in ppm) recorded are reported relative to TMS (8 = 0.0 
ppm). 
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A Reicher-Jung thermovar (temperature range 0 - 350°C) apparatus was 
used to detennine melting pOints of the new chalcones synthesized. Since 
cover slips were used, the melting points obtained are uncorrected. 
All the new chalcones synthesized were also subjected to Mass Spectrometric 
analYSis on an API 2000 (from Applied Biosystems) VG micromass 16F 
machine at 70 eV with 4 kV as accelerating voltage. 
Elemental analysiS was also perfonned to establish the purity of the new 
compounds. It was carried out on a Fisons EA 1108 CHNS-O instrument 
Infrared spectra of new compounds were recorded either in solution using 
chloroform on NaCI disks or as compressed solids (KBr pellets) on a Perkin 
Elmer spectrum FT -IR spectrophotometer. 
The numbering system used in this thesis is as shown in Figure 2.4 below. 
2' 2" 
o 
Figure 2.4 Numbering of chalcon ... 




Synthesis of chalcones with varying substitutions in rings 
AandB 
Materials 
Acetophenone, acetonitrile, methoxyethoxylmethyl chloride (MEM-chloride), 
2-hydroxyacetophenone, 4-bromobenzaldehyde, 2-nitroacetophenone, 3,5-
dichorophenol, 3,5-difluorophenol, 1-(2',4',6'-trihydroxyphenyl)ethanone 
monohydrate, 2-iodobenzaldehyde, 3-iodobenzaldehyde, 4-
iodobenzaldehyde, 4-chlorobenzaldehyde, 1,4-dioxane, pyridinium 
dichromate, tetrahydrofuran, methylmagnesium bromide as well as deuterated 
NMR solvents (chloroform-d3, acetonitrile-dB, acetone-dB and 
dimethylsulfoxide-dB) were purchased from Aldrich while 4-hydroxy-3-
nitroacetophenone was purchased from Fluka. They were all used as 
received. Silica gel thin layer chromatography (TLC) plates and silica gel for 
preparative TLC were obtained from Merck while Celite filter gel was 





Synthesis of (2E)-1-(2' ,6'-dichloro-4'-hydroxyphenYI)-3-(4"-
iodophenyl)prop-2 .. n-1-one 
Method 
Synthesis of (2E)-1-(2',6'-dichloro-4'-hydroxyphenyl)-3-(4" -iodophenyl)prop-2-
en-1-one was done in four steps: 




2,6-d ich lor0-4-hyd roxybenzaldehyde 
To a 10 mL water mixture of Na2C03 (18.9 mmol), Ca(OH)2 (23.6 mmol), and 
3,5-dichlorophenol (5.5 mmol), chloroform (4.4 mmol) was added drop-wise. 
The temperature of the mixture was then raised to 70°C at which pOint it was 
refluxed for 2 h. The reaction mixture was cooled to room temperature and the 
pH reduced to 2 with concentrated HCI. The product of the reaction in the 
mixture was then extracted into diethyl ether. The diethyl ether extract was 
then dried by use of anhydrous magnesium sulphate. Excess diethyl ether 
was removed under reduced pressure. The concentrated crude mixture was 
placed on silica gel column chromatography and the product isolated by use 
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of 20 % EtOAc in hexane. The solvent was removed by use of reduced 
pressure and the product dried on a vacuum pump. 
A key 1 H NMR spectroscopic indicator for confirmation of the synthesis of 2,6-
dichloro-4-hydroxybenzyaldehyde is the presence of a singlet resulting from 
the single proton in the region of 9 to 10 ppm due to -CHO. It is a new atom in 
the molecule (absent in the starting material) and so its detection is a positive 
indicator that the reaction has taken place. 
The hydroxyl proton was not detected in the DMSO-d6 NMR solvent used. 
Further confirmation for the synthesis of 2,6-dichloro-4-hydroxybenzyaldehyde 
is in the 13C NMR data, where detection of a carbonyl group at 195 ppm is a 
positive indicator. 
Step 2: Synthesis of 3,5-dichlor04-(1-hydroxyethyl)phenol 
HO 
CI OH 
3,5-dichloro-4-( 1 '-hydroxyethyl)phenol 
2,6-dichloro-4-hydroxybenzaldehyde [0.2 g, (1.05 mmol)] was dissolved in ice-
cold 6 mL anhydrous THF under a stream of nitrogen and cooled to about 0 
°c in an ice-water bath. 0.9 mL (2.70 mmol) of a solution of 3.0 M 
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methylmagnesium bromide in diethyl ether was then added to the aldehyde 
solution drop-wise also under a stream of nitrogen. The resulting mixture was 
then allowed to warm to ambient temperature where upon it was stirred for 2 
h. 1 mL saturated ammonium chloride solution was then added to the reaction 
mixture to quench the reaction. The reaction mix was then extracted into 50 
mL diethyl ether. The extract obtained was washed consecutively with an 
equal volume (50 mL) of saturated ammonium chloride and brine. It was then 
dried with anhydrous magnesium sulphate and concentrated under reduced 
pressure. The concentrated crude product was then purified on a silica gel 
column [10 % (v/v) MeOH in OCM]. The product was analysed on silica gel 
TLC (20 % MeOH in OCM) and the relevant fractions were pooled together 
and the solvent was removed under reduced pressure. The solid product 
obtained was dried on a vacuum pump. 
The detection of protons in the methyl group (doublet that integrates for 3 
protons around 2 ppm) and the proton attached to the C-atom linked to 
secondary alcohol (quartet that integrates for 1 proton at 6 ppm) are positive 
markers for confirmation of synthesis of 3,5-dichloro-4-(1' -hydroxy-
ethyl)phenol. Both these sets of protons are absent in the starting material 
(2,6-dichloro-4-hydroxybenzyaldehyde ). 
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Pyridinium dichromate 1.361 g (3.62 mmol) was suspended in 9 mL 
anhydrous dioxane. To this suspension, 0.24 g (1.166 mmol) 3,5-dichloro-4-
(1'-hydroxy-ethYI)-phenol was added and the reaction mix stirred for 3 days. 
The reaction mix was filtered through Celite and the residue washed with 
OCM. The filtrate was washed with an equal volume of 10 % (v/v) HCI 
followed by another wash with distilled water. After separating the aqueous 
phase from the organic phase (OCM), excess OCM was removed under 
reduced pressure. The concentrated filtrate was then purified on silica gel 
preparative thin layer chromatography using 30 % (v/v) EtOAc in hexane as 
mobile solvent. The product was then extracted from silica gel into 100 % 
EtOAc. EtOAc was removed under reduced pressure and the product dried. 
In 1H NMR, the presence of a singlet at - 3 ppm that integrates for 3 protons 
(-CH3) is the key signal for positive confirmation for the synthesis of 1-(2',6'-
dichloro-4'-hydroxyphenyl)ethanone. This signal is absent in the starting 
material. 
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(2E)-1-(Z ,S'--dichlor0-4'-hydroxyphenyl)-3-(4" -iodophenyl)prop-2-en-1-one 
8M 01 
(2E)-1-(2' ,6' -dichloro-4' -hydroxylphenyl)-3-(4 D -iodophenyl)prop-2 -ene-1-one 
(8M 01) chalcone was synthesized using a method developed by Mukherjee 
et al (2001). This method is a variation of the Claisen-Schmidt method (see 
Chapter 1). Approximately 20 mg (0.098 mmol) of 1-(2,6-dichloro-4-
hydrophenyl)ethanone was dissolved in 1.45 mL absolute ethanol. To this 
sollJtion, 16 mg (0.0836 mmol) Ba(OH)2.H20 was added, followed by 24.7 mg 
(0.107 mmol) 4-iodobenzylaldehyde. The reaction mix was then refluxed for 4 
h (monitored on silica gel TLC using 10 - 30 % (v/v) EtOAc in hexane with and 
without anisaldehyde staining). When the reaction was deemed to be 
complete, the reaction mixture was washed with 3 mL 5 % (v/v) HCI followed 
by extraction into 50 mL neat EtOAc. Excess EtOAc was then removed under 
reduced pressure. Finally, the product was purified on silica oxide prep TLC 
using 15 % (v/v) EtOAc in hexane as mobile solvent. It was then dried. 
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Confirmation for the synthesis of (2E)-1-(2',6'-dichlorophenyl)-3-(4'-
iodophenyl)prop-2-en-1-one, and chalcones in general (this is applicable to all 
chalcones whose synthesis is reported sections 2.3.2.2, 2.3.2.3, and 2.3.2.4), 
is the detedion of two doublets ( in 1H NMR) with large coupling constants. 
These doublets are for two new protons across a trans double bond (also 
new). They generally appear in the region 6 - 9 ppm and the coupling 
constant is the neighbourhood of 15 - 17 MHz. 
As mentioned earlier all new chalcones were subjeded to full charaderization 
and BM 01 being one such chalcone, complete analysis (NMR, IR, Mass 
Spedra, MP, and elemenatal analysis) was performed. 
2.3.2.2 Synthesis of monohydroxylated chalcone (2E)-1-(2'-







The method employed for the synthesis of (2E)-1-(2'-hydroxyphenyl)-3-(4"-
iodophenyl)prop-2-en-1-one (BM 02) is same as that for synthesis of BM 01 
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except potassium hydroxide and methanol were employed instead of barium 
hydroxide and ethanol respectively. 
For spectroscopic indicators for BM 02. please refer to section 2.3.2.1 (as 
described for BM 01). 
2.3.2.3 Synthesis of chalcones containing both a nitro group as 












The method used is as described in 2.3.2.2 above without any modification. 
As this set of chalcones (BM 03, BM 04, and BM 05) is being reported for the 
first time, full characterisation was carried out [same as was done for BM 01). 
For key spectroscopic indicators, please refer to 2.3.2.1 (as described for BM 
01). 




Figure 2.1 2',4',S'·trihydroxylated chalcone (x represents a halogen at any of the 5 
available positions in ring B) 
2.3.2.4.1 Method 
Synthesis of chalcones containing three hydroxyl groups in ring A, that is, 
2',4',6'-positions (see Figure 2.1 above), was carried out in three steps: 
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Step 1 Protection of hydroxyl groups using MEM-CI 
The method employed to protect two of the three -OH groups is that 
developed by Clark at a/. (2004). In this method, 2.06 equivalents of K2C03 
was placed in 10 mL DMF. The mixture was stirred at room temperature for 
30 min at which point 1 equivalent of 2',4',6'-trihydroxyacetophenone was 
added followed by 2.04 equivalents of MEM-CI. The reaction mix was allowed 
to stir at room temperature for 16 h after which water (3x the volume of DMF) 
was added to quench the reaction. The organic portion was then extracted 
into EtOAc. It was washed several times with water, dried and purified on 
silica gel column using 20 % (v/v) EtOAc in hexane. 
"" ~o'-..../o o 
OH 0 
1-(2'-hydroxy-4' ,s' -bis[(2~ethoxyethoxy)methoxy]phenyl)ethanone 
There are 2 key 1 H NMR spectroscopic indicators that may be used to confirm 
the successful synthesis of diMEM protected 2,4,6-trihydroxylacetophenone 
{1-(2' -hydroxy-4'6 'bis[(2-methoxylethoxy)methoxy]phenyl)ethanone}, (see 
structure above), and they are: 
a) disappearance of a broad singlet between 4 and 10 ppm that integrates 
for 2 protons in -OH groups (H-4' and H-6'), and 
b) appearance of a singlet - 6 ppm that integrates for 4 protons (8n-
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Step 2 Synthesis of diMEM-protected chalcones 
Chalcones with varying substitutions in ring B were synthesized following a 
method used by Bois at 8/ (1998). In this method, typically 0.145 mmol of the 
diMEM-protected acetophenone and 0.15 mmol of a halogenated 
benzaldehyde were placed in 30 mL of methanol. 1.2 mL aqueous 50 % (v/v) 
KOH was added and the reaction mix refluxed at 70°C for 2 - 3 h [the 
progress of the reaction was monitored by silica TLC using 50 % (v/v) EtOAc 
in hexane]. When the reaction was deemed to be complete, 20 mL water was 
added, methanol removed under reduced pressure and the organic portion 
extracted into OCM. The OCM was then removed under reduced pressure. 
Step 3 Deprotection of diMEM-protected chalcones 
Approximately 50 mg of crude diMEM-protected chalcones were either 
pu rified on silica gel column using 50 % (v/v) EtOAc in hexane followed by 
acid treatment [30 mL methanol containing 1 % (v/v) Hel in 10 mL Et20] to 
remove the MEM-protecting group or they were simply acid treated and the 
MEM-free chalcone purified on preparative TLC using 50 % (v/v) EtOAc in 
hexane to obtain the final chalcones products (BM 06, BM 07, 8M 08, BM 09 
and BM 10). 
Confirmation of this group of chalcones is done in the same manner as that 
described in section 2.3.2.1 for 8M 01. 
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Chapter 3 RE5Ul T5 
3.0 Molecular biology aspects, protein expression, purification 
and activity determination 
3.1 Molecular cloning 
The objective of this segment of the project was to transfer the malaria 
HGXPRT gene from pET -15b (with his-tag) to pET -17b (without his-tag) and 
incorporate the recombinant plasmid in an expression strain of E. co/i. 
The first step was to increase the quantity of the two plasmids by making 
competent cells, transforming them with the plasmids, and generating plasmid 
preparations. 
3.1.1 Preparation of competent E. coli Xli blue cells and their 
transformation 
Competent E. coli XL 1 blue cells were successfully made using the CaCI2 
method and stored in aliquots at - 80°C. The plasmids were incorporated 
into the competent cells by use of a standard heat shock protocol. The 
transformed E. coli XL 1 blue cells were grown for 1 h in 2x TV medium and 
plated on LB agar plates. The transformation efficiency (using pUC 18) was 
2.1 x 106 colony forming units per J,lg DNA. 
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3. 1.2 Plasmid DNA preparations 
Individual colonies were selected and grown tn LB liqUId medium In 
preliminary e.pellments, difficultIes were experienced in elCtraCling the 
plasmlds, and two methods were tned, standard alkaline lySIS combmed with 
organic sol .... ent (Isopropanol) preCIpitation and alkaline lySIS followed by DNA-
bindmg si lica. A culture of cells was split inlo equal volumes and processed to 
yield the same volume, and equal allquots were analysed by agarose gel 
electrophoresis The results are shown in Figure 3 1. and clearly the rapid 
alkaline method provided superior Yields of both plasmlCls, and was adopted 
Silica method Organic solvent ppt. method 
Fogure 3 1 Comparison of OHA-blndlng silic i \/S orgiOnic solvenl precipitation methods 
fo< plasmid DNA p.e~r'lion PIa"",,,, DNA was ana lys.ea on 08 % &;a.ose QeI aM 
.... sua"se<J Un<leo" VV Ioghl u"'9 e\h:o,um oromoOe 
Control Ndll Sam HI 
Flgurl 3 3 Digntion of ,-,mOda DNA bV Sam HI ind Nde I D.geshon was at 37'C for 2 
h The d,gesis were anal)'Sed on 0 8 '" agarose gel Tile control had no 'esmCl!on enzyme 
Both pET. 17b clnd recombinant pET·15b were capable 01 being digested by 
Nde I and Bam HI. as shown 111 Figure 3.4. Indicating !he presence 01 the 
cleavage sites 
Ndel (A)-. 




Figure 34 Single d lg .. llonl of pET·11b ,nd Ih' recombln.nt pET· 1Sb plasmid DNA 
with Sam HI and Ndl I. file dIQeSIJ were anal ~sed on a B % agaron gel and vlsuabsed 
..,der UV ~nl 
" 
3.1.4 Purifi cation of Insert and cluved pET-17b and their ligation 
The restriction digests 01 pET-17b and recombinant pET-15b were run In a 
thick agarose gel WIth ethKllum bromide and visualised briefly under UV light 
(Fogure 35) The gel bands containing the deaved pET-17b and HGXPRT 
eDNA (msert) from the recombinant pET -15b were eXCised and the DNA 
extracted uSing an extraCtion kit 
L kb O'1A 
""'" 
" 00''', _ 10. 
pET-lIb Recombinant pET-ISh 
Ndel.mel &ai-li (WIth In!oelt) 
""'" 
- --
F>gure 35 Com bined /oIde I ,nd Bem HI relt riction digest ion 01 pET-15b end pET-H b. 
D.gestlOll was earned 0..1.1 37 'c overn1llht wl IIl botn enzymH The bandl correSponding 10 
I~e Insen ,nd cleaved pET-17b we" cui OUI and Ihe DNA ' . Vae!eO 
The extracted DNA was then ligated and transformed Into either XL I Blue or 
BL21(DE3)pLysS cells. The plasmid preparations of selected colontes were 
analysed on 0 8 % agarose gel (Figure 3 6). Lanes 1. 2. 3 and 7 (from XLI 
Blue cell colonies) each had one prominent plasmid DNA band although one 
plasmid (lane 7) was obviously different from the other three Lanes 4 , 5 and 
6 (from BL21(OE3)pLysS cells) showed that one colony had no plasmid, whi le 
the other two had several prominent bands Two of the plasmlds from XL I 
Blue celis (lanes 3 and 7) and one of the BL21 (DE3)pLysS 
Fl\lur, 36 An.tyslS of ptnmid preparations lOll owing 11,,"tlon o f Inn" Into pET .17b. 
TI'Ie 1'II<IlIon ~actJ()tl producls were Ifanslonned ,nto XL1 BUI clli l and BL21(DE3)plYIS 
CeDI and p'asmld DNA ot>ta:ned !'om IN selected coiontu anaiy$ld on 0 B .. &gltfon Till 
tHt lanl .rtowl pET ·17b ""thou! ,",sen lor companson 
90 
(lane 5) were selected for analysIs by restriction digestIOn with Bam HI and 
Ihe results are shown en Figure 3.7 Only lanes Band C showed bands of the 
correct molecu lar size (~4000 bp) and Ihe plasmid prep In lane B was laken 
for further analvsls Figure 3 8 shows Ihat combined digestion WIth 8am HI 




Figure 3 1 Analysis 01 plnmid prep •• auons by S.m HI digestion A 1 _0 DNA iad'Oer IS 
III ~n" A and E wn .... me &m HI 'e$l.;ebOf\ ClIgests ot pl&mod DNA Imm com, .... snown 1'1 
.. nes 3 5. ana 7 01 Fogur. 36 ... ... lwIes B C lind 0 ana the .. I~ cool101 dt~lS 





FIgure 3 8 E~C:)lion of Insert from pE'T.l1b Pla~ld DNA. ootall1ed from coIo!Iy snown In 
lane 3 01 F,gur. 36 witS digested with both Nde t and Bam HI The re51f1Ctooll dIgest lane 
l.oeJIed t end the respecbve COIltroilane IabeHe<1 2 analysed on a 0 8 "110 aga.ese gel 
3.1.5 Transformation of BL21 (OE3)plysS w ith pET·17b 
TransformatIon of BL21 (OE3)plysS WIth pET ·17b and recombinant pET·17b 
was camed out The Iransformallon effiCiency (using pUC 18) attained was 
2 1 .. 10' colony forming units per ~g DNA Glycerol stocks of trans formed 
Bl21 (DE3)pLysS cells were made and stored at· 80 °C 
9' 
3.2 Malaria HGXPRT expression 
3.2. 1 Induc tion ilnd co ntrol by IPTG 
Figure 39 shows the time dependence of expreSSion of a protein of the 
correct molecular size of malaria HGXPRT (26 232 OaltOrls) The protem IS 
present at 30 min following Induction with tPTG al"ld becomes more obVIOUS 
after longer times No such protein IS expressed in the control cells (without 
Insert) 
Cont rol (pET ·17b without inse rt) pET _11 with Insen 
FlOur!! 3 II Time "curse o f exp.e$Sion of malaria HGXPRT in E. coli BL21(CE3)pLysS 
ceUs. Cultures of E col , eel:, contillnlng pET ·17b w"nout Of w,'n ,nsen were glown to optcal 
denSity 01 0 4-0 6 ane then treated W,Ul 0 4 mM IPTG lor lne Ir.dicated lImes The cells were 
analyse<! by 5DS·PAGE WI !n 15 % (IIII/V) i'Crylamide and sUi.ned ""til Commass ll! Blue Tne 
arrowneao on Itle lell IndICates too 30 000 MW marker protein The arrowhead on the right 
points to :he putative HGXPRT protein (MW 26 232 oal:ons) 
FlQure J 10 ShOWS the response of Bl2t(OEJ)plysS cells containing malaria 
HGXPRT gene to the presence of IPTG. As can be seen, the malaria 
HGXPRT enzyme IS produced in boIh the presence and absence of IPTG 
IndICating that Its expressIOn IS nOI tightly controlled by IPTG This IS despite 
the fact that the cells were grown in the presence 01 chloramphenicol, which 
makes thiS strain maintain the pACYC plasmid ThiS plasmid IS meant to 
ensure a tight control of protein expression in thiS strain However, slightly 
more recombinant protein IS produced and host protein expression IS lower In 
the presence of IPTG Ihan in ItS absence, and therefore we conllnued to use 
IPTG In future experiments 
NolPTG With tPTG 
MW 0' '" '" 0' ,.' 
F'9ure 3 10 EHect 01 IPTG on mal.ria p,otein exprflsslon In these exptlnmen1s two 
cutt\Jres we< e grown IJ":~ lhe apl.cal denuy was 0 4-08 1·'8 hi 31 wl'uch sl3ge IPTG 10 4 
mM) was 3dGed 10 the one and Inl cultu,es contInued for 5 h "",1M 311<;1\1015 laken 3\ tne 
.... doc.iled Im'l" and .nalysed by SOS·PAGE The .rro ... ms3d on Ihe lefl Ind,cates the 30 000 
da"on MW ma,~er prole;n and thai on tn. fight .nd.oc.:es the putilliole malaria prolliin 
3.2.2 lri;11 of three methods of lysis of E. coli cells 
Lysis of BL21(DE3)pLysS cells containing malana cDNA had previously been 
successfully achieved in our laboratory by resuspending the cells In lns-CI. 
pH 7 9 and 500 mM NaCI. end digestion with 1 mglml lysozyme for 1 h on ice. 
followed by freeze-thawing repldly with liquid nitrogen and a bath of room 
temperature water (Phehane. 2002) However. we wanted to use ion 
exchange chromatography as the first step m the purification of HGXPRT (see 
below) and needed a buffer With a low salt content. Th iS procedure failed to 
provide adequate lYSIS under these condiliOns Therefore a trial of 3 different 
methods. which are elaborated OfIln the legend to Figure 3 11 . but essentially 
conSisted of (i) a sIngle freeze over a long period and thaw. (ii) lysozyme 
treatment al high MgCI~. or (IIi) lysozyme treatment at low salt. The results In 
Figure 311 show that the lengthier freezmg followed by a thaw m the 
absence of lysozyme provided almost as much HGXPRT In the supernatant 
as the other two procedures In the presence of lysozyme It Will be seen later 
that some purification experiments, especially those on a small scale were 
earned out With lysozyme. but the procedure we finally adopted was the first, 
namely prolonged freezing Without lysozyme. In order not to contaminate the 
preparation With another protein added In large amounts (see Figure 3.11 for 
level). 
It can be seen thaI most of the expressed HGXPRT remams With Ihe pellet 
fraclion, probably In Inclusion bod ies ThiS was Ihe usual reSUlt we obtained. 
but occasionally a beller proportion in the supernatant was achieved (see 
below) The pellet fradron was discarded 
Pvtallve 
30000 Oa HGXPRT 
Lysozyme 
F'gu,e J II Lysis 01 BL21(OEl)pLYIS cells using Ihr.. dill"enl methods 
BL21(OE3)pLysS cetts COnlalnmg mal""a HGXPRT cONA wefe cvr.ured centnluged and Ihe 
peI:er lysed US.ng m'lIe dofle'enl methOds MethOd 1 PeIIeIltozen at - 8O · C for 1 h IoIIowed 
by ' I!-SuspenslOn WI 50 mM Tns-Cr pH 80 25 mM NaC! 1 mM PMSF 2 mM EOTA 1 mM 
OTT (lanes 2 and 3) MelhOd 2 Re-suspens.on 01 pellet .. 100 mM Tns-CI pH 7 4 110 mM 
MgCl, 1 mM PMSF 1 mM lI-mercaptoe!hMOl anc 1 m~mL lysozyme (lanes 4 and 5). 
Me:rlod 3 Re-suspensll)tl ol ~'1et 11'1 50 mM Tr.s-CI pH 80 25 mM NaCl I mM PMSF 2 
mM EOTA. 1 mM on ana 1 mglmL ~ (IaOH 6 and 7) Tile s!J$penSlOn was 
cenUrluged al 21000 x 9 lor 20 m.. T"'- ge!Iet WII$ ,esu~ In !he...me YOlume as the 
suoomatanl and the ..,me ~uffe-r salvi on and bol~ wi!fe 8n8tysa1 by SOS-PAGE wt:/l 
Comm8SS", 81 ..... stain Lanes 2 4 6 are resuspended peI'e!s and 3, 5 7 supem8lams 
.. 
3.3 Purification of Malaria HGXPRT 
VarIOus purification procedures have been tried for the purificallon of non-hlS-
tagged HGPRTs from a vanety of sources Early purification of the human 
enzyme was achlelled WIth ammonium sulfate preCipitation, heat treatment, 
and amon exchange chromatography (Olsen and Milman, 1978) This 
enzyme IS extremely stable and such harsh treatments are not SUitable for 
malaria HGXPRT Laler pUrifications Include ammonium sul fate precipitation 
combined With phenyl Sepharose (hydrophobic interaction) and anion 
exchange chromatography (Eads er ai , 1994) Recombinant malana 
enzyme has been punfled from E coli uSing either Hg-sepharose directly or 
follOWing anton exchange chromatography (Keough el aJ 1999) Another 
group used anton eJfchange chromatography and gelliliral ion (LI et al 1999) 
A peculiarity was that the former study lound thai the malaria enzyme did not 
bind to anion eJfchange reSin, whereas the laller did 
3.3.1 Small scale purification 
3.3.1.1 Ion eJfchilmge chromatography 
We tested the abi lity of the malaria enzyme and all other proteins to bind the 
Ion eJfchange resins on a small scale by using cation and anion eJfchange 
5ep·Pak car1f1dges The results are shown In Figure 3.12 In these 
eJfperiments and some SUbsequently the eJfpressed HGXPRT appeared to 
migrate In 50S·PAGE as fWO bands, for an unknown reason It Wi ll be seen 
Ihal lhe bottom band disappea rs wi th further pUrification In general HGXPRT 
bound poorly to bolh resins at all three pH condlhons, but significant 
pH 6 pH 7 pH . 
MW 1 2 1 2 1 2 
pH 6 pH 7 pH' 
MW 1 2 1 , 1 , 
Figure 3 12 Elle<:1 of pH on binding of protem. In crude .upernIU,nl 10 cal ion (A) and 
IInion (e ) u ehllnge Sep.Pak CIIn,idgltti 2 ml of supernalanl was passec Illrough each 
Sep-Pak after aOJusMg Ihe pH to the requored ~alue In Ihe case 01 the pH 6 • • penment, 10 
mM s()d,ym phosphate was ildoed al wel l Lanes 1 show lhe flow-through fract'oo a~o Lanes 
2 show the ptole,n, eMe<! from IN! Cil i1f":!ge wi ll 1 M N.el '1"111 mit!l" to tile same volume 
AnalySis Dy SOS-PAGE 
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purification was achieved at alkaline pH with the anion exchange resin , 
through contaminating proteins binding wel l, consistent with the results 01 
Keough et ai"~ 1999 
fhe difference between the two reSins IS better demonstrated In ~ Igure J 13, 
where the experiment is performed at pH 8 9 It can be seen that Virtually no 
proteins, HGXPRT and olher protems. bound to the cation e)(change resin, 
whereas with the anion exchange resin the malaria protein is virtually the only 
protein thai does not bind, pro\llding a Significant purification. 
Cation exchange resin Anion exchange .!!'Sin 
Pellet Supernatant Flow th", 1 M wash FIQW th", 1 M wash 
~~~:"":::'::==;;.;;;.-....., 
Fogyr8 313 Comparison 01 protein binding to calion ami an ion aKehange Sep·Pak 
canridges at pH 8.9. A ~ ml E col' lysate was pe lleted (and resuspended to': mil aM tM 
s~P<'rnatanl d,v,ded Into two and passed th ro~gh each Sep-Pak cartridge The proteins 
bound '0 'h" caltrod9~' we..., eluted Wltl> 1 M NaC t wash 10 the .~me votume CqoJ<l l a 'quot. 
of the fractIOns were anatysed by SDS-PAGE The atrowMiJd ,nd lcates putattve HGXPRT 
., 
3.3.1.2 Reactive Red 120 chromatography 
Reactive Red 120-agarose IS commonly used 10 purdy enzymes with 
NAD/NADP cofactors or nucleoslde/llde substrates (e 9 Coli and Murphy, 
1984, Stons and Bhauacharzee. 1967, Bukl et ai , 1987 Nakajln ef 8/ 1989, 
Muro·Pastor and Florencio, 1992. Peeh and Nelson, 1994 Urbatsch el af" 
1994) On this basIs we lested whether it could be used to PUrify malaria 
HGXPRT following an anion exchange Sep-Pak cartridge 
Figure 3 14 shows the purification achieved uSing a small column of Reactive 
Red 120-a9ar05e A comparison of Lanes 4 (sample applied to the column 
after passage through Sep-Pak cartridge) and 6 (sample afterwards), 
demonstrates how HGXPRT (and some other proteins. e 9 lysozyme) is 
retained on the column The column was then washed with buffer containing 
200 mM NaCI (Lane 7). fo llowed by almost selective elution of HGXPRT with 
50 mM PPi The proteins remaining on the colUmn, including lysozyme are 
shown m l ane 10 
We lned to elute HGXPRT With 10 mM IMP or 1 mM PRPP In the presence of 
10 mM MgCI1 Without success 50 mM Pi could elute the protem, bUI not as 
effectIVely as PPI (results not shown) 
HGXPRT could also be eluted with high salt concentrallons, but not 
selecuvely Figure 3 15 shows the effect 01 increasing NaCI concentratIOns 
on protein elullon from the ReactIVe Red 120 column Virtually all proteins 
''''' 
... 
F,gure J 14 PurificatIon 01 miliaria HGXPRT on Reaelive Red 120 column A CU~Uf' 01 40 
ml '''is pe'leted and re-s\lspe!'l(le(l 10 4 ml, cens lysed cen:r,jugea and :ne superna-..lInt 
passed tmougn an anlOl1 '~change sep-Pa~ elr1ndge wnned wnll \ mI D!lffer (comb,nfld 
w,tn flow Hlfough) and tnen tile eombJned sample wu app/oe(l 10 II &mall ~umn of Rflae:Jve 
Red 120 Tne column was wasned WIth I mL buffer cQIl/a,n'l\g 200 mM Natl and tnen 
o,ot.,ns eluted w,th 2 • \ mL al;quots of 50 mM pp, and lnen 1 ml I M NilCl l..lnfl \ 
orote,n marker Lane 2 pe llet fracllOf1 (', -suspenoed to same volume as S"I'l<!matanlj. lane 
3 supernilt.nt tractoon. Line" Stop-Pak flow Inougn Lane 5 Sep-Pak wash Lane 6 
Reac!iva Red 120 IlQw though lane r Reactovo! Red 120 wash Lane 8 and 9 el~uon W11n 
pp, Lilne 10 I M Nae] wasn The white arrowhead snows Ine 30 000 Da ltl)O MIN marker 
prote,n and the h laell one the pos~lon of IN! putal,vo! HGXPRT Anatys,s by 5DS-PAGE 
started being eluted at 300 mM NaGI, but 1 M NaCI was needed to clear the 
column. ThiS mdlcates that the Na~·PP I is effective not merely because Il lS a 
salt. but there must be se~ct!Ve Inleractlon with HGXPRT As a result 01 this 
e)(penmenl. the Reactive Red 120 column was routtnely washed with buffered 
200 mM NaG! pnor to elution WIth PPi (see below) 
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FLgure 315 Step.w,se elution from Reactive Red 120 column by Increasing salt 
concent,"Uon 40 mL of ceU culture "'os pelleted re·suspended to 4 ml, lySed the debriS 
pe lleled (re-suspended ~o the same volume as the supernatant, Lane I), ano the supernatant 
(Lane 2) passed !hrough an anion exchal1ge Sep-Pak cannage (Lane 3) . and then placed on 
a small column 01 React"e Reo 120 The llow through 15 in Lane 4 The column was 
developed w,th 6 x 1 mL soi!!l,ons of increas,ng NaCI COOCenlra!lon (50 mM, Lane S- tOO mM 
Lane 6, 200 mM, Lane 7; 300 mM. Lane S, 500 mM Lane 9 1 M Larle 10) The top 
arrowl1eac InolCates the poSition of the pu:auve HGXPRT, and the lower Orle lysozyme 
Ana!),sls by SOS·PAGE 
Figure 3 16 shows the effect or omitting the anion exchange Sep~Pak 
cartridge and purifying by Reactive Red 120 on its own. Lane 4 (Reactive 
Red 120 flow through) indicates t~at all the HGPXRT bound to the resin and 
allowed several contaminating DrotelnS through Lane 7 shows the 
eHectiveness of the 200 mM wash . PPi elutes the HGXPRT but with 
sign ificant contaminating proteins (Lane 8). On th iS basis it was conSidered 
preferable to use a prior anion e(change chromatography step This also 
helped m preserving the expensive Reactive Red 120 resin for reuse 
1 2 3 4 5 6 7 8 
-
Figure 3 16 Pu, i1icalion of HGXPRT by Reactive Red 120 column ~ Ion e 40 ml of cu lture 
was processed by the stanoard procedure to \'le ld pellet (Lane 2) and supernatant (Lane 3) 
fractIons The supernatam was passed !l1/e<;t I1 througn a sma ll column of Reactive Red 120 
10 g,ve me ftow-tnrougn (Lane 4) Tile col~mn was wasned w,:h buflere<l 200 mM NaGI (Lane 
7). and elu:ed w'ln II/51 50 mM pp, (Lane 8) and then 1 M NaCI (lane 9) Lane 1 conta",. 
markers and Lanes 5 and 6 afe empty The arrownead snows me 30 000 Dallon marker 
prote,n 
3.3.2 Large-sca le pu rification 
The results obtained with sma ll-scale purification (using a Sep-Pak cartridge 
and a small column of Reactive Red 120) suggested thai larger columns of 
anion exchange and Reactive Red 120 reSinS would achieve a large-scale 
purification. The amount of each resin for aiL cultu re was determmed 
empirically The result of a typical experiment using DE52 anion exchange 
resm IS shown m Figure 3 17 The amount of soluble HGXPRT in the 
~upernalanl I ~ approximately 40%, as before A comparison of lanes 3 and 4 
show that vinually all the HGXPRT passed through the column . but with 
s~nlfican t punfica tlOn The protems bound to the column are seen m lane 5, 
and HGXPRT is a small proportJon of these Severa! non-HGXPRT proteins 
came straight Ihrough the ReactIVe Red 120 column (lane 6) E!utlon of 
HGXPRT occurs mainly In lanes 12·17, and IS accompamed by a higher 
molecular weight protein of apprOJ; lmately gO 000 Oallons ThiS protein was 
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Fig".e 3 17 La~.·acil. 1I".;l lc" lon 01 HGXPRT u51ng anion . xchlng. and R.Kt''''' 
Red 120 col"mna 1 L c.u cull".e was pel letea, lhe ce ll s .e$uspendeo .n 100 mL lySIS 
llufIeo' lysed .no e.~lr~ugea to prlXluee pelle! (Lane 2 ,esuspended) ane tupelna!lnl (Lane 
3) The tupefll8lanl w .. paneo ttxougll DE52 and then ReactIVe Reo 120 columns Materral 
OI8""'glllrough lhe DE52 column" In Lane 4 and the prOle.tlS bound (eluted With I M NaCI) 
In Lane 5 The ma: ..... 1 OI8ss,ng 51I'a'lolhl through the Re8Cl .. e Rei;) 120 column 8M InclUd ng 
a ~O ml DOffeled 200 mM Nacl wasil IS In Lane 6 Pro~e,"s were elule(! from the ReactIVe 
Red 120 COlumn wtll 11 . 2 mL PPI (Lanes 1·\8) and fl!'\it:Jy \ M Nacl (L_ III). Equal 
volume a:rquots of the samples we,e appl,ed to the gel The 01"'11,".1 ... alum" Irom whlCl'llhe 
.lquois wo'e e'fI"ed are shown below the gels Molecular weight markers a'a shown ,n 
Lanes I ,n(I \ 1 
'''' 
fragments of trypsin dJgestJon results not shown) , and Identi fied 11 as E co/! 
matlodexlnn phosphorylase a dimenc protein with subunits of 90 000 
Daltons This contaminant 1$ probably the same "persistent phosphatase" 
Identtfied by U at a/" 1999 They reduced Its level by including 1 0 mM 
phosphate In the cell culture growth medium and we adopted this ploy as 
well 
The success of this punficallon system suggested Ihat the protocol could be 
combined 1010 vlnually a single manoeuvre, with tandem anion exchange and 
Reactive Red 120 columns. in which the crude supernatanT is first passed 
through a top amon exchange column straight 1010 a React ive Red , 20 
column underneath, the columns separated, and the HGXPRT eluted from the 
second column With PPi 
The results of sudl a strategy are shown in Figure 3 18 The last lane (9) 
shows the result of the PP. elution, follOWing dialysIS of the eluote. 
concentra tJon by lyophihsat iOn, and dialySIS agam The finol sample wos 
fi ltered through 0 45 11m filter and, as can be seen In lane g, IS approximately 
95% pure The volume was 2 ml and protem concentration 2 5 mglml The 
Yield was therefore 5 mg of protein from 1 l culture. rather Similar to the yield 
of 10 mg from 2 5l culture obtamed by Keough 81 al . 1999. 
Further purification mostly to eliminate the maltodextrin phosphorylose, was 
attempted WIth gel 'iltrallon, and some separallOn was achieved , but the 
differences in moleaJlar weight (Telrameric HGXPRT = 105 000 Dallons, 
IUS 
OlmeriC phosphorylase = 1aO 000 Dattons), meant a long column and some 
loss of HGXPRT (results nol shown) 
, 2 , 
. ;;iii'ii~--~·;;"-'~-'-:·i-":.::'::.~l1 
Vol l mL) 100 ,,. ,. • , 
F>gure 3.18 Large-$cale puril icalion with tandem anion uch;ange and Reactive Red 121) 
columns 1 L cultu.e WIIS p.ocessed as 'n Figu.e 3 17 The anion uChange COlumn was 
placea allectly cnlop of the React., RII<! 121) colu..,n and lMe supernatant (Lane 31 PI!$se(I 
tmaugn by 9,a. ,ty cwem>ghl Tne cotu..,ns were separatll<! and an aliquot was taken of the 
matenallll oetweell tne columns I' e cn~ beell tn.oogh OE52 lor all&11"I'' only Lal\tt "'1 Till! 
COlUMnS wele reJOIne<l ar>O an ;JOOrtlOnal 50 ..,1 of Iysr' buUIlf wn adaed 10 bmlg al l tne 
5UPl!fnatani cOl"lpietel y througn both columns (Lane 6) The columns were Mparattta ana 
!he p<o:eons bound to !he DE52 were eluted w" h 1 M NaCl (Lane 5) . • no lne Reach.e Red 
120 column was washe<l W1th 5(1 mL buffered 200 I"\M NaCl (Lene 7) followed by 6 ml 50 mM 
pp, (Lane 6 no HGPRTI. ~ [\'len 15 ""I (HGXPRT) Tile lar.e< was a'atysea concentrated 
Dy tyoprubzilllOn red!$SOIved Wlrn WiliM d"IySed 119'111 end r \I!(ed tnrougn I) 45 ~m flr.er 
(Lane 9) Equal voIurrIe et.quots were ar\iIlyse<I by SOS-PAGE The .elevan! volumes or the 
OI''9'nal Sa'I'Iptes are Shown below tne 9&i The Ie'! ~ arrownua ,nthCat" the 30 000 
Dalton molecular we.gnt .... rker an<! \lie r'9llt Mnd one tile pu:alIVe HGXPRT 
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3.4 Activi ty of malaria HGXPRT 
The crude supernatant fraction exhibited very low HGXPRT activity Partial or 
comprehensive purification by any of Ihe procedures mentioned above 
resulted In Inactive enzyme Various modifications to the punficatlOn protocol 
were tned including more rapid processing of the cell pellet, and Inclusion of 
PRPP and/or 10% (IItv) glycerol in lysIs buffer These procedures had helped 
to obtain partially active hIS-tagged enzyme (Phehane. 2002) However, 
none of them did so In thIS Instance 
Active HGXPRT could be obtained followmg actIVation by Incubation With 
substrate similar to the findings of Keough 91 al . 1999. and Phehane, 2002 In 
our laboratory We found dlalySlng the non his-tagged HGXPRT against 10 
mM sodium phosphate or MOPS, pH 7 0 and , mM OIT ollernight pnor to 
activatlon an Important step Activation was genera\l~ achIeved b~ IncubatIng 
overmght at 4 "C either with 1 mM PRPP + 10 mM MgCI, or 1 mM PRPP .. 60 
).1M h~poxanthlne, Guanine was also effective, bul Kanthine poorer Without 
the prior dial~sis . or even with , h dia l ~s ls , aClivalion was ineffective It 
appears thai the Just-Isolaled InactJVe protein changes to another inactive but 
actlvatable, form during extended dlal~sls 
The time dependences of activallon with PRPP .. h~poxanthlne at two 
temperatures are shown in Figure 3 19 Activation was complete In 5-10 h 
irrespective of whether II was done at 0 .,c Of room temperature The 
maximum activll~ ranged from 1-6 j.lmol GMP formed1mln/mg of protein for 
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different preparations, which is approximately 10-fold lower than the human 
enzyme, but comparable to what has been found for the malaria one (Keough 
91 a/. , 1999, Phehane, 2002). 
,,------------------------------, 
o o o 
o ~ 
Time (h) 
F'gure 3 19 Actlv:trion of HGXPRT Punfied HGXPRT, WIHCh Ma been d,,,lysed 3g31nSl10 
mM sOd ium phosphate, pH 7 O. artd 1 mM DTT overnight was activated by Ine add l\lOn of 1 
mM PR PP + 60 ~M hypoxanthIne. and the sample either placed at room temperature (dotteo 
line, open circles) or on ice (confinuous Ime, dots) for the limes sh(l'o,O.'n aM then actNl:Y 
measurements maae on aliquets 
The activities at each slep of one particular preparation of HGXPRT and with 
tne three different pUrine substrates are shown in Table 3 1. The reason for 
negligible activity at the Supernatant step may be due to use of the activating 
108 
substrates by other enzymes In the mix. As reported by many others, there IS 
substantial actlYl ty with xanthine as substrate 
Table 3 1 Tha a ~l ivity of malar ia HGXPRT A/;tlVIly of HGXPRT aller Supernatant. Sep.Pak, 
and ReactIVe Red 120 steps Ollefn l~nl act l~al,on was In 50 I'M hypoxanthIne arid 1 mM 
PRPP aller dlaJyslS In 10 mM soc:hum pnospMille buffer pH 6 8, 1 mM DTT, and 1 mM PMSF 
The assay COIIOltions are In Ma'.enals arod Melnods Section 2 2 t 1 
Malaria HGXPRT specific activi ty 
(j.lmot GMPI mil'l l mg protein) 
I Fraction 
I 
Hypounthlne I Guanine Xa nthine I 
pH 8.5 PH 8.5 pH 7.4 
Supernatant od, I- od, od, 
Sep-Pak " 3.6 2.5 I 
I Reactive 21 5.4 72 
Red 120 
I I 
The pro tein pnor to actIVation was QUite stable al room temperature or on ice. 
in terms of being able to be subsequently activated (Figure 3 20) It was also 
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Figure 320 SUlbil'ty of HGl(PRT prior to iI~t l".llon. Folowong ooatrs.s HOXPRT was 
placed at foam temperatUfll (dolte<! l one 0Pef1 QICIes) Of on oce (conlln<lOUS line DO!! ) fOf tne 
lome!. lO!iocale!! ana lhen actr ... r.1KI OYefnoghi by aOClJlion of 1 mM PRPP • 6(1 101M 
n\1lOxantnane 3IId assayed fof ac1M'Y "",!II guan roe as substrate 
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Table J 2 Stability of j,CU .... lted HGXPRT HGXPRT was ,nc;ub3l1lO uno. :nll conaitlOn1 and 
bmeslndocalea 3r>(I tnen assayea ror act:V"f 
HGXPRT incubation conditions 
4 DC In 60}lM Hx· 1 mM PRPP 
0% 1 4 oc in 60 I,M Hx .. 1 mM PRPP .. 5 
~'Y'-'-"-'---------­
_20°C in eOI'M Hx" 1 mM PRPP" 5 
glycerol 






(lMflol GMP/min/mg protei n) 




1.3 No detectable 
activity 
was less stable with Mg2• and PRPP over 30 days, due most probably to Mg2< 
dependent hydrolysis of PRPP 
Rather remarkably, HGXPRT could be activated. Inactivated, and reactivated 
several times with no decline In actIVity (Table 3 3) PRPP or Mg2> alone was 
not suffICient for actIVation 
, 
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Tabla 1.3 Rlve ... lble ICllvation Ind Inactivation 01 HGXPRT. DtaIyRd HGXPRT (a) was 
aCIIV~tlld b~ an ovtll'ltghl I nc~tl3!,Of1 w,1h to mM Mg" and 1 mM PRPP (D) dlal~ed 
overmght agalnlt t o mM sodl~m phosphate pH 70 and 1 mM OTT (e) actIVated overn_<jll 
With 1 mM PRPP • 60 ~M hypOxantlllne (d) d alvsed aga;n (e), at:emp:e<,l ilct>valJOO 
overn>ght With t mM PRPP If) , actIVated overn ight WIth t o mM Mg" • 1 mM PRPP (g) and 
f",any d,alysed agaln$! 10 mM Mg" 10 mM sodIum phosphate. and t mM OTT (g) The 
p,ocedyres were .,erformf!d 51!quenu lly on the Same sample and assayed lor achv,ly al the 
I 
, 
Specific activity I 
Stage Procedure (~mol GMP/minlmg 
protein) 
• Prior 10 activation i -<0.2 




, Removal of Mg • and 0 
PRPP 
, Acllvatlo n Wlth Hx + ' .3 
PRPP 
• Remova l 01 Hx + PRPP 0 
I Activation with PRPP 0 
I alone 
9 Activation Wltn Mgl 00' .. ,
PRPP 
h Removal of PRPP 0 
I 
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The actIVIties reported In all the above expenments were deduced from the 
Inihal rates of the reaction as followed Speclrophotometncally Figure 3_21 
shows a typical progress curve obtained for the conversion of guanine to 
GMP b~ malana HGXPRT The reaction ceases after about 300 s with a total 
absorbance change of approximately 0.06 units This IS not due to exhaustion 
of substrates. but rather inactivation 01 the enz~me because the total 
absorbance change for the formation of 60 IJM GMP should be approximatel~ 
a 35 unitS The slow fall off In activity IS also indicative of inactivation, 
beeouGe the K,.. 1& lIpproximlltely 1 j.lM (Keough c/ al . 1!)!)O) end therefore the 
rate should be linear until the K,., IS approached 
• • 
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FogUfl!! 32t progrn_ (UN_ lor converBion 01 guanine to GMP The reaction was 
performed WI 100 mM 111 • .(:1 pH 8 5. 110 mM Mgel, I mM PRPP and 60 ,.M lluan,ne II 
was staned w,th me IIOd,llOn 01 an abquot 01 enzyme Ito gM! 7 2 ~~mll anc mormored at 257 
om 
ILl 
The fact that the amount of guanine IS not limiting IS shown more clearly In the 
series of experiments shown in Figure 3.22. In panel A addition of anolher 
60 IJM guanine at approximately 800 s does not result In an Increase In 
acl ivity, which can also be seen in the insert In panel B, an Initial amount of 
A 
~ • • ,0 , tt' c • , • I '-~ " -0 • -" .""~'11 ~
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Figure 3 22 Activity 01 HGXPRT Assays were performed as in F.gure 3 21 , e, cept that 
the amoum 01 guanone was va/ iable In A. 60 ~M guanme was present Initially, and mOle 
added laler as shown. Insert Spectra recorded dunnQ the e~perunent In 8 tile add<\lons 01 
guanrne are as indicated 
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guanine was not suffiCient to ,""chvClte the enzyme, as a lurthel 1ILlu,lIun dfler 
about 500 (s) produced delectable activity. but a third addition gave less 
activity_ These results Ind ica te that during enzyme turnover unstable 
intermediates are formed that decay to an inactive species Following 
addition and consumption 01 20 IJM guanine, the enzyme reverts to the 
E.Mg2· PRPP complex, wh ich IS stable A further addition results in the 
generation of unstable species again and inactivalion 
The pH and Mg" dependence of ocli",ty IS :3hown In Figure 3 .23. Acti¥ities 
were highest at alkal ine pH with Intermediate Mg2+ concentratlons, In the 1-
30 mM range of concentrations of Mg2' , the pH dependence IS apparently 
biphaSIC However II IS not clear whether the lack of activity at pH 5.0 IS due 
to the protonation of catatyt lca lly Important residues or denaturation, and 
therefore it is safer 10 conclude that there is merely activation in the alka lme 
pH range 
It wil l be seen tater that the chalcone stock solutions are made in OMSO and 
therefore II was of Interest 10 determine the effect of thiS organic solvent on 
HGXPRT activity 
2 .,--------------------------------, 
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Figure 3 23 pH ~nd MQ" dipendi/Kel o f HGXPRT . etlv ily ne auay was per/ormed as 
In F'!;ure 3 21 except tile b1Jf!er$ (100 mMlwere liS fol~ Ace:ate (pH 5 0) MES (pH 6 0), 
MOPS (pH 7 0) EPPS (pH 8 0) alld CHES (pH 90) alld 1M Mg" ecncemrabOllS as SIlOw"-
FIgure 3 24 shows that the effect depended on concentration o f PRPP A t 0 2 
mM of thIS substrate. low concentra tIOns actIVated the enzyme approxImately 
, 














Fig ure 324 ElfKI of DMSO 011 HGXPRT ilctivlty HGXPRT actMty was perloflTled as ,n 
Ftgure 3 21 wrth a 2 mM (contmUO<Js Ime dots) 01 , mM PRF'P (optfl eortles (lOlled 10 .... ) WIlli 
the aUCluons of DMSO shown 
3-fold , and htgh concentratIOns were inhibitory AI 1 mM PRPP. the solvent 
had no effecl l.lp until above 10 % where 1\ became mhlblto,), Above 30 % 
DMSO there was ew!ence of preciplta tlon probably MgPRPP The activation 
211 low PRPP and low DMSO concentration is possibly due to Increased 
formation of the complel( Mg1PRPP hom Mg2< and PRPP In the presence of 
the organic solvenl 
Since the malaria HGXPRT bound 10 Ihe ReSCllVe Red 120 agarose column 
and was selectively eluted WIth PPi, II was of interest to determine whether 
the free dye affected the activity of the enzyme The results With Reactive 
Red 120 and Reactive Blue 2 are shown in Figure 3.25 Both dyes are fa irly 
117 
potent Inhibitors of activity. with K, values In the ~M to sub-~M range (see 
legend for values with and without competition with PRPP) 
The structures of the dyes are shown in Figure 3 26 
The binding of the Reactive dyes to HGXPRT was not Irreversible (i e 
covalent derivatisatlon via the reactive CI group) since both could be visibly 
separated from the protein by 50S-PAGE (results no! shown) 
'18 
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[Reacti'le dye] (101M) 
flgu'!! 325 EMee! of Reactive dyH on HGXPRi itCtiYily "nays Wefe perlorme<l as In 
Fogur, J.2.1 wdh H'lcreas'llg concentraU)I\S 01 Reaetlve Reo 120 (open e"c~I)..,d Reactive 
Blue 2 IdolS) as n:hca'e<l The concenlrallDl'l ot HGXPRT wat 0 32 ~M The dala were filted 
10 a hyper!)ohc .... h'blloon (u/Vi! ~ " Yo Koo/(Ko I • S) wllell! Y. " the ""bal amOunt ot maler lal, 
Ko , the coocentratoon ot I"IhobllO( at naif· maximal acllV~y. and S (he eonc:enlf;otion 01 'MIMo' 
The vaJua for Ko . from the besl ~I of !he oatil 3A! 1 7 uM ana 3 0 ~M for Re3Cuve Red 120 
ana Reacwe Blue 2 r~uveIy assum"'g!hal thll cor><:entrauon of free dye IS equal 10 Ihe 
loIal concel1lJanon Tn.s equa:.on assumes that ll\efe " no compel bon between lhe Inrllb,tor 
and Ine wbstrates II the Reactive dyes ant compel"", w'lh PRPP !of blnOlnlllO the ao:\ove 
5le !hen the compe!<bve blndll!,! equabOrl Kr" Ko1l'(1 • IPRPPj/K., .... ,) lakes th ,. Into 
account <Ina )'It'Ics K." 05 j.lM and 08 ~M lOf Reac!ve Red 120 and Reac! lve Blue 2 
~ lakell as 036 mM (Keough sf <II 1999) and the 
concentratJorl 01 PRPP 'lithe <lS~Y I'; 1 mM 
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.. 
Rtletivt Red 120 
Reactive BI",. 2 
Fogu re 3 26 Structures o'th. R.actlv, dyes tested "9.11151 malarla HGXPRT. 
3.5 Chemical synthesis 
3.5.1 Synthesis of (2E)-1-(2',6'-dlchloro-4 '-hydroll:yphenylj-3-(4"-
iodophenyl )prop-2 -en-l oon e 
As indicated earlier (see Matenals and Methods), synthesIs of (2E)-1-{2' 6 -
dichloro-4 '·hydroxyphenyl).3-(4"· ioc!ophenyl)prop-2-en- \ -Qne (BM 01 ) was 
carried our in four reaction steps These sleps are summarrsed in scheme 3 1 
Compound 1 (obtained from commerCial sources) was us.ed to synthesize 
compounds 2. 3 and 4. The final product in the scheme (compound 6, 
chalcone, 8M 01 ) was synthesized follOWing the linking of compounds 4 and 5 
(also obtained from commercial sources) The charaeerisalian data for these 





Seneme 3 1 Summary of reactlon1i feldlnlillo 1iynlhnl1i 01. dlchlorlnl led Chllcone 
(2E)-1-(2' 6'-dochlor0-4 -hydro.yphenyl)-J..( 4 -oodophenyl)Pfop·2 ... n-l-one (5" text lor 
3.5.1.1 Synthesis of 2,6-d lc hloro-4-hydroxybenlyaldehyde 
• I , 
2.6-dlchloro-4-hydroxybenzyaldehyde (labelled 2 In scheme 3 1) was obtatned 
as yellow crystals tn 19 % (205 mg) yield. Rt [20 % (v/v) EtOAc In hexane. 
01 4] Formation of tl1rS aldehyde was confirmed by carrymg out a 'H NMR 
(400 MHz. DMSQ-d5); s.. 102 (s, 1 H, -CHO), 69 (s. 2H, H-3', and H-S') and 
IlC NMR (400 MHz, DMSO-d!). Oc 188 (·CHO). 163 (C·4). 139 (C-2 and C-6). 
122 (C-l). 118 (C-3 and C-5) 
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3.S.1.2 Synthesis of 3,S-clichloro 4-(1 '-hydroxyethyl) phenol 
HO 
CI OH 
3, 5-dchlor0-4-( 1'-hydroxyethyl)phenol 
3,5-dichlor0-4-(1'-hydroxy-ethyl)phenol (labelled 3 in scheme 3.1) was 
obtained as a yellow solid in 50 % (128 mg) yield; Rf [10 % (v/v) MeOH in 
OCM1. 0.48. 1H NMR (400 MHz. acetone--d,); 8H 6.8 (s. 2H, H-3. and H-5), 5.5 
(q. 1H. J = 8.4. H-1'), 1.5 [d, 3H, J = 8.4, 3(H-2')]. 13C NMR (400 MHz, 
acetone-d,); Be 127 (C-1), 134 (C-3, and C-5), 129 (C-2'), 117 (C-4), 69 (C-1'), 
21 (C-2'). 




1-{2', 6' -dichlor0-4 '-hydroxyphenyl)ethanone 
1-(2',6'-dichloro-4'-hydroxyphenyl)ethanone (labelled 4 in scheme 3.1) was 
obtained as a cream coloured solid in 47.9 % (54 mg) yield and gave an Rf 
122 
[30 % (v/v) EtOAc-hexane, 0.37]. 1H NMR (400 MHz, CDCI3); 5H 6.8 (s, 2H, H-
3' and C-5'), and 2.6 (s, 3H, 3[H-2]). 
3.5.1.4 
HO 






(2C)-1-(2' ,6'-{jichlor0-4' -hydroxyphenyl)-3-(4" -iodophenyl)prop-2-en-1-one 
BM01 
The chalcone product (labelled 8 in scheme 3.1), (2E)-1-(2',6'-
dichlorophenyl)-3-(4'-iodophenyl)prop-2-en-1-one (8M 01), was obtained as 
cream coloured crystals in yield 53.6 % (54 mg), mp 167-169 °c. Rf [30% (v/v) 
EtOAc in hexane], 0.25. Vm. (NaCI)/cm-1 3287 (O-H), 3054 (C-H), 1656 
(C=O), 1621 (C-C), 1602 (C=C aromatic), and 1260 (C-O). 1H NMR (300 
MHz, CDCI3) gave the following peaks: 5H 7.7 (d, 2H, J = 8.5, H-3" and H-5"); 
7.3 (d, 2H, J = 8.5, H-2" and C-6"); 7.2 (d, 1H, J = 16.2, H-2); 6.9 (d, 1H, J = 
16.2, H-3); 6.9 (s, 2H, H-3' and H-5'). 13C NMR (300 MHz, CDCh); 5c 194 
(C1), 157 (C4'), 147 (C3), 138 (C2', C3", C5", C6'), 133 (C1"), 130 (C1'), 123 
(C2", C6"), 127 (C2), 115 (C3', C5'), and 98 (C4"). Elemental analysis gave 
the following results: % C = 43.40, % H = 1.82 (calculated values; % C = 
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42.99. % H = 2.16, % 0 = 7.64, % CI = 16.92. % I = 30.28, Mol. wt 419.0 and 
Mol. formula C1sH9CI2I02); calculated mlz417.9. Actual MS mlz419.0 [M+1t. 





The (2E)-1-(2'-hydroxyphenyl)-3-(4"-ioclophenyl)prop-2-en-1-one (BM 02) was 
obtained as a orange crystals in 45 % (22 mg) yield, Rf [10 % (v/v) EtOAc in 
hexane, 0.78] and mp 144-146 °c. 1H NMR (400 MHz, CDC1a) 3H 12.7 (s, 1 H, 
-OH), 7.9 (dd. 1H, J = 1.5 and 7.8, H-6'), 7.8 (d, 1H. J = 15.6, H-3), 7.8 (dd, 
2H, J = 2 and 4, H-2" and H-6"), 7.7 (d, 1H, J = 15.6, H-2), 7.5 (m, 1H, H-4'), 
7.4 (dd, 2H, J = 2 and 4, H-3" and H-5"), 7.0 (dd, 1 H, J = 1.5 and 7.8, H-3'), 
and 6.9 (m, 1H, H-5'). laC NMR (400 MHz, CDC1a); ac 194 (C1), 163 (C2'), 
144 (C2 and C3), 138 (C3", and C5"), 136 (C5'), 134 (C1"), 130 (C4' and 
C6'), 129 (C2" and C6"), 120 (C-1'), 116 (C3'), and 98 (C4"). 
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3.5.3 Synthesis of chalcon .. containing both a nitro group as 
wen as a hydroxyl group in ring A 




(2E)-1-(4' -hydroxy-3' -nitrophenyl)-3-(4" -iodophenyl)prop-2-en-1-one (BM 03) 
was obtained as yellow crystals in 25 % (31 mg) yield, Rf [20 % (v/v) EtOAc in 
hexane, 0.24] and mp 199 -200 °C. Vmax (NaCI)/cm-1 3273 (O-H). 3055 (C-H), 
1663 (C=O), 1597 (C=C aromatic). 1533 (N02) and 1240 (C-O). 1H NMR (300 
MHz, CDCb) gave OH 8.8 (d, 1 H, J =2.1, H-2'), 8.3 (dd, 1 H, J = 2.1 and 6.5, H-
6'),7.81 (d, 1H, J= 15.3, H-2), 7.77 (d, 2H, J= 8.4, H-2" and H-6"), 7.5 (d, 1H. 
J = 15.3. H-3), 7.4 (d, 2H, J = 8.4, H-3" and H-5"), 7.3 (d, 1H, J:II 6.5, H-5') 
while 13C NMR (300 MHz, CDCI3) Oc 186 (C-1), 158 (C-4'), 145 (C-3), 138 (C-
6', C-3" , and C-5"), 137 (C-3'), 134 (C1"), 130 (C-1'), 129 (C-2', and C-6'), 126 
(C-2"), 120 (C-2, and C-5') and 97 (C-4 "). Elemental analysis gave the 
following results: % C = 46.07, % H = 1.83, % N, 3.44 (calculated values; % C 
= 45.59, % H = 2.55, % I = 32.12, % N = 3.54, % 0 = 16.20. Mol. wt 395.15 
and Mol. formula C1sH10INO .. ); calculated MS mIz 394.97. Actual mIz 396.0 
[M+1t· 
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3.5.3.2 (2E)-1-(4' -hydroxy-3' -n Itrophenyl)-3-(3" -lodophenyl)prop-2-
en-1-one 
(2E)-1-( 4'.hydroxy-3' -nitrophenyl)-3-(3" -iodophenyl)prop-2-en-1-one 
BM04 
(2E)-1-(4'-hydroxy-3' -nitrophenyl)-3-(3" -iodophenyl)prop-2-en-1-one (BM 04) 
was obtained as yellow crystals in 22 % (31 mg) yield. mp 139-140 °c, Rf[60 
% (v/v) EtOAc in hexane, 0.86]. Vmax (NaCI)/cm-1 3300 (O-H), 3055 (C-H), 
1668 (C=O), 1624 (C=C), 1600 (C=C aromatic), 1541 (N02) and 1265 (C-O). 
This chalcone gave the following 1H NMR (300 MHz, CDCI3); 8H 10.9 (s, 1 H, 
4'-OH), 8.8 (d, 1H, J= 2.1, H-2'), 8.3 (dd, 1H, J= 2.1 and 9.0, H-6'), 8.0 (t, 1H, 
J = 1.8, H-2"), 7.8 (d, 1H, J = 15.6, H-3) 7.8 (d, 1H, J = 7.8, H-6") , 7.6 (broad 
d, 1H, J = 7.8, H-4), 7.5 (d, 1H, J = 15.6, H-2), 7.3 (d, 1H, J = 9, H-5'), and 7.2 
(t, 1H, J = 7.8, H-5"). 13C NMR (CDCb, 300 MHz), 8c 186 (C-1), 158 (C-4'), 
144 (C-3), 140 (C-3'), 137 (C-1', C-1" and C-6'), 131 (C-2" and C-4") , 130 (C-
5"), 126 (C-6" and C-2'), 121 (C-2) 121 (C-5') and 95 (C-3"). Elemental 
analysis gave the following results: % C = 46.14, % H = 1.89, % N, 3.42 
(calculated values; % C = 45.59, % H = 2.55, % N = 3.54. Mol. wt 395.15 and 
Mol. formula C15H10IN04), calculated mIz 394.97. Actual mIz 396.1 [M+1t. 
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(2E)-1-(4' -hydroxy-3' -nitrophenyl)-3-(2" -iodophenyl)prop-2-en-1-one (BM 05) 
chalcone was also obtained as a yellow crystals in 25 % (29 mg) yield Rf [60 
% (v/v) EtOAc in hexane, 0.81], and mp 186 -190 °C. Vmax (NaCI)/cm-1 3419 
(O-H), 3054 (C-H), 1664 (C=O), 1624 (C=C), 1600 (C=C), 1540 (N02) and 
1260 (C-O). The 1H NMR (300 MHz, CDCI3): 8H 10.9 (s, 1 H, 4'-OH), 8.8 (d, J 
= 2.4,1 H, H-2'), 8.3 (dd, 1 H, J = 2.4 and 9.0, H-6'), 8.0 (d, 1 H, J = 15.6, H-3), 
7.9 (dd, 1H, J = 1.5 and 8.4, H-6"), 7.7 (dd, 1H, J = 2.1 and 8.0, H-3"), 7.4 
(broad d, 1H, J = 7.8, H-4"), 7.3 (d, 1H, H-2, J = 15.6) 7.3 (d, 1H, J = 8.7, H-
5'),7.1 (td. 1H, J= 1.5 and 7.8, H-5"). 13C NMR (CDCI3. 300 MHz), Oc 189 (C-
1), 158 (C-4'), 149 (C-3), 140 (C-1", C-3"and C-6'), 137 (C-3'), 127 (C-6" and 
C-5"), 130 (C-4"), 126 (C-2'), 124 (C-2 and C-1'), 120 (C-5'), and 102 (C-2"). 
Elemental analysis gave the following results: % C = 46.07, % H = 1.98, % N, 
3.40 (calculated values; % C = 45.59, % H = 2.55, % N = 3.54. Mol. wt 395.15 
and Mol. formula C1sH10lNO,d, calculated MS mIz 394.97. Actual MS mIz 
395.6 [M+1t. 
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3.5.4 Synthesis of chalcones containing 2,4,6-trihydroxy groups 
In ring A 
The synthesis of chalcones containing a trihydroxyl moiety was carried out 
following a sequence of reactions summarized in scheme 3.2 (see Materials 
and Methods for details). While compounds labelled 2 and 5 were 
characterised (see below), compound labelled 4 was directly converted to 5 
(final chalcone product of this series). The characterisation of type 5 chalcone 
products as well as the MEM-protected acetophenone (compound labelled 2) 
is shown in the sections that follow. Compounds 1 and 3 were obtained from 
commercial sources. 
Hl(Y ME~EM I + I 
H I H """'YY"'~ () 
1 • >---- ~x 
xOy H • 
3 
Scheme 3.2 Sequence of reaction. in the .ynth .... of chalcon .. containing trlhydroxyl 
moiety. X stands for a halogen at the ortho, meta, or para position of the benzaldehyde. 
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3.5.4.1 Protection of 2' ,4' ,6' -Trihydroxyacetophenone using 




DiM EM protected 2',4',6'-trihydroxyacetophenone (compound 2 in scheme 
3.2) was obtained as a clear oil in 83 % (90 mg) yield. 1H NMR analysis (300 
MHz: CDCI3 solvent): 8H 6.2 (s, 2H, H-3' and H-5'), 5.3 (s, 2H, Ar-OCH2-), 5.2 
(s, 2H, Ar-OCH2-), 3.8 [m, 4H, -O(CH2)r], 3.6 [m. 4H. -O(CH2)r], 3.4 (s. 3H. -
OCH3). 3.3 (s. 3H. -OCH3), 2.6 (s. 3H, 3[H-2]). 
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3.5.4.2 Synthesis of (2E)-3-(4" -iodophenyl)-1-(2' ,4' ,6'-
trihydroxyphenyl)prop-2-en-1-one (4" -I-chalcone) 
HO 
(2E) .. 3·W -iodophenyl)-1 .. (2' ,4' ,6' -trihydroxyphenyt)prop-2-en-1-one 
aMO. 
[(2f)-3-(4" -iodophenyl)-1-(2' ,4' ,6' -trihydroxyphenyl)prop-2-en-1-one] also 
referred to as 4"-I-chalcone (BM 06) was obtained as a yellow powder in 83 % 
(31 mg) yield, Rf [50 % (v/v) EtOAc, 0.41] and mp 189 - 190°C. The 1H NMR 
(400 MHz, acetone-d8); 8H 8.2 (d, 1H, J = 15.6, H-3) , 7.8 (d, 2H, J = 8.3, H-2" 
and H-6") , 7.7 (d, 1H, J = 15.6, H-2), 7.5 (d, 2H, J = 8.3, H-3" and H-5"), 5.9 
(s, 2H, H-3' and H-5'). 
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3.5.4.3 Synthesis of (2E)-3-(3" -lodophenyl)-1-(2' ,4' ,1'-
trlhydroxyphenyl)prop-2-en-1-one (3" -I-chalcone) 
HO 
OH 0 
(2S)-3-(3"-iodophenyl)-1-{2' ,4' ,6'-trihydroxyphenyl)prop-2-en-1-one 
aM 07 
[(2E)-3-(3" -iodophenyl)-1-(2' ,4' ,6'-trihydroxyphenyl)prop-2-en-1-one] or 3" -1-
chalcone (BM 07) was also obtained as orange crystals in 49 % (27 mg) yield, 
Rf [50 % (v/v) EtOAc in hexane, 0.52] and mp 95 - 98°C. Vmax (KBr)/cm-1 3100 
(O-H), 1631 (C=O), and 1218 (C-O). 1H NMR (300 MHz, acetone-de); BH 8.2 
(d, 1H, J= 15.6. H-3) , 8.0 (t, 1H, J= 1.5, H-2"), 7.7 (dd, 1H, J= 8.1 and 1, H-
4"),7.7 (dd,1H, J= 8.1 and 1, H-6"), 7.6 (d.1H, J= 15.6, H-2), 7.2 (t,1H, J= 
8.1, H-5") , 5.9 (s, 2H, H-3' and H-5'). 13C NMR (300 MHz, acetone-de); 8c 186 
(C-1), 166 (C-6'), 158 (C-4'), 158 (C-3), 140 (C-1'), 139 (C-1"), 137 (C-2", C-
4", and C-5"), 126 (C-2' and C-6"), 120 (C-2) 104 (C-3'), and 95 (C-3" and C-
5'). Elemental analysis gave the following results; % C = 45.14 and % H = 
2.96 (calculated values; % C = 47.14, % H = 2.90. Mol. wt 382.15 and Mol. 
formula C1sH11 10 .. ); calculated MS mIz 381.97 [Mt. Actual MS mIz 382.8 
[M+1t. From elemental analysis, expected molecular weight is 17 units higher 
than actual. A water molecule (18 MW) accounts for this difference. Hence, 
actual molecular formula is C15H1110 ... H20. 
3.5.4.4 Synthesis of (2E)-3-(2"-iodophenyl)-1-(2' ,4' ,6'-
trihydroxyphenyl)prop-2-en-1-one (2" -I-chalcone) 
(2E)-3-(2" -iodophenyl)-1-(Z ,4' ,6'-trihydroxyphenyl)prop-2-en-1-one 
aMOI 
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[(2E)-3-(2"-iodophenyl)-1-(2' ,4',6'-trihydroxyphenyl)prop-2-en-1-one] or 2" -1-
chalcone (8M 08) was obtained as yellow crystals in 55 % (21 mg) yield, R, 
[50 % (v/v) EtOAc in hexane, 0.41] and mp 157 - 159°C. Vmax (KBr)/cm-1 
3100 (O-H), 1620 (C=O), and 1268 (C-O). 1H NMR (400 MHz, acetone-d~; OH 
8.1 (d, 1 H, J =15.6, H-3), 8.0 (dd, 1 H, J = 1.2 and 8, H-3") , 8.0 (d, 1 H, J = 
15.6, H-2), 7.8 (dd, 1H, J = 1.6 and 8, H-6") , 7.5 (t, 1H, J = 8, H-5"), 7.2 (td, 
1 H, J = 1.6 and 8, H-4"), 6 (s, 2H, H-3' and H-5'). 13C NMR (400 MHz, 
acetone-d~; Oc 205 (C-1), 166 (C-2', C-4' and C-6'), 144 (C-3), 140 (C-1"), 
129 (C-4", and C-6") , 128 (C-2, C-3" and C-5"), 97 (C-1', C-3' and C-5') and 
95 (C-2"). Elemental analysis gave the following results; % C = 47.95 and % H 
= 3.11 (calculated values; % C = 47.14, % H = 2.90. Mol. wt 382.15 and Mol. 
formula C15H11IO .. ); calculated MS rnIz 381.97 [Mt. Actual MS rnIz 382.6 
[M+1t· 
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(2E)-3-(4" -c:hlorophenyl)-1-(2' ,4' ,6' -trihydroxyphenyl)prop-2-en-1-one 
BMII 
[(2E)-3-(4"-chlorophenyl)-1-(2',4',6'-trihydroxyphenyl)prop-2-en-1-one] or 4"-
CI-chalcone was obtained as yellow crystals in 72 % (21 mg) yield; Rf [50 % 
(v/v) EtOAc in hexane, 0.37], mp 157 - 158°C. The H NMR (acetone-d6 
solvent, 400 MHz); SH 8.2 (d, 1H, J = 15.3, H-3), 7.7 (d, 1 H, J = 15.3, H-2), 7.6 
(d, 2H, J = 8.3, H-3" and H-5"), 7.4 (d, 2H, J = 8.3, H-2" and H-6") , 5.9 (s, H-3' 
and H-5'). 
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3.5.4.6 Synthesis of (2E)-3..(4"-bromophenyl)-1..(2',4'6'-
trihydroxyphenyl)prop-2 .. n-1-one (4" -Br-chalcone) 
HO Sr 
(2E)-3-(4" -bromophenyl)-1-(2' ,4' ,8' -trihydroxyphenyl)prop-2-en-1-one 
BM10 
[(2E)-3-(4"-bromophenyl)-1-(2',4',6'-trihydroxyphenyl)prop-2-en-1-one] or 4-
Br-chalcone (BM 10) was also obtained as a yellow solid in 64 % (31 mg) 
yield. Rf [50 % (v/v) EtOAc in hexane, 0.49], mp 160 - 164 °C. 1H NMR 
analysis (acetone-de solvent, 400 MHz); 8H 8.3 (d, 1 H, J = 15.6, H-3), 7.7 (d, 
1H, J = 15.6, H-2), 7.6 (m, 4H, H-2" , H-3", H-5" and H-6") , 6.0 (s, H-3' and H-
5'). 
3.6 Attempted synthesis of other chalcon .. 
An attempt at synthesizing other chalcones [(2E)-1-(2',6'-difluor0-4'-
hydroxyphenyl)-3-(4" -iodophenyl)prop-2-en-1-one and (2E)-3-(4" -iodophenyl-
1-(2'-nitrophenyl)prop-2-en-1-one] was made, see structures in Figure 3.27. 
The attempted synthesis of the difluorinated chalcone was to be carried out in 
the same way as described for the dichlorinated chalcone following the 






(2E)-3-( 4"~phenyl)-1-(2' -nitropheny!jprop..2-en-1-one 






difluorinated chalcone, the Reimer-Tiemann reaction conditions (see section 
1.6.2.1) could not generate the required benzaldehyde. Instead of the 
expected 2' ,6'-difluor0-4'-hydroxybenzaldehyde, analogous to the 2',6'-
dichloro-4' -hydroxybenzaldehyde, only the 3,5-difluorophenol (starting 
material, see structure above) was obtained as identified by TLC and 1H NMR 
at the end of this reaction. The 1H NMR analysis was identical with that of the 
commercial product, 3,5-difluorophenol; (CDCI3 solvent, 300 MHz), ~H 6.4 (m, 
3H, H-2, H-4, H-6). The aldehyde proton, which is supposed to be a key 
spectroscopic indicator for the formation of the benzaldehyde, was absent in 
the 1H NMR spectra. The strongly electron withdrawing nature of fluorine in 
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the 3,5-difluorophenol may be a reason for the failed Reimann-Tiemann 
reaction in this case (see mechanism in Figure 1.24). 
H 
(4'-iodophenyl)methanol 
Synthesis of the chalcone containing a nitro group at pOSition 2' in ring A (see 
Figure 3.27) yielded a Cannizzaro reaction product. Instead of the Claisen-
Schmidt reaction product (following the retrosynthetic scheme given in Figure 
1.21), the benzaldehyde underwent a reduction to form a primary alcohol (4-
iodophenyl)methanol, see structure above). The 1H NMR (COCh solvent, 300 
MHz) analysis of the reaction product gave the following: OH 7.7 (d, 2H, J = 
8.4, H-2', H-6'), 7.11 (d, 2H, J = 8.4, H-3', H-5'), and 4.6 (s, 2H, 2[H-1]). This 
NMR spectral data is consistent with that of the 4-iodobenzaldehyde that has 
been reduced to a primary alcohol. One possible reason for this reaction 
occurring instead of the desired Claisen-Schmidt one, is that the base (KOH) 
used to carry out the reaction was too strong (see section 1.6.1). It ought to 
be pOinted out however that this benzaldehyde was used successfully in the 
synthesis of several other chalcones using the same conditions (see sections 
3.5.1.4 to 3.5.4.2 for examples). 
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Another possibility is that the strongly electron-withdrawing nitro group, which 
is in close proximity, renders the enolate generated poorly reactive. The 
extended conjugation (Figure 3.28) facilitates the electron-withdrawal by the 
nitro group. The poor reactivity of the enolate presumably makes the 
Cannizzaro reaction competitive to the Claisen-Schmidt. 




Figure 3.28 Ba.e initiated conjugation of enolate double bond with nitro group. 
3.7.0 Drug targeting 
3.7.1 Effect of chalcone. on HGXPRT activity 
The effect of increasing concentrations of the various chalcones [see 
structures in Figure 3.29 (a) and (b)] on HGXPRT activity is shown in Figure 
3.30. In addition to the chalcones synthesised, 4 chalcones (extracted from 
natural sources) obtained from University of Botswana were also tested. Two 
of these are somewhat similar to those synthesised and are included in Figure 
























Figure 3.29(b) Structu ..... nam .. (andlor cod .. ) of the chalcon .. (.xtracted from 
natural.oure .. ) that w.,. obtained from the Unlv .... ,ty of Botswana. 
Only the 4"-1-, 4-Br"- and 4-CI"-chalcones (8M 06, 8M 09 and 8M 10 
respedively) showed significant acceleration of catalytic turnover, up to 2.5 
fold. The concentration of half maximal effed is approximately the same for 
the three chalcones at -10 IJM. There seemed to be a small effed of the 
(2E)-1-( 4'-hydroxy-3'-nitrophenyl)-3-(4" -iodophenyl)prop-2-en-1-one (8M 03). 
The experiment was repeated with 3 other preparations of HGXPRT at 30 IJM 
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Figure 3.30 Effect of chalcon .. on HGXPRT activity. The assay conditions were 100 mM 
Tris-CI, pH 8.5, 30 mM MgCI2, 1 mM PRPP, 60 ~M guanine, 0 - 60 ~M chalcone as indicated, 
and 7 ~g HGXPRT/ml at room temperature. The reaction was started with a small aliquot of 
protein and the initial rate determined. Each data point represents mean +/- SEM (n = 4). 
The identity of the chalcones [structures provided in Figure 3.29 (a> and (b)) is as follows: 
_al101 
.....0- alia 
........... aM Oil 
~aM. 
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Figure 3.31. Effect of fused chalcon .. on HGXPRT activity. The assay conditions are the 
same as in Figure 3.30. The data points are mean +/-SEM (n = 4). The code names for the 
chalcones are provided in the box and their structures are in Figure 3.29 (b). 
3.7.2 Attempts to alter the rate-limiting step and effect of 
chalcon .. 
The main rate-limiting step in the catalytic cycle of human HGPRT has been 
found to be release of nucleotide (Xu at al., 1997), but it is not known for the 
malaria enzyme. The identity of the particular step that slows catalYSiS has 
implications for the nature of the accelerating site and the underlying 
mechanism. The true catalytic acceleration of turnover provided by the 
chalcones may also be obscured due to rate-limitation being spread over 
several steps. In order to probe these possibilities, we attempted to change 
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the rate-limiting step(s) through changing pH and divalent cation cofactor. 
For example, in the latter case, if the chemical interconversion was slowed 
significantly, and acceleration by the chalcones persisted, then the chalcone 
binding site had to be located outside of the catalytic site. 
3.7.2.1 Varying pH 
It has been shown above (Figure 3.23) that malaria HGPRT was increasingly 
more active as the pH became more alkaline (pH 6 to 9). It was therefore of 
interest, as indicated above, to determine if the accelerating effect of the 
chalcones persisted in the low pH range. Table 3.4 shows results of including 
the chalcones in assays at pH 6 compared with at pH 9. Even though limited 
experiments were performed (no repeats) all three chalcones seemed to 
exhibit a similar activating effect at both pHs. 
Table 3.4 Effect of chalcones on activity at pH 8 and 9. The assay was performed in either 
100 mM MES or 100 mM CHES, at pH 6.0 and 9.0 respectively, 30 mM MgCI2, 30 ~M 
chalcone, 1 mM PRPP, and 60 ~M guanine at room temperature. Structures of the chalcones 
are given in Figure 3.29. 
Chalcone Activity 
(30 IJM) (IJmol GMP/mln/mg of protein) 
pH 8 pH 9 
Control (no chalcone) 0.6 1.2 
4"-I-chalcone (or BM 08) 0.9 2.0 
4"-CI-chalcone (or BM 09) 1.1 2.0 
4"-Br-chalcone (or BM 10) 0.8 1.8 
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3.7.2.2 Varying d ivalent ca tion cofactor 
Vv'hen Mg~' was replaced with other divalent metal ions (Mn2 ' , Ca 2., and Sr' ) 
In the reaction assay concentrations higher Ihan 1 mM resulted in prob~ms 
with precip'tahon . and therefore 1 mM was chosen. As shown In F;gure 3 32, 
no activity was detectable in the absence of added divalent cations. In 1 mM 
Mg~'. the two halogenated chalcones (BM 06 and BM 09) examined provided 
approximately 2·fold accelerallon, close to what was observed al 30 mM The 
activity in Mn2' was identical 10 that of Mg2. , but the in presence of chatoones 
N. ""tol ,. 
• 
F,gure 3 32 EHe~1 01 d,vatent ~a l 'ons and aeut .... tlng ehaleon .. on HGXPRT a~tivity, 
The ~uay conamons were 100 mM TrtS·CI pH 8 5. 1 mM DIValent ~on iiIS IIlDoca:1!<l WlIJlOUI 
(blown bar) or W'IJI 60 11M 4 -CI-d'lalcolle 8M 09 (orllf'>ge bar) or '" -I.a,atcone 8M 06 (green 
bill). 1 mM PRPP 60 11M guan''''' anc:l 0 Cl14 rng HGXPRT/ml at room IItmperaU,I,e The 
cooeentr,):ed enzyme was r~st d;aly5e(l ,n 10 mM MOPS pH 70 10 remove PI and 
convened 10 me ac:JVe rorm by ~lIloght lOCuba:ooo wrtI1 PRPP .. hypoxanll'one The value'S 
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Figure 333 Inhibition 01 m~lari, HGXPRT ifI 1 mM CI ' ·. The enzyme was OoMysed In 
MOPS pH 7 0 as oescnbeO., Figure 3 32 The assay was carfled out !II tOO mM Tflt·C. pH 
85 I mM CaCl: \ mM PRPP 30 ~M ijuamne varllb" 4 -I<ha:tone (8M 06) n .ndated 
and 0,014 fl'glmL prot"" to 53 ~M monomer HGXPfH) at room temperMule The ciata 
$~WS the mean . /- SEM ( n~4) an(! was also "t to ltandaro brt>drr.g algonmm to yield IC ... 
o 11 ~M Note that tOlal chalcone concentration II ~Olleo 01\ the X·axl' and tht coneenlrauon 
of enzyme III 0 53 11M mOl"lOm" Thu. tile Ko. woulo oe lowe, II f," chalcone coocenlratoon 
(th. appropflate parameter) coulo be pkltteo If tI1e Dlnomg it ccmpew", w th PRPP then 
thIS atso netdl to oe take" into conu;:eratlQn usl"Sl the COfT'petM.e bl~olng equatIon 
reservat,on about Ko. aM assumrng K". ... '~I - K... .... ., ano the latter IS slmltar in Car- as 
1\ it lor tne human enzyme with guamM as subst rate (Xu et a/ 1997), th en K,,"" ...... , " 0,8 
,M 
'4' 
(8M 06 and 8M 09), significant activatIOn was observed The activity in 1 mM 
Ca2- was about half but the chalcones (8M 06, 8M 09, and 8M 10) 
unexpectedly completely inhibited this There was no actIVity w ith 1 mM S~· 
The inhibition by the chalcones In Ca~' was Inveshgated further Figure 3.34 
shows the Inhibition by 8M 06 In 1 mM Ca2., which yie lded an lese 01 0 11 
~M , when total chalcone concentration IS plotted on the x-axis It should be 
noted that the concentration of HGXPRT was in this range as well (0.53 ~M 
monomer. not all of which may be active). and essentially the prolein IS being 
htrated The Ko5 (obtained when free chalcone IS plotted on the x-a xis) would 
be lower than the IC~ If competition with PRPP IS occurring, then thiS needs 
to be taken InlO account 10 prolllde a K" ThiS value could be extremely low , 
as the K., may be much lower than the I<M (0 36 mM, Keough al al 1999) - it 
IS 50-fold lower for the human enzyme (Xu at ai , 1997), For example, if a 
value of 0 11 liM IS taken as an indication of the Ko ~ then the K., works out to 
be 0 8 nM, If competition with PRPP IS occurring and the above parameters 
are Incorporated (see Figure 3_34 for equations and calcula tions) 
Importantly, chalcones that do not accelerate the rate of turnover in the 
presence of Mg", such as 8M 07, 8M 08, and 8M 01 , showed no inhibition of 
activity in 1 mM Ca~ ' (results not shown) 
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3.7.3 Effect of chalcones On transition from inac tive to active 
HGXPRT 
The above experiments demonstrated that, in the presence of Ca2>, and 
under turnover conditions. the cr itical chalcones (8M 06, 8M 09 and 8M 10) 
bound tightly 10 HGXPRT. The importance of the divalent ca tion Identity and 
the fact that such cat ions are only known 10 bind at the catalytiC s ite . strongly 
suggests that the chalcones bind at th is site. Another possible way of 
monitoring bonding 10 the catalytic sole may be through the requirement fo r 
substrate blllding to convert the isolated Inactive HGXPRT to an active form. 
Here activation normally requires preincubation with either Mg'> ... PRPP or 
PRPP ... hypoxanthine. as seen above In Section 3 4. If the chalcones 
compete With PRPP or hypoxanthine, they could either inhibit or substitute for 
the substrates III the activation process. SUCh an experiment is shown in 
Table 3.5, where a preincubation under certain conditions IS performed , and 
Ihen the enzyme assayed for activity m high concentrations of Mg2• follOWing 
a large dilution of the protein. in order to reduce the effect of pOSSible 
inhibition durmg the assay from Cal. + chalcone Under our two standard 
activatmg conditions the activity was changed from zero to 1 2 IJmol 
GMPlmllllmg of protem for thiS particular preparation (rows 1. 2 and g). 
Substituting 8M 06 for PRPP in Mg'> gave good activation (row 3) Addition 
of thiS chalcone With Mgl> and PRPP gave a similar result (row 4) Cal> (1 
mM) could not substitute for Mg'> In the activation with PRPP (row 5). 
However, addition of chalcone With Ca2> and PRPP produced activation 
(rowS). Prior mcubation with Cal' ... 8M 06 for 30 mill followed by Mg2' ... 
'" 
Tao!!! J 5 Activation of mal",,, HGXPRT HGXPRT (' 4 mg 01 proteorll ml 53 iJM monomer 
eoncemr"t:on) ""<IS prlHncuDated as Indoeated O~ ,ee II)( 16 haMer which al'quotl were 
diluted loo.lokI m'o tile anay mechum 01100 mM Tns-CI pH 85 110 mM Mgel" 1 mM 
PRP? a'ld 60 11M guan~ and me Mlal KlI~ I~et mlNlwred Structures of the chaleones are 
on F'lIure 3 29 
j.- Pre.incubatlon cond,tlons Activity 
~lImol GMP/min/mg prol ein) 
, HGXPRT alone No deteetaole act,v,ly 
, 10 mM Mg'· .. 1 mM PRPP " 
13 10mMMli - • 60 11M aMOS " , 10 mM MIl'" • 60 11M Bioi 06· I mM PRPP " 
• , mM Ca .1 mM PRP? <03 
• , mM Ca'· .. 60 11M 8M 06 .. PRPP " , .- , mM Ca" .. 60 11M Bioi 06 IOf 30 min, !hen added " 
1 mM PRPP • 10 mM Mg" 
• 1 mM Ca .. 60 11M 8M 06 " -, 60 11M Hx .. 1 mM PRP? " -
" 60 11M Hx . 1 mM PRPP" 1 mM EOTA No detectaole aclMly 
" 60 11M H • • 1 mM PRP? 1 mM EGTA " 
" 60 ",M H •• 60 I'M 8M Il6 0.14 
" so 11M H. " SO 11M aM 06. 1 mM EDTA " 
" 6O .. M 8M 08 " 
" 6OI.IMH.· 6OI.IM BM01 No detect.ote ilCtlvlty , 
' '7 
PRPP olso resulted in nelil/tll'on , show"'9 thot the Ca2' -cholcone did nol 
covalently modify the protein In an inhibitory manner (row 7) A surprising 
result was that Ga'" + 8M 06 alone provided act ivation (row 8), EDTA 
destroyed the activating effect of hypoxanthine and PRPP (row 10). 
suggesting the presence and a requirement for contaminating divalent 
ca tions. EGTA was not effective, further suggesting Mg2• is the most 
important calion (row 11), Activa tion was also achieved with hypoxanthine 
and 8M 06, or 8M 06 alone, In a manner that did not require divalent cations 
(row 12, 13, and 14) A non-accelerating chalcone (BM 01 ) plus 
hypoxanthine failed to activate (row 15). 
These results demonstrate thai the BM 06 mimiCS PRPP in act ivation, but, 
contrary to PRPP, does so both in Ca l + and in the absence or divalent cations. 
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Chapter 4 Discussion 
4.1 Molecular biology ",spects 
The constructIOn of a recombinant pET -17b with the gene for malans 
HGXPRT was successfully carried OUI The malana HGXPRT eDNA was 
exCIsed from recombinant pET-15b uSing Nde 1 and Bam HI and mserted 
Into pET-17b that had been cut by the same enzymes Problems were 
expenenced WIth plasmid emactlon and different methods of Isola\lng the 
plasmid were tried. Including a silica-binding method However. the slarldard 
and faster isopropanol precipitation evenlllally wor1o::ed the best We think that 
init ially there were problems with removing all of the 70 % ethanol in the final 
wash, which may have had an effect on the ac\wlly of the restriction enzymes 
Ligation of the Insert In to the pET-17b vector also gave trouble A procedure 
that eventually worked was to combine the agarose cut·outs of insert and 
vector With the former DNA J(1 excess over the latter, and extract together In 
the same tube The ligation was successful when the volume was reduced 
from the recommended 50 jJL to 15 jJL 
4.2 PrOleln expression and purification 
ExpreSSion 01 malaria HGXPRT was achieved by growing the cells overnight 
at 37°C to OD600 0 4 • 06. and then IndUCing with IPTG over 3 h The 
recombinant protein was vIsible on 50S·PAGE gels after 30 min of induction 
The e~presslOn was not under tight control by IPTG. but thiS method of 
,.0 
Inducing appeared to increase the proporuon of HGXPRT over the 
background protern synthesIs 
HGXPRT IS a soluble protein and e~pected to be in the crude supernatant. 
However, we consistently found thai a signi ficant proportion appeared in the 
crude Iysed·cell pellet most likely as inclusion bodies. We tried lowering the 
temperature during the Induction phase In order 10 increase the proportion of 
folded (soluble) protein but it did not appear to help 
We initia lly experienced some problems w1th cell lysIs which may have 
contnbuted to the poor release of protein into the supernatant Malaria 
HGXPRT has been found to be unstable bOlh in our hands (Phehane. 2002) 
and others (Queen el al 1988, Keough et al . 1998. Keough et al • 1999), and 
therefore a harsh lysis method like sonication was avoided Phehane In our 
laboratory. routinely lysed the cells containing the His-tagged protein by 
combining osmOIiC shock (500 mM NaCI). lysozyme treatment and rapid 
freeze-thaw, We wanted to aVOid high salt as we planned 10 use Ion 
exchange chromatography as the first step In the purification Our Initial 
attempts at lySIS uSing lust lysozyme veatmenl and rapid freeze-thaw were 
nol successful. as Judged by the lack of Increase In VISCOSity (DNA release) 
and analySIS by 50S-PAGE Some success was achieved by adding EDT A 
and a small amount of salt (25 mM NaCI) However. we found thai prolonged 
freeZing of the sample. pflor to freeze-thaw. was very successful even in the 
absence of added lysozyme BL21 (DE3)pLysS cells pflxluce their own 
lysozyme and often obViates lhe need 10 add extra 
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Initial punficatlon of the enzyme was tested With anion and calion exchange 
Sep-Pak cartndges, and the protem dtd not bind well to either resin This IS 
rather a surpnse, as it appears from the electrostatic surface of the protem 
that there may be an excess of positive charge, and could perhaps be 
expected to bind to a calion exchange resin (FlQure 4 1) We found, however, 
that many of the contammatlng cellular protems bound well 10 the anion 
exchange resin at alkaline pH, and we could take advantage of the Inability of 
HGXPRT to do so, as did Keough alai . (1999) 
Fogure ~ , SubunilS A and B 01 maLana HGXPRT . i tnout ( ~II) .nd •• tn (right) 
~1~l;troltatlc lu rlaCI In tne 1111 hand ""age the SuDSlrate an.~ pp, . nd Mg" a re 
shOwn ,n CPK repf&Mntaloon The o,ua and red COIOutt <!enole pO$~''''' .nd oe~ve 
electrOSta l:<: pot~n~al IMpact vely S"I)Un.it C and 0 (nol '!'IOwn) are PO$ltooned d,rectly 
belllnd A and B ,n me pallK:uiaor _ snown SIfUC1ure taken /fOrI Snl el III l1999b) In • 
lra nUIOn st.te com~l 
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LI el al .. (1999). employed an anion exchange {Q·sepharose} as the first step 
to punfy this protein, and it appeared that the protem did in fact bind. Our 
inclusion of 25 mM Nael may have contributed to th is. We did find that the 
purer protein on 10 mM sodium phosphate, pH 7.0, bound to the reson , and 
that it was eluted on very low sal\. 
Reactive Red 120-linked agarose was used In the ne~t puri fication step 
Reactive Red t 20 is a large symmetrical polycyclic ring system with 6 
negatively charged sulfonate groups (Figure 4.2) 
Figure': 2 Structure of Reactive Red 120 ReactIVe Red 120 Is linked to agarose through 
me chloro groups (green). Tne S of the sulpnonate groups 15 coloured orange 
Selecllve elution of the HGXPRT from the Reactive Red 120 was achieved 
with PPi in Tris·CI, pH 8.5. High salt (300 mM or greater) could also elute the 
protein, but in a non-selective fashion Specific Interaction of protem and dye 
was also suggested from the fact that the protem bound to what IS actually a 
cation exchange resin (negatJVely charged), WhiCh , as shown In the results, 
the HGXPRT protein did not bind (0 Furthermore, the free dye strongly 
Is:? 
inhibited activity. All these results pOint to a portIOn of the dye occupying the 
catalytic site. As alluded to In the Results sechon , Reactive Red 120 agarose 
IS often used for the pUrifICatIOn of NAOH and/or nucleotide binding proteins, 
and it is possibly Interacting with the IMP site of HGXPRT However, as can 
be seen In Figure 4.3, the portion of ReactIVe Red 120 containing the 
sulphonate groups overlays PRPP. as bound in the ternary complex With 
PRPP, 9-deazaguanlne and Mg2' in T gondu. ra ther we tt 
F.g~fe 4 3 Overlay of PRPP and ~ portion 01 Reactive Red 120 The $t""tl~ re of PRPP 
IlIght greer\) was ta~en llnaltere<t from T gondl/ HGXPRT IHerO\;~ ef IIi 2000) The 
phosphorous atoms of PRPP an<llhe 1\.11plM ~toms of Reactive Red 120 art indoclle<t 
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4.3 HGXPRT ac tivity 
The recombinant malaria HGXPRT, both In crude fractions and In almost pure 
form. was mactlve It could be activated by dlalysing in 10 mM sodium 
phosphate buffer. pH 6 8. over several hours followed by incubation at 4 °c in 
the presence of hypoxanthine + PRPP (Keough al ai , 1999) or Mg2• + PRPP 
(Phehane. 2002) The process IS reversible - dlalysmg out the substrates 
causes mactlvation and remtroducln9 them activates The inacllve protein IS 
stable In the sense that It can remain at room temperature for severa! days 
and stili be able to be actIVated With substrates 
It appears thai the actl~al1on by hypoxanthine + PRPP requires contamlnallng 
dl~alent callons in partICular Mg2' Hence slow catalysIs may be taking place 
and. in fact, Raman 01 al. (2005) report that IMP is the major acti~ator 
Howe~er , as mentioned above. Mg" + PRPP is equally effecll~e 4"-1-
chalcone (8M 06 ) substitutes for PRPP in Mg2' . but. In addition. has the 
property 01 activating In the presence of Ca2' , as welt as With hypoxanthine 
when dl~alent calions are absent. Thus the chalcone binds and acti~ales in 
the absence or presence 01 divalent calion unllk.e PRPP, which cannot bind 
Without calion (Xu el a/ . 1997) 
The mechanism 01 aCllvation and inactivat ion IS not known, bullhere seem 10 
be two pOSSibili ties (see Figure 4 4). one In whICh there IS a slow equiltbflum 
of Inactive and active forms and only the latter binds substrate CAl. and in the 
other case where the inactive enzyme binds substrate and slowly converts to 
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the active form (8 ) The fact that we have not been able 10 pick up any 
activity at all with the enzyme as Isolated perhaps suggests that the second 
alternative IS operating 
These mechanisms could be distingUished If one could find a method for 
measunng tllMdlng fairly rapidly, as only In the second case'Would the binding 




Flllure 4 4 PoUibl. routes by which malari. HGXPRT is .diY'ted. 
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The HGPRT enzymes from a variely of sources eXist as a telramer Keough 
at 81 (1999) found that the malaria enzyme was much more senSitive to KCI 
Ihan the human, and 1 2M converted the former into an inactive dimer, 
whereas il did not affect the latter Inactivation therefore may be related to the 
requirement for tetramer formation, with correct subunit interactions 
ActivalJon experiments are done with fairly concentrated enzyme ( ~ 1 mg of 
proteinfml) Under conditions of assay Ihe enzyme is much more diluted 
( ~tOO-fotd) and turnover with the full complement of substrates causes rather 
rapid (-1 min) lnactJVallon Diluting the enzyme could favour break-up of Ihe 
telramer, but enzyme cycling through unstable Intermediates that do nol 
contain substrates or products probably also contnbutes 10 instability 
The motivation for expressing the malana HGXPRT Without a hIS-tag was to 
try to express acllve enzyme and Increase its stabil ity A prevIous study In our 
laboratory (Phehane. 2002) had found that malana HGXPRT WIth a his-tag 
was expressed as an inactive largely soluble protein. With poor stability 
during enzyme turnover once It had been actIVated With substrate The 
instability seemed much more than thaI found by Keough 81 81 (1999) who 
found approximately 50% activity remain ing after dialySIS in 10 mM 
phosphate, pH 7.1, over 5 h and then a further 50% decline over 90 h 
However, we found that the tag-less protein was inact ive In the crude 
homogenate and remained so In the pure form, un less activated Once 
aclJVated , It had the same Inactiva tion kinetiCS as we had found previously for 
the tagged enzyme, and was mUCh more unstable dunng dialYSIS In 
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phosphate buffer (no activity afler 16 h) than found by the Keough gruufJ W", 
conclude that recombmant tagless and tagged proteins have equivalenl 
instability We do not understand the discrepancy with respect 10 the Keough 
findings It is not due to an Incorrect sequence, as it had been checked 
previously (Phehane, 2002). 
We opted to continue with the tagless protein because Ihe purification 
procedure was not all that more cumbersome than Ihe NI-chelate protocol, 
and , in the future, we wanted to produce crystals of the protein , for which Ihe 
lagless protein would be preferable 
4.4 Structure activity relationships (SARs) 
PIlOf to this study , we had identified a halogenated-chalcone (BM 06) as an 
accelerator 01 the catalytic cycle In the presence 01 Mg2+ This we reler to as 
Ihe accelerating activity 01 the chalcones The present study has uncovered 
that the chalcones also show Inhibitory actiYlty in the presence 01 Ca<-. as 
well as an activating activity that converts the inactive Isolated protein to an 
active lorm. 
4.4.1 Accelerating activity 
Nme chalcones had been tested previously for any inhibitory effect on human, 
T. gondii. and P falc!parum HGPRT (Phehane 2002) Of these, seven were 
2' ,4·,6·-lrihydroxylated, but changed at position 4"" (see Figure 4.5 lor 
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other three were substituted With I, F, or OH The other two were 2' ,4',4" -OH, 
with either a prenyl substitution al 5 (also caHed broussocha[cone A) or 3 
None were found to be inhibitory, but. as mentIOned before, 4" -[-cha[cone 
(BM 06) unexpectedly accelerated cata[ytlc turnover, and only of the malaria 
HGXPRT, 
The above results , together with what has been found In this study, allow 
structure aclp.lily retatlonshlps to be explored with respect to the accelerating 
activity of the chalcones A summary IS provided in Figure 4 _5 . Looking at the 
2'4',5-trihydro~y[ated chalcones first, the lodo group at position 4" can be 
replaced With Br and Ct, but not with F or O-aliphatics The poSition of the 
iodo group cannot be changed to 2" or 3" 
2',6' -CI nollo[eral ed 
Single OH here nol enough 
I, Sf. Cl. bul nol F 
4" position only, 
at leasl fa t I 
4" halogen cannol 
be replaced by 
O-atiphatic group s 
Fogure 4 5 Summa'Y of StruCture activity relations hips 10. the aCCI'-.ating ell ect on 
ca talysi •. 
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Substitutions at nng A, when the 4"-1 is fixed are also not toterated. 
Changing 2',6'-OH to two chloro groups destroys the activallng effect. 
Removing the 4',6' -OH also prevents it. Adding a 3'-NO, group to the 
chatcone without 2',6'-OH has little effect. With this grouping In ring A, 
changing the posllion of the lodo group In nng B to 2" or 3" does not lead to 
activation 
The chalcones fused through ring A showed no actiVity 
Therefore the requirements for exhibi ting the accelerating effect are very 
stringent. the only changes allowed in the lead compound were replaCing the 
4'-iodo group In nng S with Sr or CI 
The mechanism for acceleration of the ca talytic cycle is not known, but some 
speculation is warranted The kinetiCS of ca talytrc cycle of HGPRT enlymes 
has only been explored in detail for the human form (Xu at al. , 1997) The 
rate constants for each step are shown In Figure 4,6 at pH 7.4 and 23 °c in 12 
mM MgCb 0 5 mM PRPP, and 0 01 mM hypoxanthine Rate limitation In the 
forward direction is pr imarily associated with nucleotide re lease (k = 6 s" ). 
The chemica l conversion is very rapid at k = 131 S·1 The human enlyme IS 
at least 10-fold faster than the malana one, and it is not known what IS slOWing 
the latter If nucleotide release remains the primary slow step, then the 
acceleratrng chalcones may be binding either at an allosteric site outside of 
the catalytic site or al the vacant PPi site 10 augment the release of nucleotide 
(assuming ordered release) On the hand If the chemical Interconversion IS 
'59 
rale IImll!rlg (slowed aboull00-fold With respect to the human enzyme) then II 
can only be at an allosterIC SIte. because the active site IS occupied 
( I ( h PRPP ) ,to. ' [ e_ PRPP. H~ I --0 1', ... 
j~ , .. .. j~ '" . ' .. 
( I ". [ E_ pp, .IMP ) e. IMP ~ - •• 
I lH , 
[ e_ pp I 
second orc~r rate conltants for IUOllra:e and ~oauci binding were eonver.ed InlO $;ng e 
oreer constants for 0 ~ mM PRPP 10 11M hypol<anthlntl , !.1M PPI 
We attempted \0 alter the Slow step(s) by altering the pH and the IdentJly of 
the divalent cation The latter. we fel! , could be particularly interesting as 
changing Ihe callon cofactor could dramatically slow the chemical 
Interconvef6lOn. making It Ihe rate-limiting step, and retention of an 
accelerating effect of Ihe chalcones would POint to an allosteriC mechanism for 
actlvahon 
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The activity was lowered about 3-lold at pH 6 compared with pH 9. However, 
the accelerating effect 01 the chalcones remained about the same at the two 
pH values, suggestmg that the rate- limiting step{s) had not changed mUCh. 
The activity of the enzyme In Mnl< was very simi tar to that In Mg1 >, and 
replacement With Ca" slowed it about 113, whereas no aCllvlty was detected 
with Sr". If Ca2> was only affecting the chemical interconversion step, It could 
mean that the chemical interconverSlon had slowed considerably and become 
rate limiting However, addition of chalcone unexpectedly produced potent 
Inhibition 
4.4.2 Inhibitory activity 
The transformation of accelerating chalcones mto mhibitors by Ca2" strongly 
suggests that they are capable of bmding at the active site and that the 
binding affinity changes from medium (acceleratory) to very tight (inh ibi tory) 
ThiS conclUSion is In harmony with the finding that the 4"-I-chatcone (BM 06) 
in the presence of Cal" activates Inactive to active enzyme by binding to the 
PRPP site (see later) Takmg the compet itive effect of PRPP into account. 
the ~ for Ca'"·chalcone binding may be as low as 1 nM , making it one of the 
most potent inhibitors found for any PRT Exammatlon of a few of the non-
acceleratmg chatcones showed that they did not aCI as inhibitors m Ca'". 
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4.4.3 Activating activi ty 
Investigating the effect of the cha lcones on the conversion of inactive to active 
HGXPRT (activating actrvity) also provided insights Into the nature 01 
chalcone binding Normally the activation process is achieved with eIther 
hypokanlhme';' PRPP or Mg<' .,. PRPP. It now appears that under the firsl 
conditions With both substrates. there is B requirement for Mgz" and that In 
fact IMP may be the activator (Raman sf al. 2005) Ca2' ... PRPP. PRPP 
alone or hypoxanthine alone are metfec\!ve (thiS worl< and Keough el al., 
1999) Vel'{ surpnsmg IS that 4" ·I-chatcone (BM 06) alone . hypo)(anthine'" 
chalcone, and Ca'·/Mg2 • .,. chalcone could activate the enzyme 
It is difficult to explain wI1y Ca2 .... PRPP was ineffective. but given thai the 
Ca-chaloone may be bind ing several orders of magmnKle tighter than Mg-
PRPP, and perhaps Ca·PRPP the binding interactions could be much more 
extensIVe (see below) 
The inhIbitory and actIvating effects of specifically the accelerating chalcones 
suggest a Single umque chalcone binding site. and together place the site at 
the calalytlc site in proxlmlly to PRPP The size and shape of the chalcones 
fit very well over that 01 bound PRPP as It appears in the aclive site 01 the T 
gondil enzyme (Figure 4 7) The rolatlon around three of Ihe bonds in the 
chain linking the two nngs provides for many alternative ways of 
supenmposing the structures 
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F"<lule 4 7 Superimposllion 01 4".j~halcon. (BM 06, yellow) and PRPP (pink). The 
51l'U<:lure 01 PRPP .. tallef' unllkered from how ~ II flOIJM In the T 9ond~ HGXPRT (Hetou~ 
II/ II/ 2000) TI'I8 fd IIV3S perlormed mllnualy 
It Is Insightfu l to compare the sizes 01 the accelerahnglinhibltlf'lg chalcones 
and in particular the contflbution of the halooen , In Figure 4.8 Ihese 
chalcones as well as the Ineffective 4" -F-chalcone aligned in a linear form. 
The size of the halogen Increases with Ihe increase In atomIC number, from F 
to I. 
The olher parameters that vary in this S&lles are polarizability, 
electronegatlvlty, hydrophobicity, and halogen and hydrogen bonding 
charactenshcs A halogen bond is formed between a halogen and an Olrygen 
atom and ils strength depends on the poIanzablhty of Ihe bond Hnklng the 
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halogen to the carbon of the halogenaled species (Auffinger et aI. , 2004). 
There is an increase in the polarizability of the carbon-halogen link and 
Increasing electropositive character on the halogen In the senes F to I 
(Auffinger el al. . 2004) Fluorine atoms are not polarizable and remain 
entirely electronegative in halogenated methane and model halogenated 
aliphatic and aromatiC compounds. The magnitude of the electropositive area 
Increases with the radius or polarizabi lity of the halogen Therefore I (Iodine) 
develops the strongest halogen bond, and F the weakest. The strength of 
hydrogen bonding decreases In the opposite senes OMe > OH > F > CI > 6r > 
I (Raevsky et al., 1995, as quoted In Bois er al., (998). and the effectiveness 
of the laller three halogens, and not the second and third groups. appears not 
related to th iS type of bonding. lipophilicity, which Increases in Ihis series 
(Hansch and Leo, 1979. quoted In 60ls et 8/ . 1998). may playa role. 
4 _Br-<:l\alcon .. 
4 -~ch ~lcon. 
F'!!ure 4 8 Compaflson 01 ' ·' .halogenated chalcones The halogen group LS shown .n 
CPK represenlatlOn Only tile bottom three chalcones accelerated calalyllc I~ rnover with 
Mg' - as d'valent cation cofactor 
,'" 
Therefore the irnp<lrtanl parameters relahng to Ihe halogen could be size, 
halogen bonding, and IlpophlllCrty. 
Turning to the other end of the moleCule, the comblna!lOn of ITi-hydroxyl 
aromatic and carbonyl groups seems to mirror Ihe pyrophosphate mOiety 
ra ther well (F!9 4 7) The 3 O-atoms potentially overlay those of the chalcone 
A difference is that the one compound IS charged and the olher nol, and this 
eVldenUy relates to the Inability of PRPP to bind to HGPRT In the absence of 
divalent cation (Xu et al . 1997) whereas the chalcone, Judging from its ability 
to activate the Inactive protem, can 
4.4.4 Models of chalcone binding 
The layout of the active site of HPRT with bound substrates IS shown In 
schematIC form In Figure 4 9 It IS presented to remind the reader of the 
orgamsatlon of loops and the fact that only one of the Mg2·s bonds to the 
protem, and thai Is only a Single link at l oop IV 
The blndmg site for PRPP can be taken from the pOSition of PPI and the 
ribose and S'-phosphale mOieties of ImmucilhnHP in the transItion state 
complex of the malaria HGXPRT (Shl et al_ , 1999b), Since the same hydrogen 
bond contacts are made for PRPP m the T gOlld;! enzyme In complex with 
PRPP and deazaguanme - each have 13 substrate-prOleln contact distances 











FIgY'e 4 iii S~h.",.tle (II'gram of HG)(PRT .etiv. I;'. NOle IlIiIt only one Mg'· IS d IreCtly 
lin ked 10 the prtIle~ Yla loop IV 
posItion of the chalcone WIth It overlaying the PRPP site IS shown m Figure 
4 10 In this pOSition. the keto group and one hydroxyl of flng A replaces two 
hydroxyls of the PPi. another hydroxyl IS 2 9 A from the second Mg" . and the 
th ird makes good contact With the amide of lys77, and the carbonyl of the 
prevIous ammo aCId On the other end the halogen mteracts With 1hr1 4g to 
form a hydrogen (Ho) and a halogen bond AromatiC n in teractions are 
possible With tyrl 16 If catalytic loop illS folded down W,lhoutthe nucleotide. 
Ihere is nothing holdmg !he Mg2 ' Ion m pOSlhon and liS locality need nol be 
fixed 
166 




Figure .. 10 Docking .... ·I-chalcon~ (8M OS) Into mal"n. HGXPRT with Mg" 
Immuc~"nHP IS In greftn PPi orange enalcone yelow and Mrj- green Tn", C'I.1c:one Wi$ 
docked nuonuall~ us n; Acc"'lrys OS VlewerPro. tmera::tll)ns .... m o;I\iI~. and prOle,,. 01 -< 3 
"are s i\own ;n 'i'_ n ,.,,,. Tn" GCOrdlflabo)M of nc MQ" s ,or" .Iw s nOWn 1)111' ''''''' .. ,~ 
In the absence of bound Mg20. other configurations for nng A are possible, 
including H-bond contacts with asp14S, ser202, asp204. and arg210 (docking 
not shown) 
The alkene double bond in the chalcone limits configurations to linear forms, 
which precludes it assuming a U-shape that would make il resemble a 
nudeollde 
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The dockmg In FlQure 4 10 with or without Mg2< could have relevance 10 the 
activating actiVity of the chalcone The chalcone would Interact first WIth an 
open inactive enzyme structure and with lime Ihe loops could come together 
and close over the chalcone so Ihal the protein structure assumes something 
more like what is presented Activation IS achieved In the absence 01 purm8 
and added divalent cation (as well as in thelf presence) suggesting thaI 
closure of the hood domain may not be necessary, which fits WIth the finding 
Ihal Mg-PRPP IS also suffiCient 
IT seems posSIble that the converSion of inactive 10 act ive con formation of the 
protein may Involve an improvement In inter-subunit contacts, and that this 
requlras a more compact or constrained structure around the active site. 
Once the oorrect Inter·subunlt contacts have been made, the activators may 
diSSOCiate to Yield the active conformation With empty acilve and attendant 
mobility of the loops There is evidence from the human enzyme that 
substrate occupancy of one subunit influences the characteristics of the 
neighbouring subum!, suggeSllng co·operatlVity between subunits (Keough at 
al. 2005) 
The chatcones became potent Inhibitors when Cal ' was substituted for Mg2' 
In the standard activity assay In considering pOSSible docking for the 
Inhibitory chatcones, we reasoned that extra Interaction With the protein must 
have been occumng when Cal ' replaces Mg1' tn alt re levant PRT structures 
determined to date. only one of the Mg1's makes contact With the protein (at 
asp204 for malaria enzyme), the other only contacts the ribose motety and 
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PPI With Ca" all the Interactions Ihat are present WIth Mg" are possible. 
but there Is the intriguing posslbllity that use may be made of the two 
carboxylate ammo acids gtul<14 and asp145 lust below Ihe one Mg1' , when 
Ca" IS present In this regard It IS Interesting that Cal. has variable 
coordmatlon (6 , 7 or 8). whereas Mg1' IS restricted to 6 , Ca", donor distances 
are longer than Mg2• (237 versus 2 11 A In model compounds), Ca" often 
coordmates carboxyls In a bJ-dentate manner and for Mg" it is extremely rare. 
Ca" tolerates devlahon for ideal geometry much more than Mg'· . and Ca" 
can move [woee as far from the oeo plane compared With Mg" (Harding 
1999, 2000. 2001)_ All these features of Ca" make it more versatile and 
capable of stronger Interactions compared With Mg'· . In Figure 4 11 , ring A of 
the chalcolle has beell moved lowards glu1 44 alld aspl45 and a Ca" 100 
placed ill between at suitable bonding distances The keto group and one 
hydroxyl coordinate the Cal' , as well as asp145 In a bl-dentate fashion The 
coordination includes glu146 and a backbone carbonyl of loop I While the 
geometry is not ideal, vanallons are pOSSible With regard to the other metal 
ion binding site. replacement of Mg" With Ca2• could Introduce the possibility 
of a bl-dentate link 10 as.p204 and one of the hydroxyls 01 flng A is also In a 
SUitable posItion for coordlnalJon, wtllch may be completed with water 
molecules It IS interesting that In one apo structure of T ganeJii, a Mg2' was 
bound at the residues eQuNalent to glu1 44 and asp1 45 (see Figure I 10) AI 
Itlls stage 1\ IS not known whether punne binding is reqUired for the very tight 
Ca-chalcone to protein interaction An Intnguing possibility. In view of the 
l ightness 01 the interaction, IS thaI the complex may resemble a transition 
state Maybe the electron Withdrawing capability of the halogen, creates an 
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electron defICient aromatic nng It can be seen from the Figure that th is 
aromatic flng is In pro~lmlly to the protonated N in the lmino-nbtlol nng. and It 
is the poSitive charge on the laller whICh creates the very light binding affinity 
of the ImmUCllhnHP when PPI IS Included However, against thiS Idea is the 
fact tha t the Inhibition with the e a-chalcone is Immediate, whereas the binding 




Fogure 41 1 Docking of . ".j·chllcona (BM 06) in malaria HGlCPRT with C~'· . 
ImmuCllionHP IS ,n green pp, orange Mg" IIreen C.I" blue and eMaieooe yellow The 
cnalcone at>d Ca" weft dOCktd mlnualy WIIn AceeI~ OS V_e<Pro 
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In regard 10 the accelerating effect. the rate-hmltmg step for the malaria 
HGXPRT IS not known, but if It IS the same as the human enzyme. it would be 
nucleotide release In which case, the relevant structure would be the 
comple)[ of enzyme ... IMPIGMP However, In this case it seems not possible 
for the chalcone to bind as a PRPP analogue as discussed above, since the 
nucleollde IS bound Nucleotide release probably consists of several phases 
(Heroux et al . 1999). and one outSide posslbihty thai we conSidered is thaI 
the ribose ... S"'phosphate IS loosened flfSt. and the slower step is the pulling 
back of the hood domain to release the puflne portIOn and the complete 
nucleotide In this scenarIO loops II. III III ' and IV move away fol lOWIng 
departure of the Mg2>s and PPI allowing the detachment of the nbose and 5'· 
phosphate mOieties while the purine nng pan IS trapped between Itet46 and 
phe197 of the hood domain Only once the hood domain opens away from 
the core domain is nucleotide released Binding of chalcone to the PRPP Me, 
particularly at the SIte of the nbose and 5'.phosphate, would disallow the 
nucleotide to regain purchase to thIS region. and help Its release The 
rebinding 01 the nbose·phosphate secMn may be also be retarded by a fast 
conformational change of the nucleollde from Its strained bound state to a 
more stable one Making Hood Domain movement the slow step is attractive 
because the domain is relative ly large. probably moves as a rigid body and IS 
constrained by inter·subunit contacts In thiS series of events. the binding of 
the chalcone may be driven by Interactions with some of the disordered loops 
menlloned above, al'\d the structure of the el'\zyme with nucleotide and 
chalcone In the vlclMy of the laUer. may not be all thaI different from the 
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transition stale complex. However, 1\ seems doubtful whether chalcone would 
be able to compete with the partially bound nucleotide 
There are several alternative possibilities for the acce~rator-b i nding site, II 
nucleotide release IS the rale-limlting step. and the chalcone binds elsewhere . 
For example, In the transition-l ike structure. ring A (the tri-hydroxyl moiety) 
could remain at the PPi site. but flipped so that ring B With the halogen IS 








Figure 412 Docking of 4"·I·cll~lcone (9M 06) In malar ia HGXPRT with ring B outside of 
the cataly tic site. The HGXPRT structure IS taken from Sh, el 81 (1999b) In:eracbon 
distances 01 "'3 A are ~own In yellow hnes Coordlnaaon of Mg'·s 's shown on green I.nes 
neighbouring subunit are within bonding distance of the halogen How this 
binding would accelerate IMP release IS unclear. but II could be via Loop IV. 
which is nexl to the Hood Domain, which In lum needs to open. A more 
relevant Slructure could be that of the binary nucleotide-bound form for which 
the T gondil enzyme may be used as a model The structure is shown In 
figure 1 12. and It is eVident that there Is a large open region vacated by the 
Mgl·s and PPI In Loop t tys79 IS facing in, the catalytic loop with tyrlt8 IS 
pulled back, loop III has less contacts With the 5'-phosphate, and loop III' 
WIth arg182 has receded There are many ways to dock the chalcone Again 
Interaction of the chalcone With Loop IV could aid pushing back the Hood 
Domain 
If the rate-limiting step is nol nucleotide release, but rather a slow 
conformational change follolllling, say IMP release, then the apo enzyme may 
be the more relevant structure to conSider, and even more pOSSibilit ies for 
binding at the active site present themselves. If the slow step IS the chemical 
mlerconverslon then an allosterIC slle needs to be conSidered 
4,5 Conctuding remarks 
As mentioned earher 8M 06 , 8M 09 and 8M 10, but none of the other 
chalcones and flavonoids tested here or previously accelerate the catalytiC 
turnover of the malaria enzyme These three chalcones also inhibit the 
malaria enzyme when Ca l < replaces Mg1- as the divalent ca tion cofactor 
Funhermore. 8M 06 has been demonstrated 10 convert malana HGXPRT 
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from an mactlve Inlo an active form Smce thef>e three chalcone,. d,ffe, ullly III 
the halogen, il is reasonable to conclude that each binds at the same site for a 
particular activit~ Further, since the same chalcones appear to exhibit each 
of the activities (accelerator, activator, and Inhibitor - With the reservation that 
for the laller activities only limited non-accelerating cha lcones were tested), it 
seems rat ional to conclude that they bind at the same/Similar site for each 
activity In the activating and inhibiting activities, there IS evidence thaI the 
chalcones bind allhe PRPP site. Therefore il is temptmg to speculate that to 
mduce an accelerating effecllhey also need to bind al the PRPP Site, which 
as we have seen, presents problems if nucleotide is stil l bound, and the 
possibi lity of a different rate limiting step needs to be conSidered. The 
transformation from an accelerator to inhibitor, if the binding IS at the active 
site, wou ld merely reqUIre that the binding energy changes from medium to 
light depending on whether Mg2< or Ca2< is the cofactor, respectively 
The halogenated chalcones initially did not seem to have obVIOUS structural 
Similarity to PRPP, but the fact that they become tight binding inhibitors With 
Ca2< strongly suggested that they bind divalent callons, and the only real 
pOSSibi lity is through the keto group and a hydroxyl group of ring A. The 
other interesting aspect IS that, unlike PRPP, they are not charged. and th iS 
feature appea rs to allow them to bmd at the PRPP site In the absence of 
divalent metal Ion. As far as we are aware these are the first uncharged 
PRPP mimics, and at least in their accelerating activity. they are speCi fic for 
the malaria enzyme They ra ise hope that they or more potent analogues 
may in hibit growth of the malaria parasite itself. either targeting HGXPRT or 
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another essentia l PRPP-llti lislng enzyme That said however, II may be 
difficu lt to prove that the death of the parasites is due to targeting such 
enzymes since other chalcones inhibit malaria growth (see section 1 5). 
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Chapter 5 Future work 
A number of strategies could be followed m order 10 underst<lnd the n<lture of 
the chalcone-HGXPRT interaction In tna Ihree <lct!vltles 
Foremost of these would be to try to crystallise the chalcone-HGXPRT 
complex Malaria HGXPRT has proven difficult to Cl)'stallise and It has only 
been accomplished with the transition state mhibitor, ImmuclltinHP + PPI, but 
the tight bindmg 01 the chalcones In the presence of Ca2' provides some 
hope It would be worth trymg With punne, or even ImmucllltnHP . /- PPI II 
may be necessary to punfy the enzyme further, and prelimmary experiments 
With another DE52 column, under conditions m which the protem bound to the 
reSin, showed that thiS is possible with this technique 
As lime did not perml!' SARs were no1 done lor all chalcones in the activation 
(Inactive to active protem) and mhibltlon (In the presence 01 Ca2') 
expenments It would be instructive to ascertain if exactly the same prolile is 
found for each activity 
It IS deSirable to determme the true Ko for Ca-chalcone binding ThiS presents 
plOblems due 10 the Iflstabl1tty of the protem at low protem concentra~ons. 
One techntque that may be sUitable IS equilibrium d ialYSIS, but thiS would 
reqUire the synthesIs of a radlOlabelled deflvallve 
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II would also be interesting to determine whether the chalcones are Inhibitory 
In rnl)rtures of Mg" and Ca", which may pertain to the situation In vivo For 
example, at physiological concentrations of Mg" (-3 mM), could the 
chalcones exhibit inh ibi tion at ~M concentrations of Ca"? The concentration 
of Ca" in the parasite within the red blood cell may not be aU tha t low. since 
there appear to be connections to the outside (New Permeabili ty Pathways 
thaI develop upon parasite effection can possibly lead to a change In levels of 
Ca" in the parasite see section 1 3_1) 
Another avenue of investigatIOn IS to determine whether the Ca-chalcones 
Inhibit the human and T yond/l enzymes In Mg2', the 4"·I-chalcone did not 
accelerate these protems (Phehane 2002). but thiS may be because rate 
limi!a!ion In the ca!alytlc cycle IS different 
Fogllre 5 I Prolumity of Immuci1tinHP Iljghl green). PPI (orang,,) and docked c hll~n" 
(y"llow) ... oc:cu" in Ih" structur. of Figure ~ . 10 The gfeen hnes show distances <3 A 
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Furmer more pOlent chalcone inhibitors could possibly be developed II the 
docking of chalcone miD the active site 01 the transition sta te structure can be 
trusted . since the 8 pOSItion of the deazahypoxanthme ring cernes close 10 the 
chalcone This is shown in Figure 51 , where the two structures are taken 
exacUy as they occur In the docked structure of Figure 4 10 The distances 
are under 3 A (green hnes). and a chalcone denvstised Wi th a purine on ring B 
could take advantage of the IsoteuClne-phenylalanlfle nng clamp and bind 
very lightly If the synthetsc chemistry does not allow thiS. perhaps a phenyl 
ring wi th an appropriate linker attached \0 lhe chalcone CQuid serve as well 
As mentioned above, the tight binding of Ihe present chalcone, in Ca lo may 
actually require a bound punne Such a compound would bear some 
resemolance to a half Reactive Red 120 molecule (Figure 4 2) 
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